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TuMour biology
Paraganglioma in the head and neck region (HNPGL) are vascular  neuroendocrine 
tumours, derived from chromaffin cells of the parasympathetic paraganglia in 98-99% 
of cases and they occur along the paraganglia pathways of embryologic migration 
extending from the skull base to the pelvic Floor [1-3].  Pheogromocytomas, adrenal 
chromaffin derived tumours, extra-adrenal abdominal- and thoracic paraganglioma are 
however associated with the sympathetic nervous system. Sympathetic paraganglioma 
are secretory tumours that mainly secrete catecholamines and dopamine [4-9]. 
HNPGL are rare tumours, representing approximately 0.012% of all head and neck 
tumours and the estimated incidence is about 1:100.000 a year [10]. 
About 60% of HNPGL show clinical growth during follow-up, and growth rates are 
indolent and generally very slow with a mean increase of 0.83 mm/year in a single 
dimension and a doubling time of about 4.2 years [11]. Furthermore, these tumours 
are benign in the vast majority of cases, yet malignancy rates have been described. 
This is mainly dependent on hereditary subtype. 
Overall, there is a 3-5% chance of malignant disease [12, 13]. 
anaToMiCal sub siTes and CliniCal PresenTaTion
The most characteristic sub sites where these tumours can be found are presented in 
figure 1. 
These tumours are usually benign and grow in close proximity with delicate neu-
rovascular structures throughout the head and neck region. Mainly, large vessels 
and cranial nerves are compromised by these tumours, which also dictates clinical 
presentation. 
Most HNPGL are found around the carotid body, resembling about 57% of HNPLG. 
Carotid body paraganglioma arise from the neural crest cells at the bifurcation of the 
common carotid artery [4]. The classification system described by Shamblin et al. is 
generally used and illustrates the relation of these tumours with the common carotid 
and internal- and external carotid artery [14] (figure 1). Tumours classified as class I 
have no or minimal attachment with the carotid arteries. Class II tumours surround 
the carotid arteries, partially encasing them. Shamblin class III tumours surround the 
vessels, adhering firmly over their whole circumference [10]. Hereby, they are also 
associated with vagal and hypoglossal nerve palsies. Intracranial extension is rare for 
these tumours. They usually (50-60%)  present with a painless swelling in the neck 
without evidence of cranial nerve palsy, the latter is found in 4-22% of cases [16, 17]. 
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The second most common subtype are jugulotympanic paraganglioma, which 
constitute about 30% of HNPGL, and they are thought to arise from the Jacobson’s 
nerve in the tympanic cavity [4]. The classification of these tumours is according to the 
Fisch classification [10, 18]: class A JTPGLs are located along the tympanic plexus on 
the promontory, and class B tumours invade the hypotympanum, but do not erode the 
jugular bulb, as opposed to class C tumours (C1 destruction of the jugular bulb/fora-
men; C2 invasion of the vertical carotid canal; C3 invasion of the horizontal carotid 
canal and C4 invasion of the cavernous sinus). In class D tumours, besides the various 
degrees of invasion described for class C, intracranial extradural or intradural exten-
sion occurs (De1 and De2 intracranial and extradural invasion of up to 2 cm or more 
than 2 cm respectively; Di1, Di2 and Di3 intracranial and intradural extension of up to 
2 cm, between 2 and 4 cm or more than 4 cm respectively). Tympanic paraganglioma 
(class A and B tumours), usually present with a pulse synchronous tinnitus that might 
be accompanied with conductive hearing loss. In patients with jugular paraganglioma 
(class C and D tumours) the presence of additional lower cranial nerve deficit is found 
in 39-40% of cases, mainly referring to the 7th and 9-11th CN [1, 16]. 
 Figure 1: The classification of Shamblin et al. of the difficulty of surgical resection. Group I tumours 
are localized and easily resected. Group II includes tumours adherent or partially surrounding vessels. 
Group III paragangliomas intimately surround or encase the vessels. ICA = internal carotid artery; ECA = 
external carotid artery. Figure 1 taken from Hallet et al. 1988 [15].
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The third most common site is at any point along the course of the vagal nerve 
(13% of HNPGL), referred to as vagal paraganglioma [4]. Therefore the clinical presen-
tation is variable and there are no proper classification systems developed. They might 
present with a wide variety of symptoms ranging from a painless lateral neck mass to 
dysphagia, snoring, lower cranial nerve deficits and Horner syndrome . CN deficit is 
found in 25-36% of cases [19, 20].
Other sub sites are nasal and paranasal paraganglioma and laryngeal paraganglioma. 
Due to the rarity of these tumours they are not within the scope of the current thesis. 
HerediTary Head and neCk ParaganglioMas
About one third of HNPGL are part of hereditary disease [21-25]. The particular as-
sociated phenotype  usually induces higher penetrance rates at younger ages, and 
multifocal and metachronous tumour presence is to be expected. Currently, there are 
ten genes associated with HNPGL syndromes, and the SDH- (succinate dehydroginase) 
associated genes are the most common forms [26-31]. The remaining germline muta-
tions are of lower prevalence (MAX, TMEM127, VhL, RET, MEN2 and NF1) [32-36]. 
The main phenotypical characterizations of these tumours is presented in table 1. 
Also, information on the hereditary transmission process is provided, please note that 
for SDHD and –B tumours, a distinguished paternal transmission pathway has been 
described [26, 27]. Also, dependent on the tumour syndrome, other clinical features 
might be apparent such as in von Hippel Lindau disease and neurofibromatosis type 1. 
diagnosTiC ProCess
Since HNPGL are potentially found to be part of a larger systemic disease, the diagnostic 
work-up of these tumours should consist of a multidisciplinary team that contains a 
dedicated endocrinologists, radiologists, clinical geneticists radiotherapist, a skull base 
surgeon and a head & neck surgeon with experience in vascular surgery. 
The first step in the diagnostic process is imaging, in which the standard is an 
MRI with intravenous contrast enhancement of the head and neck region, potentially 
complemented with an MRA. In case a close relation to the skull base is found (e.g. 
in jugulotympanic paraganglioma) a subsequent CT-scan is required to determine loco 
regional expansion and tumour class in cases of jugulotympanic tumours. Imaging 
should also be focused on synchronous tumour presence [37-40]. 
Moreover, since 1-2% of tumours are part of the sympathetic nervous system 
and hereby they are potentially secretory, endocrinological analysis, focusing on cat-
12 Chapter 1
Ta
b
le
 1
: p
he
no
ty
pe
 a
ss
oc
ia
te
d 
w
ith
 g
en
et
ic
 s
ub
ty
pe
.
SD
H
D
SD
H
A
F2
SD
H
C
SD
H
B
SD
H
A
V
H
L
TM
EM
12
7
M
A
X
M
EN
2
N
F1
%
 H
N
PG
L
91
-9
8%
88
-1
00
%
12
-8
7.
5%
27
%
2.
2%
0.
53
%
0-
42
%
1.
12
%
-
0.
1%
Ra
ng
e 
ag
e 
pr
es
en
ta
tio
n
25
-3
8
33
-3
4
38
-4
6
19
-7
5
32
15
-4
2
24
-5
1
-
15
-4
2
-
%
  m
ul
tif
. D
is
ea
se
60
-7
9%
70
-9
1%
69
-8
1%
13
%
N
D
N
D
N
D
N
D
N
D
N
D
Ph
eo
/ e
xt
ra
- 
ad
r. 
PG
L
8-
21
%
N
D
12
.5
-4
4%
2-
52
%
/1
3-
85
%
N
D
10
-1
5%
0.
9%
1.
12
%
30
-5
0%
1-
14
.6
%
A
ss
oc
ia
te
d 
di
se
as
e
N
D
N
D
N
D
Re
na
l c
el
l 
ca
./ 
M
A
LT
 
ly
m
ph
om
a
N
D
Le
ig
h 
sy
nd
ro
m
e
-
N
D
M
EN
2 
as
so
ci
at
ed
 
tu
m
ou
rs
N
F1
 a
ss
oc
ia
te
d 
di
se
as
e
%
 m
al
ig
na
nt
8%
N
D
33
%
33
%
N
D
N
D
N
D
N
D
N
D
N
D
tr
an
sm
is
si
on
Pa
t.
Pa
t.
Pa
t.
/ m
at
Pa
t.
/ m
at
N
D
N
D
N
D
N
D
A
ut
. d
om
in
an
t
N
D
N
D
 =
 N
ot
 d
es
cr
ib
ed
; P
at
 =
 p
at
er
na
l t
ra
ns
m
is
si
on
; M
at
. =
 m
at
er
na
l t
ra
ns
m
is
si
on
; A
ut
. d
om
in
an
t 
=
 a
ut
os
om
al
 d
om
in
an
t.
General Introduction 13
1
echolamine overproduction, is required. Particularly in the case of enhanced plasma 
catecholamine levels, treatment with beta-blockers is required. Even more so in case 
surgical excision is required as this might result in enhanced catecholamine release 
per-operatively which is associated with potential detrimental complications such as 
hypertensive crisis, cardiac arrhythmia’s, cardiogenic shock, pulmonary oedema and 
cerebral haemorrhage. Endocrinological analysis is also mandatory in case a hereditary 
tumour subtype is found since associated comorbidities such as SDH-related tumours 
such as pheochromocytoma, gastrointestinal stroma tumours, renal cell carcinoma’s 
or pituitary adenoma’s, or MEN2 associated tumours need to be managed [41-43]. 
Furthermore, a clinical geneticist is required to manage the hereditary diagnostics. 
It is suggested to test all patients presented with HNPGL. Also those with apparent 
sporadic disease since research has illustrated that about 25-56% of patients with 
apparently sporadic tumours do show a germline mutation [3]. 
The results of the above mentioned diagnostic work-up should be carefully dis-
cussed by a specialized working group with experience in HNPGL management. All of 
the above should be taken into consideration while determining the best treatment 
for each individual patient. Besides an experienced radiologist, clinical geneticist and 
endocrinologist, the working group should contain an otolaryngologist with particu-
lar experience in skull-base surgery and a head & neck surgeon with experience in 
vascular surgery (or close cooperation with vascular surgeons) is required. Also, an 
experience radiation oncologist is required as an alternative for surgery. Details on 
clinical management are presented underneath. 
CliniCal ManageMenT
The clinical management of these tumours remains a hot topic of debate and concerns 
the main subject of this thesis. Despite the benign nature of these tumours, morbidity 
can be considerable due to the close proximity of these tumours to delicate neural and 
vascular structures. This makes determining the moment of treatment and the treatment 
modality debatable. Particularly in the case of hereditary tumour syndromes, with an 
enhanced chance of presentation at younger age (generally with larger tumours) and a 
higher chance of multifocal and/or metachronous tumour growth. Managing clinicians 
need to keep a constant eye on the risk of tumour induced morbidity, respective to the 
risk of treatment induced morbidity. 
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Wait and scan
Recent studies have suggested that since merely 60% of HNPGL show tumour growth, 
and tumour since growth is generally slow, an initial wait and scan strategy should 
always be considered. Key studies of van der Mey et al. and Jansen et al. have illustrated 
that refraining from detrimental invasive strategies such as surgery or radiotherapy 
shows high functional CN preservation rates which enhances quality of life [11, 43]. 
Dependent on complaints, loco regional extension and comorbidities, tumour growth 
should be evaluated on a yearly basis. In case tumour growth is found, dependent on 
the size, location, age and comorbidities of the patient treatment should be considered 
again. As stated by Suarez et al. it can be argued that a wait and scan policy will increase 
the risk for development of additional cranial nerve deficits. Nevertheless, only 3 of 40 
patients with VPG in whom a wait and scan policy was chosen, developed cranial nerve 
palsy during an average follow-up of 8.5 years [11, 45]. Nevertheless, the precise risk 
of such a wait and scan strategy remains uncertain and requires further refinement. 
surgery
In case treatment is mandatory, e.g. dependent on tumour growth or clinical symptoms, 
historically surgery is the treatment of choice, as this is the sole treatment modality 
capable of gross tumour removal.  Recent work of Suarez et al. however, has illustrated 
that there is a considerable risk associated with surgery of HNPGL [45-46]. Particularly 
for larger tumours such as Shamblin class 2 and 3 in case of carotid body tumours and 
Fisch class C and D jugolotympanic tumours or those in close proximity to the vagal 
nerve. Local control rates are acceptable, yet morbidity in terms of permanent cranial 
nerve damage and strokes are imminent. For smaller (Fisch class A and B and Shamblin 
class 1 tumours) however, surgery might be a more viable option when executed by 
an experienced otologist/head and neck surgeon respectively. Currently however, the 
risk of surgery for smaller tumours when being part of multifocal disease has not 
been described. For larger Fisch class C and D, Shamblin class 3 and all vagal body 
paraganglioma morbidity is potentially considerable, and expertise in skull base surgery, 
neurosurgery and vascular surgery should be present [3, 45-46]. To date, the exact risk 
profile of surgery for different HNPGL of different tumour class remains uncertain and 
requires further research. 
radiotherapy 
Alternatively, recent studies have illustrated the use of radiotherapy as an alternative 
treatment modality. Local control-rates seem to be promising, yet even more promising 
is the absence of collateral treatment induced morbidity when compared to surgery 
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[45-46]. There are however concerns with the use of radiotherapy, mainly referring to 
long term side effects. The precise risk of irradiation induced secondary malignancies 
and vascular damage remains uncertain for these tumours. As outlined by Suarez et al. 
other head and neck neoplasm’s treated with similar radiotherapeutic techniques and 
dosages illustrated a risk of 0.5 and 0.1-3% for tissue necrosis and irradiation induced 
secondary malignancies, respectively over a course of 30 years [45-46]. Furthermore, 
Wilbers et al. found an increased incidence of stroke in 49 patients suffering from head 
and neck malignancies seven years after radiotherapy compared to the general Dutch 
population (8.9 versus 1.5 per 1.000 person years) [47]. It is uncertain whether or not 
these results apply for HHPGL treatment as well, particularly since radiotherapeutic 
techniques have advanced. Radiotherapeutic planning is becoming more and more 
accurate, and stereotactic radiation techniques have reduced the risk of collateral tissue 
damage. Nevertheless, although with the modern fractionated radiotherapeutic and/
or stereotactic techniques these risks are reduced, the precise long-term risk remain 
largely uncertain. This is of particular concern for younger patients, or those in which 
metachronous tumour growth requiring additional treatment later in time. 
debulking
An alternative for complete tumour surgery is a dual approach. Recent studies have 
investigated the possibility of gross tumour mass debulking with safe margins from 
delicate neurological structures. The residual tumour mass might in turn be subjected to 
a wait and scan strategy and in case of growth it might be treated further, potentially 
by radiotherapy [48-49]. This new technique however requires further research. 
Keeping in mind the individual risk profiles associated with each different treatment 
modality, we believe it is the managing clinicians task to propose an individualized 
treatment regimen for each patient, keeping in mind the clinical presentation, age 
and comorbidities of the patient. There is no “one size fits all” principle in this respect. 
Furthermore, it is our current understanding that past researches have failed to 
properly investigate the use of a wait and scan strategy. Moreover, no research applied 
careful stratification per tumour type and class, and rather evaluated the effect of 
individual treatment modalities on mixed HNPGL cohorts. Moreover, little research 
is conducted on multifocal tumour presence and its impact on clinical management.
16 Chapter 1
referenCes
 1. Boedeker CC, Ridder GJ, Schipper J. Paragangliomas of the head and neck: diagnosis and 
treatment. Fam Cancer 2005;4:55-59.
 2. Myssiorek D, Ferlito A, Silver CE, et al. Screening for familial paragangliomas. Oral Oncol 
2008;44:532-537.
 3. Boedeker CC, Hensen EF, Neumann HP, Maier W, van Nederveen FH, Suárez C, Kunst HP, 
Rodrigo JP, Takes RP, Pellitteri PK, Rinaldo A, Ferlito A. Genetics of hereditary head and neck 
paragangliomas. Head Neck. 2014 Jun;36(6):907-16. doi: 10.1002/hed.23436
 4. Erickson D, K. Y. C. E., M.J., Thompson G.B., Grant, C.S., Heerden, J.A., Young W. F. . (2001). 
Benign Paragangliomas: Clinical Presentation and Treatment Outcomes in 236 patients. The 
Journal of Clinical Endocrinology and Metabolism, 86(11), 5210-5216. 
 5. Patetsios P, Gable DR, Garrett WV, et al. Management of carotid body paragangliomas and 
review of a 30-year experience. Ann Vasc Surg 2002;16:331-338.
 6. Neumann HPH, Pawlu C, Peçzkowska M, et al. Distinct clinical features characterize paragan-
glioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004;292:943-
951.
 7. Bausch B, Malinoc A, Maruschke L, et al. Genetics of pheochromocytoma. Chirurg 2012;83:511-
518. [in German]
 8. Fishbein L, Nathanson KL. Pheochromocytoma and paraganglioma: understanding the com-
plexities of the genetic background. Cancer Genet 2012;205:1-11.
 9. Taïeb D, Timmers HJ, Hindié E, et al. EANM 2012 guidelines for radionuclide imaging of pha-
eochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2012;39:1977-1995.
 10. Capatina C, Ntali G, Karavitaki N, Grossman AB. The management of head-and-neck paragan-
gliomas. Endocr Relat Cancer. 2013 Aug 23;20(5):R291-305.
 11. Jansen JC, van den Berg R, Kuiper A, van der Mey AG, Zwinderman AH, Cornelisse CJ. Estima-
tion of growth rate in patients with head and neck paragangliomas influences the treatment 
proposal. Cancer. 2000 Jun 15;88(12):2811-6.
 12. Jafri M, Whitworth J, Rattenberry E, Bradley L, Kilby G, Kumar AV, Izatt L, Lalloo F, Brennan 
P, Cook J Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of 
individuals with non-syndromic phaeochromocytoma and paraganglioma 708 and head and 
neck 709 paraganglioma (HNPGL). Clinical Endocrinology 2013 78 898-906
 13. Manolidis S, Shohet JA, Jackson CG & Glasscock ME III 1999 Malignant glomus tumours. 
Laryngoscope 761 109 30-34.
 14. Shamblin WR, ReMine WH, Sheps SG & Harrison EG, Jr. Carotid body tumour (chemodectoma). 
Clinicopathologic analysis of ninety cases. American Journal of Surgery 1971; 122 732-739.
 15. Hallett JW, Jr, Nora JD, Hollier LH, Cherry KJ, Jr, Pairolero PC. Trends in neurovascular com-
plications of surgical management for carotid body and cervical paragangliomas: a fifty-year 
experience with 153 tumours. J Vasc Surg. 1988;7:284–291
 16. Powell S, Peters N & Harmer C Chemodectoma of the head and neck: results of treatment in 
84 patients. International Journal of Radiation Oncology Biology Physics 1992 ; 22 919-924.
General Introduction 17
1
 17. Sajid MS, Hamilton G & Baker DM A multicenter review of carotid body tumour management. 
European Journal of Vascular Endovascular Surgery 2007; 34 127-130.
 18. Fisch U & Mattox DE Microsurgery of the skull base. Stuttgart: Thieme. 1988
 19. Neskey DM, Hatoum G, Modh R, Civantos F, Telischi FF, Angeli SI, Weed D & Sargi Z Outcomes 
after surgical resection of head and neck paragangliomas: a review of 61 patients. Skull Base 
2011; 21 171-176.
 20. Biller HF, Lawson W, Som P, Rosenfeld R. Glomus vagale tumours. Ann Otol Rhinol Laryngol 
1989;98:21-26.
 21. Neumann HPH, Pawlu C, Peçzkowska M, et al. Distinct clinical features characterize paragan-
glioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004;292:943-
951.
 22. Schiavi F, Boedeker CC, Bausch B, et al. Predictors and prevalence of paraganglioma syndrome 
associated with mutations of the SDHC gene. JAMA 2005;294:2057-2063.
 23. Hes FJ, Weiss MM, Woortman SA, et al. Low penetrance of a SDHB mutation in a large Dutch 
paraganglioma family. BMC Med Genet 2010;11:92.
 24. Burnichon N, Rohmer V, Amar L, et al. The succinate dehydrogenase genetic testing in a large 
prospective series of patients with paragangliomas. J Clin Endocrinol Metab 2009;94:2817-
2827.
 25. Neumann HPH, Erlic Z, Boedeker CC, et al. Clinical predictors for germline mutations in head 
and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as 
fall-out. Cancer Res 2009;69:3650-3656.
 26. van der Mey AG, Maaswinkel-Mooy PD, Cornelisse CJ, Schmidt PH, van de Kamp JJ. Genomic 
imprinting in hereditary glomus tumours: evidence for new genetic theory. Lancet. 1989 Dec 
2;2(8675):1291-4.
 27. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II 
gene, in hereditary paraganglioma. Science 2000;287:848-851.
 28. Niemann S, Müller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. 
Nat Genet 2000;26:268-270.
 29. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB 
cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum 
Genet 2001;69:49-54.
 30. Hao HX, Khalimonchuk O, Schraders M, et al. SDH5, a gene required for flavination of suc-
cinate dehydrogenase, is mutated in paraganglioma. Science 2009;325:1139-1142.
 31. Bayley JP, Kunst HP, Cascon A, et al. SDHAF2 mutations in familial and sporadic paraganglioma 
and phaeochromocytoma. Lancet Oncol 2010;11:366-372.
 32. DeAngelis LM, Kelleher MB, Post KD, Fetell MR. Multiple paragangliomas in neurofibromatosis: 
a new neuroendocrine neoplasia. Neurology 1987;37:129-133.
 33. Boedeker CC, Erlic Z, Richard S, et al. Head and neck paragangliomas in von Hippel-Lindau 
disease and multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 2009;94:1938- 1944.
 34. Jafri M, Whitworth J, Rattenberry E, et al. Evaluation of SDHB, SDHD and VHL gene susceptibility 
testing in the assessment of individuals with non-syndromic phaeochromocytomaand paragan-
glioma and head and neck paraganglioma (HNPGL). Clin Endocrinol (Oxf) 2013;78:898-906
18 Chapter 1
 35. Qin Y, Yao L, King EE, et al. Germline mutations in TMEM127 confer susceptibility to pheochro-
mocytoma. Nat Genet 2010;42:229-233.
 36. Abermil N, Guillaud-Bataille M, Burnichon N, et al. TMEM127 screening in a large cohort of pa-
tients with pheochromocytoma and/or paraganglioma. J Clin Endocrinol Metab 2012;97:E805-
E809.
 37. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP et al Pheochromocytoma and 
paraganglioma: an endocrine society clinical practice guideline.J ClinEndocrinolMetab. 2014 
Jun;99(6):1915-42. 
 38. Taïeb D1, Varoquaux A, Chen CC, Pacak K.Current and future trends in the anatomical and 
functional imaging of head and neck paragangliomas.Sem inNucl Med. 2013 Nov;43(6):462-
73
 39. Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C et al.Imaging work-up 
for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a 
multicenter prospective study from the PGL.EVA Investigators.J ClinEndocrinolMetab. 2013 
Jan;98(1):E162-73
 40. Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, Pacak K; NorthAmericanNeuroendocrine 
Tumour Society (NANETS).The NorthAmericanNeuroendocrine Tumour Society consensus 
guideline for the diagnosis and management of neuroendocrine tumours: pheochromocytoma, 
paraganglioma, and medullary thyroid cancer.Pancreas. 2010 Aug;39(6):775-83
 41. Favier, J., L. Amar, and A. Gimenez-Roqueplo, Paraganglioma and phaeochromocytoma: from 
genetics to personalized medicine. Nat Rev Endocrinol, 2014.
 42. Pasini, B., et al., Clinical and molecular genetics of patients with the Carney-Stratakis syndrome 
and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, 
SDHC, and SDHD. Eur J Hum Genet, 2008. 16(1): p. 79-88.
 43. Evenepoel, L., et al., Toward an improved definition of the genetic and tumour spectrum 
associated with SDH germ-line mutations. Genet Med, 2015. 17(8): p. 610-20.
 44. Van der Mey AG, Frijns JH, Cornelisse CJ, Brons EN, van Dulken H, Terpstra HL, Schmidt 
PH. Does intervention improve the natural course of glomus tumours? A series of 108 
patients seen in a 32-year period. Ann Otol Rhinol Laryngol. 1992;101:635–642. doi: 
10.1177/000348949210100802.
 45. Suarez, C., Rodrigo, J. P., Bodeker, C. C., Llorente, J. L., Silver, C. E., Jansen, J. C., . . . Ferlito, 
A. (2013). Jugular and vagal paragangliomas: Systematic study of management with surgery 
and radiotherapy. Head Neck, 35(8), 1195-1204. doi: 10.1002/hed.22976
 46. Suarez C, Rodrigo JP, Mendenhall WM, Hamoir M, Silver CE, Gregoire V, Strojan P, Neumann 
HPH, Obholzer R, Offergeld C, Langendijk JA, Rinaldo A, Ferlito A. Carotid body paraganglio-
mas: a systematic study on management with surgery and radiotherapy Eur Arch Otorhinolar-
yngol; 2014 Jan;271(1):23-34.
 47. Wilbers J, Dorresteijn LD, Haast R, Hoebers FJ, Kaanders JH, Boogerd W, van Werkhoven ED, 
Nowee ME, Hansen HH, de Korte CL, Kappelle AC, van Dijk EJ. Progression of carotid intima 
media thickness after radiotherapy: a long-term prospective cohort study. Radiother Oncol. 
2014 Dec;113(3):359-63. 
General Introduction 19
1
 48. Willen SN, E. D., Maciunas RJ, Megerian CA. (2005). Treatment of glomus jugulare tumours 
in patients with advanced age: planned limited surgical resection followed by staged gamma 
knife radiosurgery: a preliminary report. Otology & Neurotology, 26(6), 1229-1234. 
 49. Miller JP, S. M., Einstein D, Megerian CA, Maciunas RJ. (2009). Staged Gamma Knife Radiosur-
gery after Tailored Surgical Resection. Stereotactic Functional Neurosurgery, 87(1), 31-36. doi: 
10.1159/000195717
20 Chapter 1
aiM of THesis
The aim of the current thesis is to evaluate the risk associated with different treatment 
modalities for HNPGL of different sub-site and tumour class to aid the constitution of 
personalized guidelines for individualized patient management. 
ouTline of THesis
The current thesis is divided in three main parts, each covering a different subject 
crucial for HNPGL management. The first subject in modern HNPGL management is 
question whether or not treatment should be executed at all, referring to the subject 
of a wait-and-scan period. Due to the high risk of treatment induced morbidity in 
case of treatment of these tumours, such a conservative management strategy is 
elaborately advised in recent literature. The rationale being, that in this was potentially 
harmful treatment strategies can be preserved for those tumours at risk for inducing 
tumour induced morbidity. However, little is known about the risks associated with 
this management strategy and literature is sparse on this matter. Therefore, in part 
one, the clinical results of a wait and scan period are evaluated in a large retrospective 
clinical cohort study was conducted, evaluating tumour biology of HNPGL of different 
subclasses is described in form of tumour growth rates. Second, tumour induced 
morbidity is evaluated and predictors are established. Third, we evaluated the potential 
of a wait and scan strategy as a predictor for optimal timing of surgery or radiotherapy. 
The second part of this thesis focuses on the evaluation of different treatment mo-
dalities for HNPGL of different sub-site and tumour class. For each different sub-site, 
a similar methodology was used to evaluate for each individual treatment modality 
tumour control rates, complication rates and rates of functional recovery. For each 
sub-site and stratified per tumour class (the Fisch classification for GJTT and Shamblin 
classification for CBT’s) treatment outcome was first evaluated through a systematic 
review of literature. For each sub-site this was subsequently complemented by a (mul-
ticenter) retrospective cohort study evaluating our own treatment results. Hereby, a 
risk profile can be constituted per tumour class regarding the risk of morbidity for 
different treatment modalities. This can then be outweighed against the in part one 
described risk profile associated with a wait and scan cohort. 
Subsequently in part three, the management of multifocal head and neck paragan-
glioma is considered.  Currently, literature is mainly focused on treatment outcomes 
per tumour, little is known about the impact of patients suffering multifocal tumour 
presence. Therefore, we additionally compared the complication-free survival of 
patients suffering multifocal disease and those suffering multifocal tumour presence. 
Furthermore, we evaluated the complication free survival of patients suffering low 
risk- (Fisch class A and B, and Shamblin class 1 tumours ) and high-risk tumours (Fisch 
class C and D, Shamblin class 3 and Vagal body paraganglioma) as part of both unifo-
cal and multifocal disease. Also, the effectiveness of the afore mentioned treatment 
modalities on the low- and high-risk tumours is evaluated in terms of complication 
free survival
Part four of the thesis integrates the above mentioned results in a general discussion 
rendering advise for the daily practice of HNPGL management. Also, a summery is 
provided. 

PART 1
Clinical Results of a 
Wait-and-Scan Period
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absTraCT
Background: The main goal of head and neck paraganglioma (HNPGL) management 
is reduction of treatment- and tumour-induced complications. In the current study, 
tumour growth rates and tumour-induced complications, during a wait-and-scan 
period are evaluated.  
Methods: Retrospective cohort study. Tumour growth was measured in axial plane 
diameter and tumour volume. 
Results: Of 59 jugulotympanic-, 71 carotid body-, and 29 vagal body tumours , 44% 
were growing (median follow-up of 63.6 months). Median growth rates were 0.41mm/
year (range 0-439), 1.6mm/year (range 0-23.68), and 1.6mm/year (range 0-23.68) 
respectively. Growth was significantly correlated to age at presentation (OR=0.974; 
P < 0.05). Seventeen tumours induced 20 complications. Six of these tumours were 
growing, and growth rates were higher than in tumours not inducing complications 
(p = 0.016; F = 6.496). 
Conclusions: These results illustrate the feasibility  of a wait-and-scan strategy for 
HNPGL. The management strategy could not prevent tumour-induced complications 
in 16% of non-growing tumours. 
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inTroduCTion
Head and neck paraganglioma (HNPGL), are slow-growing, benign tumours with 
an indolent growth pattern, growing in close proximity to delicate neurovascular 
structures [1]. Although surgical techniques have advanced, surgery poses a threat to 
the surrounding structures and is highly  associated with morbidity, particularly due 
to cranial nerve damage [2-4]. Radiotherapeutic options have been suggested as an 
alternative and results are promising, with reduced iatrogenic morbidity. The long-term 
results of advanced radiotherapeutic options (fractionated stereotactic techniques), 
however, remain unknown and complications such as xerostomia, sensorineural hearing 
loss, vascular stenosis with consecutive CVAs, and irradiation-induced malignancies 
have been described [2, 3]. Therefore, a preceding wait-and-scan period has been 
suggested as a viable initial management strategy for HNPGL to potentially prevent 
treatment-induced morbidity [5-10]. However, leaving a tumour untreated potentially 
results in tumour-induced complications (TICs). The main reason for implementing a 
wait-and-scan period is to prevent patient morbidity (particularly in the case of multiple/
bilateral HNPGL), both iatrogenic and tumour-induced. A successful management 
strategy might be, to reserve potentially harmful treatment strategies for growing 
tumours, initiated before the growing tumour could itself induce morbidity. 
To date, no risk factors have been isolated or related to tumour-induced complica-
tions induced by a wait-and-scan period. The assumption in applying a wait-and-scan 
period is that growth is a predisposing factor for future TICs. Several factors have been 
suggested to be of influence. It has been described that intermediate-size tumours 
show enhanced tumour growth [6]. Moreover, hereditary syndromes and being of 
young age could be related to enhanced tumour growth [1, 7]. In the current study, 
we describe our results in applying a wait-and-scan policy, and evaluate the influence 
of several predictors on growth rates. Moreover, risks associated with this conservative 
management strategy are further described. Thus, the current study aims to isolate 
predictors for tumour growth and tumour-induced complications by evaluating the 
outcome of standardized wait-and-scan treatment regimen in the case of 157 tu-
mours. Hereby, we aim to contribute to the development of guidelines for HNPGL 
management. 
MeTHods
A retrospective cohort study was conducted for which records of patients presenting 
between 1980 and 2016 in the Radboudumc, the Netherlands, were accessed. All 
HNPGL cases at this location were evaluated, and a total of 358 patients were reviewed. 
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To gather data from patient files, a standardized extraction protocol was used to obtain 
the following: gender, age at presentation, symptoms at presentation, tumour type, 
genetic analysis, clinical signs for tumour progression, radiological signs for tumour 
progression, actual tumour progression in millimetres, and complications due to tumour 
growth. 
Eligibility criteria for participants were patients suffering from a jugulotympanic tu-
mour  (JTT; classified according to the Fisch class); carotid body tumour (CBT; classified 
according to Shamblin classification); or vagal body tumour ( VBT classified according 
to Obholzer et al.) [12]. Patients suffering from metastasized tumours were excluded. 
All patients were enrolled in a routine follow-up period. For the current study, in 
the case of tumour growth, follow-up was ended when the patient was treated. In 
general, patients attended a routine follow-up every year. In the main, MRI scans 
using the HNPGL-protocol were used. In cases where the tumour remained stable for 
five years, two-year follow-up intervals were considered; hereafter, five-year follow-up 
was considered. This regimen was, however, individualized depending on factors such 
as: age at presentation, mutation presence, tumour size, and comorbidities. 
The outcome assessment in this model was twofold. First, tumour growth was 
defined as the primary outcome measure, and defined in two ways by the radiologist. 
First, because the craniocaudal dimension was measured less accurately, growth rates 
were calculated from the largest increase in dimension in the axial plane. Tumour 
volume measurements were also performed according to measurements described 
by Jansen et al. [6,] in which tumours were assumed to be ellipsoid. The following 
equation was used to estimate tumour volume: V  = 4/3 *π ((1/ 2 A) * (1/ 2 B) * (1/ 2 
C)) in which ‘V’ refers to volume, ‘A’ to  the largest dimension in the anteroposterior 
direction, ‘B’ to the largest dimension in the mediolateral direction, and ‘C’ to the 
largest dimension in the craniocaudal direction. The tumour volume increase was 
extrapolated to mean/median volume increases, provided in mm3 per year. Tumour 
growth was defined as an increase of more than 15%, ascertained by a standard 
group of neuro-radiologists with expertise in this field using the same methods for 
growth evaluation, which likely decreased intra-observer variability. The second out-
come measure was tumour-induced complications (TICs), which were defined by the 
clinician as major complications attributed to tumour growth, such as (cranial) nerve 
damage (including perceptive hearing loss and vertigo), or potentially life-threatening 
complications such as respiratory distress, carotid artery compression, or brain stem 
compression. The outcome measures were assessed at every clinical contact. 
Age at presentation was a predictor of tumour growth, and was defined as age at 
first diagnosis of HNPGL. Mutation presence was defined as the presence of SDH-
associated paraganglioma syndrome (SDHA, -B, -C, -D, and AF2) gene mutations. 
Type of tumour was defined as described above. Larger tumours were Shamblin class 
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3, Fisch class C, and Obholzer class 3 tumours. For prediction of tumour-induced 
complications, tumour growth itself as a binary value, and mean percentage of spheri-
cal increase per year, was examined. 
The number of patients lost to follow-up are reported. Missing data were handled 
by using multiple imputation methods. Predictors implemented in the model were 
isolated from previous research and analyzed using multiple logistic regression. Binary 
logistic regression was employed, and the best predictive model was constituted using 
Wald backwards step-by-step variable exclusion (probability for stepwise entry was set 
at 0.05 and removal at 0.1). Internal validation was optimized using bootstrapping 
sampling techniques. 
The data was collected using FileMaker Pro, and was analysed using IBM SPSS 
Statistics 22 (IBM, Armonk, New York, United States). 
resulTs
Participants
Of 258 tumours, a total of 157 tumours were evaluated by wait-and-scan, spanning 
109 patients (61 women, 56%) with a median follow-up of 63.6 months (range, 2-260 
months). After one year, three patients were lost to follow-up (1 JTT and 2 CBTs); after 
two years one additional patient suffering a JTT was lost. After five years, 79% of JTTs, 
82% of CBTs, and 89% of VBTs (overall 86%) were still in follow-up. After 10 years, 
this rate was 41%, 43%, and 72% respectively. Of the 109 patients, median age at 
presentation was 65, and ranged from 13 to 90. Mutations were related to 93 tumours 
(59%); 42% were SDHD; 9.6% were SDHA; 7% SDHAF2; and 2.5% were SDHB and 
0.6% SDHC. Further baseline characteristics are presented in table 1.
Age of presentation was significantly related to hereditary tumour syndromes (p = 
0.016 CI:-16- -6). The median age at presentation when a mutation was present was 
41.01 (SD13.7), and 52 (SD 17.6) when there was no mutation present. 
Tumour growth
As demonstrated in table. 1, 70 of the 157 tumours (44%) grew. For all tumours, median 
follow-up was 51 months, (range, 6-261 months) (20 years). Non-growing tumours had 
a median follow-up of 57 months (range, 6-261 months). In cases of tumour growth, 
follow-up was measured until the point of treatment, and median follow-up was 35 
months (range, 0.9-131 months). Tumour growth was generally found after 32 months 
(range, 0.5-131 months). Overall, 90% of tumours showed growth within 52 months. 
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Median growth rates were 0.41mm/year (range 0-439) for JTT; 1.6mm/year (range 
0-23.68) for CBTs; and 1.6mm/year (range 0-23.68) for VBTs. Using a one-way anova, 
there was no significant difference between tumour growth rates for different tumour 
types (df = 2, F=1.87, p = 0.157). In the case of tumour growth, average growth rates 
were 2.68 (range 1.23-4.9), 6.36 (range 0.29-23.68), and 10.9 (range 2.57-23.62) 
mm/year respectively. Again, there was no significant relation (df = 2, F=1.89, p = 
0.171). Median percentage spherical volume increases in mm3/year were 31.2 (13-53), 
37.39 (10-97,) and 25 (15-42), for JTT, CBT, and VBTs respectively (df = 2, F=1.92, p 
= 0.671). 
Furthermore, we found a significant relation between tumour growth incidence 
and age at presentation (t=-2.46, df 145, p = 0.015). In investigating a cut-off point, 
a Chi square test revealed that growth incidences were significantly higher when 
patients presented before the age of 50 (58.6%) versus patients presenting later in 
life (31.7%; df = 1, p = 0.001). Furthermore, using a Pearson’s Correlation test, we 
found a significant inverse correlation between age at presentation and growth rates, 
measured both in median spherical volume increase per year (p=0.011; r = -0.439); 
and growth in mm/year (p = 0.021; r = -0.237). The younger the patient, the higher 
the volume increase per year (figure 1).  Using logistic regression analysis, we found 
that age at presentation remained a significant predictor of growth after stepwise 
adjustment for the potential confounders of age, mutation, tumour type, and tumour 
size (B=-0.026; OR=0.974; P < 0.05). 
The accuracy with which age predicts tumour growth was evaluated using an ROC 
curve, for which an AUC of 0.629 was found, indicating poor predictive value. When 
Figure 1: growth rate and age of presentation
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determining a cut-off point, we found that being younger than 50 is associated with 
significantly higher growth rates when compared to baseline growth rates. 
Moreover, we found that there is no significant relation (p= 0.31; df 1) between 
mutation presence and tumour growth incidence (65.7 versus 57.7%) or growth 
rates, when compared to the no-mutation group (median 39.7 mm3/y versus 21.38 
mm3/y; p = 0.064). 
Complications 
Tumour-induced complications are presented in table 2. Of 17 tumours inducing 20 
complications, six  were growing, and these illustrated a significantly higher tumour 
growth rate when compared to those not presenting complications (75.6 mm3/y versus 
30.3 mm3/y resp.; p = 0.016; F = 6.496). However, using a logistic regression, with 
step-by-step correction for the confounder’s age, mutation presence, and tumour 
type and size, tumour growth rate was not found to be an independent predictor for 
tumour complications (B=11.418; OR=90937,576; P = 0.963). Moreover, we did not 
find higher complication rates in younger patients or patients with a mutation; nor 
was there a relation between type of tumour and complications. We further stratified 
our results for larger tumours such as Fisch class D, Shamblin class 3, and Vagal class 
3 tumours, and again no relation was found (results not shown). Eleven tumours were 
not growing, of which six (55%) illustrated a tumour syndrome, and seven (64%) were 
larger-size tumours.
Table 2: Number of tumour induced complications
Complication No. Total No. growing tumours 
(% of total)
Local complications due to tumour mass 7 2 (28)
Perceptive hearing loss 5
Carotid stenosis 1 1 (100)
Tracheotomy 1 1 (100)
Cranial nerve paresis 13 4 (31)
VII paresis 2
IX paresis 1
X paresis 5 2 (40)
XI paresis 1
XII paresis 2 2 (100)
Total 20 6 (30)
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Motivation for secondary intervention 
A total of 52 patients underwent additional treatment. The main reasons for intervention 
were: reported growth (44%); tumour-induced complications (50%); and patient prefer-
ence (6%). For 31 tumours in which growth was found (out of a total of 70 growing 
tumours), no intervention was executed and no complications due to tumour growth 
found after a median follow-up of 36 months (range 8-72). Fourteen (45%) of these 
were smaller tumours. The mean age at presentation in this group was 47, and in 65% 
mutations were found (these differences were not statistically significant). Moreover, 
in 14 patients, multifocal HNPGL disease was found. Reasons for non-intervention 
were: small tumour without morbidity (39%); prevention of bilateral CN damage in 
the case of bilateral HNPGL (32%); patient preference (20%); and patient not fit for 
treatment (10%). 
In the case of secondary treatment due to TICs, for two patients’ cranial nerve func-
tion improved post treatment: one facial nerve paresis (House-Brackmann 3) in a Fisch 
class C3 tumour improved after an inftratemporal fossa approach with facial nerve 
rerouting. After an initial decline to full facial paralysis, 11 months postoperatively a 
House-Brackmann grade 1 facial paralysis was found. In the second case, a jugulo-
tympanic tumour Fisch class C1 was treated with gammaknife, rendering full regain of 
function of an initial IX, X, and XI pareses approximately 10 months’ post treatment.  
disCussion 
This study illustrates the feasibility of a wait-and-scan period as the primary management 
strategy for HNPGL. Evaluating 157 HNPGLs, we found tumour growth in 44% of cases 
after a median follow-up of 63.6 months (range, 2-260 months). Tumour-induced 
complications were found in 12% of patients, and all received consecutive treatments, 
rendering regain of CN function in 2 patients (and 4 cranial nerves). Overall, 51 patients 
(32%) were treated, and for  67% of patients, a potentially harmful treatment regimen 
was prevented.
In cases of TICs, growth rates were significantly higher when compared to patients 
remaining free from TICs. On the other hand, the presence of tumour growth itself 
– as opposed to growth rate – was not a risk factor for TICs. Furthermore, we found 
that in 14 out of 20 complications, no radiological growth was found; neither was 
any relation between age of presentation, mutation presence, tumour type, or tumour 
size found in this sub-population. On the other hand, 31 out of 70 growing tumours 
were not treated, and no complications were found after a median follow-up of 36 
months. 
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We could not associate genotype, tumour type, or tumour class with either tumour 
growth or TICs. The age of presentation, however, was an independent predictor of 
tumour growth and showed a significant inverse correlation with growth rates: the 
younger the age of presentation, the higher the growth rate. In investigating the 
cut-off point determining higher growth rates and incidences, we found that being 50 
years of age or younger was associated with higher growth incidence, when compared 
to being older than 50. These results suggest that an initial wait-and-scan strategy is 
a feasible management strategy for HNPGL of different subclasses, whereby poten-
tially harmful treatment regimens are reserved for those patients suggested to be at 
risk of high morbidity by established tumour growth. The management strategy as 
presented by the current authors could not prevent TICs, as complications were found 
in 17% of non-growing tumours. However, the risk of treatment with radiotherapy 
and surgery is potentially higher. Systematic reviews have illustrated that there is no 
significant difference in tumour control rates between radiotherapy and surgery. The 
risk of complications such as cranial nerve damage has been found to be 0.9 per 
patient post surgery, and 0.08 post radiotherapy [2,3]. For Shamblin class 2 and 3 
tumours, these reviews have illustrated that surgery induced new cases of permanent 
cranial nerve deficit in 22% of 2175 patients; before radiotherapeutic treatment, a 
total of two cranial nerves were affected, which decreased to one post-radiotherapy. 
The follow-up rates of the studies included in these reviews were variable, and all 
radiotherapeutic techniques were pooled in this analysis. A more recent large study 
evaluating the long-term effects of radiotherapy in 131 patients with 156 benign 
paragangliomas however, describes no severe complications post treatment with 
a minimal follow-up of 11.5 years [13]. Considering these results, the risk of TIC 
brought about by an initial wait-and-scan policy should be weighed against the risk 
of treatment, of which radiotherapy seems to be the better option. Physicians taking 
this approach should recognize that cranial nerve deficits that may result from tumour 
progression are potentially more permanent, and should be weighed against the 
morbidity of radiotherapy [13]. Therefore, a wait-and-scan policy can be considered 
a viable treatment option, particularly when radiotherapy is not a treatment option. 
Tumour-induced complications
To date, it remains uncertain which factors might generate an enhanced risk of complica-
tions. Several studies have described the results of a wait-and-scan approach, and these 
found a wide variety of complication incidences (4-30%); tumour growth incidences 
also widely differed, at between 5 and 60% [5,7-10]. Methodological differences in 
growth estimation and small sample sizes, however, make it hard to interpret these 
results. Considering the results of the current study, it seems reasonable to suggest two 
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main mechanisms as being responsible for TICs. The first of these is enhanced tumour 
growth. Although this was not an independent predictor of complications, tumour 
growth rates in patients suffering TICs were significantly higher when compared to 
baseline growth rates. 
The overall median growth rate found in our study (1.09), is similar to that described 
by Jansen et al. (0.83), who used the same methods for volume estimation [6]. Sec-
ondly, although we could not predict TICs, we did find that age of presentation was 
an independent predictor of tumour growth, and being 50 years or younger was 
associated with significantly higher growth rates. Huy et al. suggested such a relation, 
based on the observation that patients presenting before the age of 20 generally 
suffered from larger C3De-type jugular paraganglioma, rather than jugular tumours 
of a lower Fisch class [11]. The finding was, however, not statistically verified. We have 
found no other reports describing age of presentation and paraganglioma growth 
rates. An important consideration in interpreting these results is that we also found 
that patients with a mutation presented at a younger age in general, which might 
mean that mutation presence is a confounder. Nonetheless, we corrected for muta-
tion presence in the analysis, and found that it could not be associated with growth 
or the incidence of complication. Obviously, we cannot exclude the possibility that 
patients presenting at a younger age (and with higher growth rates) in our series did 
not suffer from a hitherto unknown tumour syndrome. This is particularly likely given 
that previous reports have illustrated that 25-56% of apparently sporadic tumours 
do in fact turn out to be part of a tumour syndrome [14-16]. Nonetheless, in the 
current series, all patients were subjected to a careful diagnostic work-up process, 
in which screening for hereditary syndromes is common practice. Furthermore, we 
also found that, in line with Jansen et al., when comparing different tumour loca-
tions, jugulotympanic paragangliomas tended to be smaller and less progressive than 
paragangliomas developing at other locations.
As we also found that in 64% of TICs no growth was found, we suggest that there 
must in fact be a second mechanism involved in TICs, other than tumour growth. It is 
suggested that there is a form of tumour activity resulting in local invasiveness rather 
than expansion, which has been described regarding HNPGL in the past. Although 
this is a mechanism that has been described before, it is one which has usually been 
attributed to the presence of more aggressive tumour types [17, 18] and genotypes 
[19]. In the current study however, we could not find a relationship with tumour type 
or the presence of mutation. Neither was age of presentation related to complications 
in this group. However, it should be noted that this finding concerns just 11 cases in 
total, which might hinder robust statistical analysis.
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Methodological considerations
There are several methodological considerations which merit discussion. The problem 
with research of rare conditions is the fact that RCTs are largely not feasible. The current 
study is a retrospective cohort study, and therefore the level of evidence provided 
remains at level 2. With respect to HNPGL research, tumour incidence, low tumour 
growth rates, and ethical considerations all combine to make  comparison between 
different prospective management strategies especially difficult. This tends to reduce 
external validity. Therefore, the current data on success rates is mainly a reflection of 
the clinical outcomes of the current centre. Nonetheless, a protocol for the employed 
wait-and-scan policy administered by our centre is provided in the Methods section.
Another important aspect is tumour growth evaluation, for which we used two dif-
ferent methods: increase per year (assessed in millimetres); and volume determination. 
It has been suggested that growth should be evaluated in three dimensions, since 
volume estimates are more reliable than two-dimensional measurements; and that 
HNPGL could be assumed to be conical [6, 20, 21]. For JTTs such an ellipsoid shape 
might not be applicable, since these tumours are largely confined to the confirmation 
of the petrous bone. 
Another limitation of this study is the follow-up interval. The mean follow-up 
interval was 51 months (range, 6-261 months). It should be noted that we found 
tumour growth up until the 245-months (20 years) mark. Given that 90% of tumours 
presented growth within 52 months, it is likely that tumour growth will be apparent 
in these cases in the future, and that such patients are to be subject to treatment 
regimens. Furthermore, in the current protocol we found that although growth rate 
is associated with complications, it should not be considered as the sole predictor 
of TICs. In this vein, we found that in none of the non-treated growing tumours 
were complications found; and in 65% of complication cases, no tumour growth 
was reported. Therefore, additional research is required into predictive parameters for 
what tumour traits are responsible for the induction of complications. 
The current study sample is subject to loco-regional factors, potentially resulting 
in a relative overrepresentation of hereditary syndromes, such as SDHA, AF2, and 
D tumour syndromes. This might also have rendered the current study population 
relatively young, due to familial screening programmes. 
ConClusion
The results of this study illustrate that a wait-and-scan policy is a feasible treatment 
option in cases for HNPGL, as it potentially prevents treatment-induced morbidity in 
the majority of patients, including those presenting larger tumours. It is suggested this 
Feasibility of a Wait-and-Scan Period as Initial Management Strategy for Head and Neck Paraganglioma 37
2
option should, therefore, be carefully weighed against the risks of alternative options 
such as radiotherapy. Moreover, the study suggests that the wait-and-scan policy should 
be altered for patients of 50 years or younger, by decreasing the follow-up interval 
between scans to evaluate tumour biology more closely. Our results also suggest that 
radiological follow-up is not an optimal management strategy, since a large group of 
tumours were found not to grow, though they did elicit complications, in the main, 
years after the initial diagnosis. Issuing long-term follow-up protocols, and careful 
clinical examination, should therefore remain crucial aspects of HNPGL management, 
in order to prevent TICs. No evidence was found for altering the wait-and-scan regime 
in cases where other theoretical risk factors are found to be present, such as hereditary 
tumour syndromes, and particular tumour types and sizes.
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PART 2
The Evaluation of Different Treatment Modalities for Head and 
Neck Paraganglioma of Different Sub-Sites and Tumour Class
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absTraCT
Objective: Key for successful jugulotympanic paraganglioma management is a personal-
ized approach aiming for the best practice for each individual patient. To this end, a 
systematic review is performed, evaluating the local control- and complication rates for 
the different treatment modalities stratified by the broadly accepted Fisch classification. 
Design: A systematic literature review according to the PRISMA statement was per-
formed. A detailed overview of individual treatment outcomes per Fisch class is provided. 
Main outcome measures: local control, cranial nerve damage, complications, function 
recovery. 
Results: Eighteen studies were selected, resembling 83 patients treated with radiotherapy 
and 299 with surgery. Excellent local control was found post surgery for class A and 
B tumours and risk of cranial nerve damage was <1%. For class C1-4 tumours, local 
control was 80-95% post surgery (84% post radiotherapy) and, cranial nerve damage 
was found in 71-76% (none post radiotherapy; p < 0.05). There was no difference 
in treatment outcomes between tumours of different C class. For class C1-4De/Di 
tumours, local control was 38-86% (98% post radiotherapy; p < 0.05) , cranial nerve 
damage/complication rates were 67-100% (3% post radiotherapy; p < 0.05). C1-4DeDi 
tumours showed lesser local control and cranial nerve damage rates when compared 
to C1-4De tumours. 
Conclusions: An individual risk is constituted for surgery and radiotherapy, stratified 
per Fisch class. For class A and B tumours surgery is a suitable treatment option. For 
class C and D tumours radiotherapy results in lower complication rates and similar or 
better local control rates when compared to the surgical group. 
Keywords: review, treatment, jugulotympanic, paraganglioma, Fisch class
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inTroduCTion 
Paragangliomas of the head and neck (HNPs) are rare, comprising about 0.6% of 
head and neck tumours and 0.03% of all tumors1. Thirty percent of HNPGLs are 
jugulotympanic tumors2. Jugulotympanic paragangliomas (JTPGL) are slow growing 
neuro-endocrine tumours that are benign in almost all cases. Despite the benign nature, 
symptomatology can be considerable and is mainly caused by growth towards delicate 
surrounding structures such as cranial nerves (CN) and large vessels. However, their 
indolent growth pattern makes it difficult to predict if and when these tumours will 
become clinically apparent; some tumours cause CN damage or invade the intracranial 
space, while others show spontaneous regression3. 
It is due to the rarity of paragangliomas, and their variable yet potentially debilitat-
ing clinical presentation that the management of these tumours remains a matter of 
debate. The more since the main treatment options considered for JTPGL, surgery and 
radiotherapy, may also cause cranial nerve damage or other serious adverse effects. 
Therefore, if clinical presentation does not require immediate therapy, most authors 
recommend an initial “wait and scan” strategy2,4,5,6. However, in case active interven-
tion is advised, it remains uncertain what the best practice would be since each treat-
ment modality has its limitations: Traditionally, surgery is considered the number one 
treatment option as it actually removes tumour mass7. However, recent developments 
have advocated the role of radiotherapy as it renders comparable local control rates 
and less iatrogenic cranial nerve damage or other complications such as cerebrospinal 
fluid leakage, wound infection or a stroke8. The long term risks of radiotherapy in 
terms of sensorineural hearing loss, tissue necrosis or irradiation induced malignancies 
remain uncertain however. 
It is clear that for JPGL there is no “one fits all” approach and the key for successful 
JPGL management, is a personalized approach, aiming for the best practice for each 
individual patient. In order to achieve this, a better understanding of the risks associ-
ated with treatment of each tumour class is required. Therefore, a systematic review 
is performed, evaluating the local control- and complication rates for the different 
treatment modalities stratified by the broadly accepted Fisch classification. 
MeTHods
ethical considerations
This study was conducted in line with the ethical guidelines of the Radboud University 
Medical Centre, the Netherlands.
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search protocol
We performed a systematic literature review according to the PRISMA statement9. We 
searched the Pub Med Database for articles using the following search strategy (no 
Mesh terms were used for inclusion of the most recent articles): 
(((Treatment [Title/Abstract] OR Treatment [MeSH Terms] OR Management [Title/Abstract] OR 
Management [MeSH Terms] OR therapy [Title/Abstract] OR therapy [MeSH Terms] OR approach [Title/
Abstract] OR approach [MeSH Terms] OR procedure [Title/Abstract] OR procedure [MeSH Terms] OR 
Radiotherapy [Title/Abstract] OR Radiotherapy [MeSH Terms] OR radiation therapy [Title/Abstract] OR 
radiation therapy [MeSH Terms] OR X-ray therapy [Title/Abstract] OR X-ray therapy [MeSH Terms] OR 
radioisotope therapy [Title/Abstract] OR radioisotope therapy [MeSH Terms] OR Radiosurgery [Title/
Abstract] OR Radiosurgery [MeSH Terms] OR Gamma Knife [Title/Abstract] OR Gamma Knife [MeSH 
Terms] OR CyberKnife [Title/Abstract] OR CyberKnife [MeSH Terms] OR Linear Accelerator [Title/
Abstract] OR Linear Accelerator [MeSH Terms] OR Linac [Title/Abstract] OR Linac [MeSH Terms] OR 
LINAC [Title/Abstract] OR LINAC [MeSH Terms] OR Surgery [Title/Abstract] OR Surgery [MeSH Terms] 
OR operative [Title/Abstract] OR operative [MeSH Terms] OR invasive [Title/Abstract] OR invasive 
[MeSH Terms] OR operations [Title/Abstract] OR operations [MeSH Terms] OR peroperative [Title/
Abstract] OR peroperative [MeSH Terms] OR perioperative [Title/Abstract] OR perioperative [MeSH 
Terms] OR intraoperative [Title/Abstract] OR intraoperative [MeSH Terms] OR excision [Title/Abstract] 
OR excision [MeSH Terms] OR resection [Title/Abstract] OR resection [MeSH Terms] OR Wait and scan 
[Title/Abstract] OR Wait and scan [MeSH Terms] OR Wait and see [Title/Abstract] OR Wait and see 
[MeSH Terms] OR Conservative [Title/Abstract] OR Conservative [MeSH Terms] OR Expectative [Title/
Abstract] OR Expectative [MeSH Terms] OR Embolotherapy [Title/Abstract] OR Embolotherapy [MeSH 
Terms] OR Embolization [Title/Abstract] OR Embolization [MeSH Terms] OR Occlusion [Title/Abstract] 
OR Occlusion [MeSH Terms]))) AND (((((((Tumour [Title/Abstract] OR Tumour [MeSH Terms] OR Tumour 
[Title/Abstract] OR Tumour [MeSH Terms] OR Tumours [Title/Abstract] OR Tumours [MeSH Terms] OR 
Tumours [Title/Abstract] OR Tumours [MeSH Terms]))) AND ((Carotid body [Title/Abstract] OR Carotid 
body [MeSH Terms] OR Vagal body [Title/Abstract] OR Vagal body [MeSH Terms])))) OR ((((Jugulare 
[Title/Abstract] OR Jugulare [MeSH Terms] OR Caroticum [Title/Abstract] OR Caroticum [MeSH Terms] 
OR Carotis [Title/Abstract] OR Carotis [MeSH Terms] OR Vagale [Title/Abstract] OR Vagale [MeSH Terms] 
OR temporale [Title/Abstract] OR temporale [MeSH Terms] OR jugulotympanicum [Title/Abstract] OR 
jugulotympanicum [MeSH Terms] OR tympanicum [Title/Abstract] OR tympanicum [MeSH Terms]))) 
AND ((Glomus [Title/Abstract] OR Glomus [MeSH Terms])))) OR ((((Head and neck [Title/Abstract] OR 
Head and neck [MeSH Terms] OR Cervical [Title/Abstract] OR Cervical [MeSH Terms] OR Temporal [Title/
Abstract] OR Temporal [MeSH Terms] OR Jugular [Title/Abstract] OR Jugular [MeSH Terms] OR Tympanic 
[Title/Abstract] OR Tympanic [MeSH Terms] OR jugulotympanic [Title/Abstract] OR jugulotympanic 
[MeSH Terms] OR Carotid [Title/Abstract] OR Carotid [MeSH Terms] OR Carotis [Title/Abstract] OR 
Carotis [MeSH Terms] OR Vagal [Title/Abstract] OR Vagal [MeSH Terms]))) AND ((paraganglioma [Title/
Abstract] OR paraganglioma [MeSH Terms] OR paragangliomas [Title/Abstract] OR paragangliomas 
[MeSH Terms] OR chemodectoma [Title/Abstract] OR chemodectoma [MeSH Terms] OR 
chemodectomas [Title/Abstract] OR chemodectomas [MeSH Terms] OR glomus tumour [MeSH Terms] 
OR glomus tumour [Title/Abstract] OR glomus tumours[Title/Abstract] OR glomus tumours [MeSH 
Terms] OR glomus tumour [MeSH Terms] OR glomus tumour [Title/Abstract] OR glomus tumours[Title/
Abstract] OR glomus tumours [MeSH Terms]))))
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eligibility Criteria
Criteria for eligibility according to the PICO methodology were used8: The investigated 
population constituted of patients affected by JPGL, stratified by Fisch class (table 1)9. 
The intervention was any form of surgery or radiotherapy, with or without a prior “wait 
and scan” period. The results of treatment outcome were compared to the patients’ 
situation before treatment. Treatment outcomes were local control, cranial nerve 
function and complications. The definitions of control and complications were adopted 
from Suarez et al.7. Post surgery, local control was defined as a patient alive without 
evidence of disease throughout the entire follow-up period. Symptom relief, e.g. in form 
of decompression of tumour mass, was not considered as local control in the current 
study. Post radiotherapy local control was defined as a patient alive with regression 
of the tumour, or without any evidence of progression of the disease throughout the 
entire follow-up period. CN damage was defined as deterioration of CN function post 
treatment when compared to the pre-treatment setting, substantiated by a physician. 
Symptom recovery was defined as any improvement of CN function in post treatment 
setting when compared to pre-treatment conditions, substantiated by a physician. 
For class A and B tumours, post-treatment hearing loss and tinnitus was considered 
a treatment outcome as well. The complications CSF leakage, wound infection, CVA, 
aspiration resulting in pneumonia and/or tracheotomy and death were included. 
study selection 
To be selected, articles had to be written in English, German, French or Spanish. Mean 
follow-up had to be at least 12 months for both treatment modalities. The short term 
results of radiotherapy (1 year post treatment), were compared with those 5, 7 and 10 
years post treatment. The tumours had to be classified according to the Fisch classifica-
tion or we personally classified the tumours in case sufficient diagnostic information 
was provided. The treatment modality (surgery, radiotherapy technique) and outcome 
measures had to be reported for each Fisch class separately. To evaluate results of 
Table 1: Fisch classification.
Tumour class Location and extension of tumour
A Tumours that arise along the tympanic plexus on promontory
B Tumours with invasion of hypotympanum; cortical bone over jugular bulb intact
C1 Tumours with erosion of carotid foramen
C2 Tumours with destruction of carotid canal
C3 Tumours with invasion of carotid canal; foramen lacerum intact
C4 Tumours with invasion of foramen lacerum and cavernous sinus
De Tumours with intracranial but extradural extension
Di Tumours with intracranial and intradural extension
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radiotherapy, we pooled C1-4 tumours as “class C tumours”, and C1-4De1-2/Di1-2 
tumours as class D tumours. For evaluation of surgical results however, results were 
presented individually. Information on at least one of the afore-mentioned outcome 
measures had to be described. This selection procedure was executed twice by the 
researcher (first author). In case of discordance, the issue was discussed with supervising 
authors (Kunst, Marres). 
risk of bias in individual studies
A critical appraisal per study was performed, with respect to risk of bias using the 
PRIMSA ‘Risk of bias’ tool. The following terms were addressed: random sequence 
generation, allocation concealment, blinding of participants and personnel, blinding of 
outcome assessment, incomplete outcome data, selective reporting and other forms of 
bias. The majority of the studies did not comply with PRIMSA and therefore we decided 
not to use this as an exclusion criterion.
risk of bias across studies and synthesis of results 
It was evaluated whether the study properly addressed the research question and the 
inclusion of subjects was assessed. Pooled results of all studies are presented, as well 
as the individual study results in Appendix A. Hereby, the internal and external validity 
of the current research was enhanced. Pooled results were provided in mean, actual 
numbers and range.  
resulTs
study selection 
Figure 1 illustrates the flow chart of study selection. Using the above mentioned research 
question 3505 articles were identified. These were screened for title and abstract, and 
a total of 81 articles were selected for full article review. Most articles were excluded 
based on different anatomical tumour localization. Out of these 81 articles, 63 articles 
were excluded mostly because results were not stratified per Fisch class. Three were 
excluded due to small sample sizes, and four were excluded due to insufficient follow-up. 
Ultimately, 18 studies were selected for the current review. 
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surgical results 
For class A and B tumours, 100% local control and no complications were found. A 
single case of NVII damage was described in a class B tumour and no cranial nerve 
damage was found for class A tumours. Post treatment, improvement of hearing loss 
and pulsatile tinnitus was found in 0%-23% (mean 11%) for class A tumours, and in 
0%-8% (mean 3%) for class B tumours.  
Surgical results for class C and D tumours are presented in figure 2,and table 3, 
describing the local control and cranial nerve damage rates per tumour class. Unfor-
tunately, complication rates, other than cranial nerve damage, were not stratified suf-
ficiently to present per Fisch class. The main complications and cranial nerve damage 
rates found for class C and CD tumours combined are presented in table 2. Symptom 
recovery was described in 2 patients (1%)post surgery. 
Figure 1: flow chart
Figure 2: local control and cranial nerve damage rates per tumour class
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A significant correlation was found between local control and cranial nerve damage 
rates and increasing Fisch class (df 11, p = 0.00; df 11, p = 0.001). Using a bonferroni 
post test, we found that having a C4DeDi tumour shows significantly worse local 
control rates when compared to tumours of lower Fisch class. For Fisch class C1-4 
tumours (without intracranial invasion), local control rates, cranial nerve damage rates 
and complication rates were not significantly related to increasing C class (df 3, p = 
0.307; df 3 p = 9.997; df 3 p = 0.7). Within class D tumours, intra-dural invasion was 
related to lesser local control rates (df1, p = 0.004) and higher cranial nerve damage 
rates (df1, p = 0.005) when compared to extradural growing tumours, independent of 
C-classification. There was no increased risk of complications in this group. 
radiotherapy results
Short and long term local control rates post radiotherapy are presented in figure 3. 
There was no significant difference between results of class C and D tumours (F = 0.054, 
p = 0.82), neither was there a difference in local control or cranial nerve damage /
complication rates in 1 versus 5 (p = 0.9; p =0.7), 7 (p = 0.99; p =0.8) and 10 (p = 0.6; 
p =0.5) years post treatment in general, nor for class C and D tumours individually. 
In 13 patients (16%) of all irradiated patients, symptom recovery was found post 
treatment.  A n. VII palsy and complete sensorineural hearing loss was found post-irra-
diation of 2 class D tumours. No further complications were found post-radiotherapy 
in the included studies. 
Comparison of treatment modalities
In table 3 the differences in treatment outcome per treatment modality are provided, 
stratified per tumour class. For class C 1-4 tumours, local control rates did not differ 
Table 2: complications and cranial nerve damage rates
Complications found (%) N/Ntotal
CSF leak 14 (43/299)
Stroke 5 (16/299)
Wound infection 3 (9/299)
Tracheotomy 2 (6/299)
Bleeding 1 (1/299)
N. VII palsy 18 (54/299)
N. VIII palsy 3 (9/299)
N. IX palsy 23 (69/299)
N. X palsy 21 (63/299)
N. XI palsy 13 (39/299)
N. XII palsy 3 (9/299)
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Figure 3: Short and long term results post radiotherapy
Table 3: Differences in treatment outcome per treatment modality, stratified per tumour class.
Local control Cranial nerve damage/ complications
Surgery Radiotherapy 
(long term results)
Surgery vs. 
Radiotherapy
Surgery Radiotherapy 
(long term results)
Surgery vs. 
Radiotherapy
% (N/Ntotal) % (N/Ntotal) P value % (N/Ntotal) % (N/Ntotal) P value
A 100 (84/84) - - 0 (0/84) - -
B 98 (39/40) - - 6 (3/47) - -
C1 95 (40/42) 84 (13/15) 0.6 71 (25/35) 0 (0/15) 0.00
C1De 86 (19/22) 98 (65/66) 0.04 83 (4/17) 3 (2/66) 0.00
C1DeDi 75 (6/8) 98 (65/66) 0.13 75 (6/8) 3 (2/66) 0.00
C2 95 (39/41) 84 (13/15) 0.28 76 (19/25) 0 (0/15) 0.00
C2De 84 (26/31) 98 (65/66) 0.01 100 (12/12) 3 (2/66) 0.00
C2DeDi 71 (17/24) 98 (65/66) 0.00 80 (12/15) 3 (2/66) 0.00
C3 92 (12/13) 84 (13/15) 0.64 75 (6/8) 0 (0/15) 0.00
C3De 85 (11/13) 98 (65/66) 0.01 100 (4/4) 3 (2/66) 0.00
C3DeDi 66 (35/53) 98 (65/66) 0.00 69 (9/13) 3 (2/66) 0.00
C4 80 (4/5) 84 (13/15) 0.78 75 (3/4) 0 (0/15) 0.04
C4De 71 (5/7) 98 (65/66) 0.02 83 (5/6) 3 (2/66) 0.00
C4DeDi 38 (8/21) 98 (65/66) 0.00 67 (2/3) 3 (2/66) 0.014
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significantly from long term radiotherapy results, yet cranial nerve damage rates were 
significantly higher post surgery. For class De/DeDi tumours local control and cranial 
nerve damage rates were significantly worse post surgery when compared to results 
of radiotherapy.
disCussion
summary of main results 
The current review evaluates the effect of radiotherapy and surgery on JTPGL of dif-
ferent Fisch class, in order to gain insights for individualized JTPGL management in the 
future. Although surgical procedures varied, class A and B tumours seem to be properly 
managed surgically with respect to local control, cranial nerve damage and complication 
rates. Presenting symptoms like conductive hearing loss and pulsatile tinnitus generally 
persisted post-operatively. Few articles described the effect of radiotherapy on class 
A and B tumours, therefore more research is required on this matter. For class C and 
D tumours, surgical treatment outcomes were less uniform between studies. A wide 
range of local control rates between studies was found as well as a higher risk of cranial 
nerve damage and complications when compared to radiotherapy. Overall, these results 
provide valuable insights for JTPGL management in daily practice: Based on the current 
evidence, early surgery is advised for class A and B tumours. For class C1-4 tumours 
local control was similar to radiotherapy results, yet radiotherapy had significantly 
lower morbidity rates. For class C1-4De/Di tumours both local control and morbidity 
rates were more favourable post radiotherapy. Therefore, in case treatment is required, 
radiotherapy is suggested as the favourable treatment option, albeit both treatment 
modalities potentially induce iatrogenic morbidity. A dual approach suggesting tumour 
debulking and occasional additional radiotherapy is discussed underneath. 
overall completeness and applicability- and quality of evidence; 
Inevitably, the level of evidence for these recommendations is low. There are no random-
ized controlled trials available on this subject. Also, there are no studies that used proper 
control-groups evaluating two treatment modalities. All studies were retrospective of 
nature with inherent biases of all sorts. In order to reduce the interpreters-bias, we 
conducted our research according to the methodology of the PRISMA statement. 
Moreover, we provided the study details of each study separately, including the meth-
odology of the study and the results of a critical appraisal. Hereby, studies could be 
assessed for reliability/methodological quality and the impact can be regarded in the 
context of other studies. 
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Potential biases in review 
A potential bias in this study is that we did not stratify for additional treatments other 
than radiotherapy and surgical techniques. The influence of pre-treatment embolization 
was not considered.  Nonetheless, whether or not these techniques were used was 
presented in the table.  
Also, we did not stratify our results for tumours with hereditary biology for which 
counselling might be different due to a higher chance of multiple HHPGL’s during a 
patient’s life. Also, the growth rate of these tumours differs and might alter counsel-
ling of patients. 
Comparison with other reviews 
There are two main reviews conducted on this matter subject and the treatment 
outcomes are in line with the current review. First, Suarez et al. described for a total of 
1084 patients with JPGs with different surgical procedures that control of the disease 
was achieved in 93.3% of patients7. A total of 715 patients with JPG were treated 
with radiotherapy: 461 with EBRT and 254 with SRS. Control of the disease with both 
methods was obtained in 89.1% and 93.7% of the patients, respectively. The treatment 
outcomes of a JPG treated with surgery or radiotherapy were compared. The control 
failure, major complication rates, and the number of cranial nerve palsies after treatment 
were significantly higher in surgical than in radiotherapy series. Unfortunately however, 
treatment outcomes are not stratified per Fisch class which hinders individual patient 
counselling. A second review was conducted by van Hulsteijn et al., which provided an 
overview of regression rates after radiotherapy in HNPGLs by means of a meta-regression 
analysis23. Fifteen studies were included, concerning a total of 283 jugulotympanic 
HNPGLs. Pooled regression proportions for initial, combined and salvage treatment 
were respectively 21%, 33% and 52% in radiosurgery studies and 4%, 0% and 64% 
in external beam radiotherapy studies. Pooled local control proportions for radiotherapy 
as initial, combined and salvage treatment ranged from 79% to 100%. Again, results 
were not stratified per tumour class, yet cranial nerve damage-, complication- and 
recovery rates are not reported in this review. 
implications for clinical practice and research 
The biology of paragangliomas has proven to be unpredictable, and spontaneous 
(partial) regression has been described3,6. This, as well as the fact that cranial nerve 
damage and complication rates post treatment are not trivial, support an initial conserva-
tive wait and scan management for class C and D tumours. Studies that describe the 
experience with a wait and scan strategy (excluding patients with brainstem compression 
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or malignant disease) illustrated that merely 20-60% of HHPGL showed further tumour 
growth, and that additional treatment was required in only 0-5% of patients due to 
progression of existing cranial nerve damage without tumour growth4,5,6,24. Huy et al. 
noted that particularly in younger patients, tumour progression rates might be higher, 
and therefore, wait and scan might be less favorable25. Conversely, Carlson et al. found 
that there was a trend toward higher rates of tumour progression in patients who were 
followed longer—a finding that was also reported by Prasad et al.4,24. Therefore, more 
information on the risks of wait and scan procedures is required. However, given the 
complication rates post class C and D tumour treatment, we believe that an initial wait 
and scan strategy is justified also for younger patients, particularly since younger patients 
have a higher life-time risk of radiation-induced malignancy and other complications 
such as atherosclerosis of the carotid artery and subsequent ischemic stroke. 
Our results demonstrate that if a conservative management strategy does not suffice 
in the case of class C and D tumours due to tumour progression, one should consider 
the use of radiotherapy over surgical management. The current results show that 
chances for achieving local control with surgery are unsatisfactory for class D tumours 
and for both C and D tumours at least transient cranial nerve damage seems inevi-
table and complications occur frequently. No difference was found between C class 
1-4 tumours, and in case of intracranial invasion intradural growth was associated 
with lesser local control rates enhanced cranial nerve damage rates when compared 
to extra-dural intracranial tumours. The adverse event rates can be explained since 
gross tumour removal often requires manipulation of delicate neurological and/or 
vascular structures. Lower cranial nerve palsies of Nn IX and X (nerves at risk during 
frequently used infra-temporal fossa approaches) impose a potential life-threatening 
risk of aspiration. In the current review, six patients required a tracheotomy post-
surgery due to such lesions. Moreover, manipulation in the area of greater vessels is 
considered a risk-factor for the development of strokes, which were identified in 16 
patients post-surgery. Additionally, physical manipulation of the dura induced CSF 
leaks (found in 43 patients), and rendered wound infection in 9 cases. In comparison, 
no radiotherapy-induced Nn. IX or X lesions were found, and merely one stroke was 
described, although this could increase with extended follow-up. 
Obviously, the risk associated with surgery of Fisch class C and D tumours is de-
pendent on multiple factors, one of the most important ones being the expertise 
of the centre. Nevertheless, when considering the large series (N > 30) published by 
expertise-centres higher cranial nerve damage and complication rates post surgery, 
and lower local control rates remain when compared to radiotherapy series 26, 27, 
28. It seems as if high local control rates come at the cost of high morbidity rates and 
vice versa . 
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However, there are also limitations to radiotherapy to be considered: First, radio-
therapy generally does not produce tumour mass reduction. It might rather cause a 
transient swelling of the lesion due to oedema which induces further compression 
of surrounding structures5. Second, little is known about the long-term effects of 
radiotherapy, although we found no significant difference in treatment outcome 1 
year post treatment, and those 5 to 10 years post treatment. However, irradiation 
induced sequelae might become apparent later in time, and the follow-up in the lit-
erature at hand is too short to allow for proper evaluation on this matter. As outlined 
by Suarez et al., other head and neck neoplasm’s treated with similar radiotherapeutic 
techniques and dosages illustrated a risk of 0.5 and 0.1-3% for necrosis and irradia-
tion induced secondary malignancies, respectively, over a course of 30 years7. It is 
uncertain whether or not these results apply for HHPGL treatment as well. Further, 
although in the current review only few radiotherapy-associated vascular complica-
tions  were found, this very likely is an underestimation. Cerebrovascular accidents 
caused by atherosclerosis of the carotids are often not recognized as potential long-
term sequelae of head and neck radiotherapy7. Wilbers et al. found an increased 
incidence of stroke in 49 patients suffering from head and neck malignancies seven 
years after radiotherapy compared to the general Dutch population (8.9 versus 1.5 
per 1.000 person years)31. Additional studies described a significant correlation with 
a longer post-RT interval and significant carotid-wall thickness, which is considered 
a risk factor for cerebrovascular accidents; P=0.008)32. The exact long term risks of 
irradiation-induced carotid atherosclerosis remains uncertain, yet it occurs after years 
in follow-up. 
Theoretically, to reduce the risk of HNPGL irradiation, stereotactic radiotherapy tech-
niques are suggested. This is supported by Suarez et al. who found more deaths due to 
tumour growth post radiotherapy when conventional radiotherapy was used (3.2%; 
CI 0.4 - 5.2 ),  when compared to deaths due to tumour growth post stereotactic 
irradiation  (0%; CI 0 – 0 respectively; p = 0.03)7. Also, more deaths due to complica-
tions post radiotherapy, were found with conventional radiotherapy (2%; CI 0.4 – 3.7) 
when compared to deaths due to complications of stereotactic radiotherapy (0%; CI 0 
– 0 respectively; p = 0.04).However, no figures about distribution by Fish class for the 
two radiotherapy techniques are provided. It is likely that stereotactic techniques were 
reserved for smaller tumours rendering less complications. Nonetheless, overall these 
results suggest that (stereotactic) radiotherapy should be considered (for class C and 
D tumours), for at least all patients older than 40. When a conventional fractionation 
schedule is used IMRT or rapid arc/VMAT is considered standard of care.
Alternatively, to minimize the treatment risks authors suggested a dual approach for 
HHPGL management using post-operative irradiation after debulking of gross tumour 
mass.  This way, critical neurovascular structures might be spared during surgery. 
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In case additional tumour growth is found with a consecutive wait and scan policy, 
radiotherapy could be applied. Although literature is sparse on this matter and sample 
sizes are small, combinations of surgery with gammaknife were described as a proper 
alternative; local control was found in 80-100%, complications were found in 0-7%, 
and cranial nerve damage in 0-20% after 11 months -7 years follow-up5, 33, 34, 35, 
36. Please note however, that these results were comparable to results of radiotherapy 
alone. Furthermore there is the risk that patients may suffer from both surgical and 
radiotherapeutic complications. 
Furthermore, hereditary HHPGL syndromes also affect HHPGL management. Par-
ticularly, tumours arising from an SDHB, -AF2 and -D mutation, are thought to show 
more aggressive growth when compared to tumours arising from other mutation 
syndromes36,37. Also, due to multifocal tumour growth, there is a risk of bilateral 
cranial nerve deterioration; for N. VII lesion this might cause a drastic decrease in qual-
ity of life, for Nn. IX and X lesions this may even cause life-threatening aspiration risks. 
Therefore, in case of a multifocal HHPGL syndrome surgery for Class C and D tumours 
should be prevented. When treatment is inevitable, for larger tumours the use of 
radiotherapy is advised since cranial nerve pareses is best avoided using this modality, 
or conservative tumour debulking could be attempted. It is important to realize that 
after radiotherapy, alterations in cranial nerve function are known to occur up to one 
year post-treatment. Therefore, consecutive HHPGL treatment involving radiotherapy 
should be performed with an interval of at least one year.  
Taken together it should be noted that HNPGL management is complex. To manage 
these patients correctly, treatment of these tumours should be confined to central-
ized multidisciplinary teams that include an extremely experienced surgeon, radiation 
oncologists, clinical geneticists, endocrinologists and speech and language therapist 
which should work together to reduce both tumour and treatment induced morbidity. 
ConClusion
The current review has demonstrated that although surgical procedures varied, for class 
A and B tumours surgery seems to be a suitable treatment option. For class C and D 
tumours an initial wait and scan period should be considered. In the case of tumour 
growth (confirmed by imaging) or clinical progression of the tumour (indication of early 
CN palsy) radiotherapy might be the better option due to lower complication rates and 
similar or better local control rates when compared to the surgical groups. The proposed 
dual approach including tumour debulking followed by a wait and scan period and 
radiotherapy in case of recurrent progression, requires more research. More research 
is required as well on the long-term effects of radiotherapy. Furthermore, research on 
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the best treatment modality for HHPGL tumours needs to be stratified in the future for 
the different (genetic) subgroups. 
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absTraCT
Objectives: To identify the risks associated with surgery, radiotherapy or a combined 
treatment approach for Fisch class C and D jugulotympanic paraganglioma, in order 
to develop an individualized approach for each patient depending on Fisch class, age, 
mutation presence, tumour size growth rate and presenting symptoms
Design: A retrospective multicenter cohort study with all patient records of patients 
with a HNPGL in the Radboudumc, Nijmegen and the St. Elisabeth Hospital, Tilburg, 
the Netherlands.
Main outcome measures: local control, cranial nerve damage, complications, function 
recovery. 
Results: We found highest local control rates after tumour debulking with postoperative 
radiotherapy in case of residual tumour growth, referred to as the combined treatment 
group, (100%; n = 19), which was significantly higher than the surgical group (82%; 
n = 17; p = 0.00), but did not differ from the radiotherapy group (90%; n = 29). There 
were significantly less complications in the radiotherapy group, when compared to 
surgery (63 vs. 27%; p = 0.002) and the combined group (44 vs. 27%; p = 0.016). 
Furthermore, using a logistic regression model, we found that pre-treatment tumour 
growth was a negative predictor for post treatment cranial nerve function recovery 
(OR = 50.178, p = 0.001), reducing the chance of symptom recovery (67.3% versus 
35.7%) post-treatment.
Conclusions: Radiotherapy should be the treatment of choice for the elderly. For younger 
patients tumour debulking should be considered, with potential radiotherapy in case 
of residual tumour growth.
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inTroduCTion
Jugulotympanic paragangliomas (JTPGL) are slow growing neuro-endocrine tumours that 
are usually benign. Due to their local invasiveness in the skull base, tumour morbidity 
can be considerable when there is growth towards cranial nerves (CN) and vascular 
structures [1]. However, their indolent growth pattern makes it difficult to predict if and 
when tumours become clinically apparent and debilitating; some tumours cause CN 
damage or invade the intracranial space, while others show spontaneous regression [2]. 
The main treatment options considered for JTPGL, surgery and radiotherapy (in-
cluding conventional radiotherapy, stereotactic radiotherapy and radiosurgery), may 
induce cranial nerve damage or other  complications. The management of these rare 
tumours should be carefully discussed with patients in order to develop a customized 
approach complying with patient’s preferences. Patient factors such as age, comor-
bidities, tumour size and hereditary tumour syndrome presence should be considered. 
In this light, it has been suggested that younger patients show enhanced tumour 
growth  and, consequently paraganglioma found in younger patients are likely to be 
of higher tumour class when compared to tumours of older patients,  which makes 
decision making more difficult due to an enhanced risk of complications rates [3, 4, 
5, 6, 7]. 
Therefore, in the current study we aim to evaluate the benefits and risks associated 
with radiotherapy, surgery and combined treatment regimens in relation to Fisch class, 
age, gene mutations, tumour size and growth rate, and presenting symptoms. 
MeTHods 
ethical considerations
The procedures followed were in accordance with the ethical standards of the Rad-
boudumc, the Netherlands and with the Helsinki Declaration.
study population and definitions
A retrospective multicenter cohort study was conducted with all patient records of 
patients presenting with a HNPGL between 1980 and 2016 in the Radboudumc, 
Nijmegen and the St. Elisabeth Hospital, Tilburg, the Netherlands. Eligibility criteria 
were patients with a benign Fish class C or D jugulotympanic tumour. 
Out of 358 patients with HNPGL, 93 patients with a Fisch class C or D JTPGL were 
identified. To collect data from patient files a standardized extraction protocol was 
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used for the following information: gender, age at presentation, signs and symptoms 
at presentation, tumour class, gene mutation analysis, clinical and radiological signs 
and symptoms of tumour progression.
The pre-treatment work-up was as follows; generally, all patients are subjected to an 
initial wait and scan period and consecutive treatment is considered in case of tumour 
growth, tumour induced cranial nerve damage or other complications (such as pulsatile 
tinnitus, pressure sensation or hematootorrhoea) or wish of patient to be treated. In 
case this is not found consecutive treatment is generally not performed. A wait and 
scan period is not applied in case at initial presentation patients suffer from cranial 
nerve damage or other tumour induced morbidity. A wait and scan period was also not 
applied in those patients presenting between 1980 and 1987 as this was not general 
practice at that time. 
Based on treatment three groups were distinguished. Group 1: patients treated with 
radiotherapy as initial treatment either with LINAC or Gammaknife. Group 2: patients 
that underwent surgery as primary treatment, in whom complete tumour resection 
was the main goal. Group 3:  patients in whom planned safe tumour debulking was 
the main goal, with preservation of delicate surrounding structures. The residual 
tumour was followed using wait and scan period and in case of tumour growth ad-
ditional radiotherapy was given.
The outcome of the treatment was compared to the patients’ situation prior to 
treatment. Treatment outcomes were local control, cranial nerve damage and other 
complications. The definitions were according to Suarez et al. [8]. Post surgery, local 
control was defined as a patient alive without evidence of disease or with a non-
growing residual tumour throughout the entire follow-up period. Post radiotherapy 
local control was defined as a patient alive without any evidence of progression of 
the disease throughout the entire follow-up period. CN damage was defined as 
deterioration of CN function post treatment when compared to the pre-treatment 
setting, objectified by a physician. CN recovery was defined as any improvement of 
CN function in post treatment setting when compared to pre-treatment conditions, 
objectified by a physician. The complications cerebrospinal fluid leakage, wound infec-
tion, cerebrovascular accident, aspiration resulting in pneumonia and/or tracheotomy, 
radiation induced necrosis, malignancies and CNS syndrome and death were included. 
Furthermore, an additional analysis was performed evaluating the control of pulsatile 
tinnitus for the different treatment modalities. 
Patients were subjected to a routine follow-up. Post treatment, patients were seen 
within 2 weeks to evaluate immediate post-treatment complications. Thereafter 
patients were seen every six months for two years and then yearly. Post-treatment 
MRI-scans were done one year post treatment and continued on a yearly basis. In case 
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follow-up intervals were prolonged, MRI’s were conducted every 2 or 5 years. This 
regimen could have been individualized.
For evaluation of tumour growth the mean percentage of volume increase per year 
was evaluated according to the protocol described by Jansen et al. [2].
statistics
Predictors implemented in the model were analyzed using multiple logistic regression. 
Binary logistic regression was used, and best predictive model was constituted using 
Wald backwards step-by-step variable exclusion (probability for stepwise entry was 
set at 0.05 and removal at 0.1). Internal validation was optimized using bootstrapping 
sampling techniques. The data was collected using filemaker pro, and was analyzed 
using IBM SPSS Statistics 22. 
resulTs
Long-term treatment outcomes of 93 Fisch class C and D tumours were evaluated. 
Table 1 describes the baseline criteria of the total wait and scan cohort, and the direct 
treatment group. There was no significant difference in baseline criteria between these 
groups. However, when we corrected for patients directly treated due to timeframe, 
we found that patients directly treated (due to cranial nerve damage at presentation) 
were generally older (56 versus 49 years; p = 0.017, F = 1.585).  
Table 2 provides  baseline criteria of patients within each treatment group. There 
was no significant difference in baseline-criteria between each group. 
In table 3, background information on pre-treatment counselling of the different 
treatment groups is provided. A total of 66 patients were subjected to a wait and scan 
period, of which 28 were not treated as no growth or tumour induced morbidity was 
Table 1: Baseline criteria of total wait and scan group and direct treatment group
Total wait and 
scan group
Total direct 
treatment group
Direct treatment due to 
cranial nerve damage
N 66 27 17
Fisch D N, (% total) 11 (17%)* 7 (26%)* 5 (29%)*
Mutation N, (% total) 25 (38%)* 12 (44%)* 7 (41%)*
Age (range) 49 (13-60)* 47 (20-77)* 56 (21-77)**
Tumour volume (range) 10.7 (0.8-55,3)* 13.3 (1.9-36.5)* 9.7 (2,5-26.8)*
*; no significant difference between treatment groups, p values > 0.05.
**; significant difference between treatment groups, p values < 0.05.
70 Chapter 4
found after a median follow-up of 52 months (range 13-281). The motivation of treat-
ment of remaining tumours is provided in table 3. Within the surgery cohort 24% of 
patients were treated directly due to timeframe, albeit not significant, this percentage 
was 14% and 11% in the radiotherapy and combined treatment group respectively. 
Table 2: Baseline characteristics per treatment modality
Radiotherapy Surgery Combined 
treatment 
modality
Wait and 
scan
Total
n 29 17 19 28 93
Fisch class D n, (%) 8 (28%)* 2 (12%)* 5 (26%)* 5 (18%)* 20 (22%)
Mutation n, (%) 8 (28%)* 7 (41%)* 7 (37%)* 15 (54%)* 37 (40%)
Median Age(range) 50 (20-77) 41 (13-78) 43 (18-66) 55 (14-90) 48 (13-90)
Median volume (range) in cc 13 (12-47) * 15 (3-55) * 15 (6-28) * 9 (1-33)* 11 (1-33)
Growing n (%) 8 (28%) * 3 (53%) * 5 (68%) * 0 (-)* 16 (17%)
Presenting symptoms
Tinnitus 9 (31%) 11 (65%) 9 (47%) 14 (50%) 43 (46%)
Hearing loss 17 (59%) 12 (71%) 13 (68%) 17 (61) 59 (63%)
CN damage 12 (41%)* 9 (53%)* 14 (73%)* 0 (-) 35 (38%)
VII 4 (13.8%) 5 (29%) 5 (26%) 0 (-) 14 (15%)
VIII 3 (10%) 2 (11%) 0 (-) 5 (5%)
IX 2 (12%) 2 (11%) 0 (-) 4 (4%)
X 5 (17%) 1 (6%) 2 (11%) 0 (-) 8 (9%)
XI 1 (5%) 0 (-) 1 (1%)
XII 1 (6%) 2 (11%) 0 (-) 3 (3%)
Median follow-up months (range) 82 (8-182)* 43 (10-372)* 98 (8-432)* 80 (13-281)* 81 (8-432)
*; no significant difference between treatment modalities, p values > 0.05.
Table 3: background information on pre-treatment counselling of the different treatment 
modalities
Motivation for treatment Surgery Radiotherapy Combined No treatment Total
Wait and scan N, (% total) 11 (66%) 14 (48%) 13 (68%) 28 (100%) 66
No growth N , (% total) - - - 28 (100%) 28
Growth N , (% total) 3 (18%) 8 (28%) 5 (26%) - 16
Cranial nerve damage N , (% total) 3 (18%) 4 (14%) 4 (21%) - 11
Wish treatment N , (% total) - 2 (7%) 3 (16%) - 5
Other N , (% total) 5 (29%) - 1 (5%) - 6
Immediate treatment N, (% total) 6 (33%) 15 (52%) 6 (32%) - 27
Cranial nerve damage N , (% total) 2 (12%) 11 (38%) 4 (21%) - 17
Timeframe N , (% total) 4 (24%) 4 (14%) 2 (11%) - 10
Total N 17 29 19 28 93
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The outcomes by treatment modality are presented in figure 1. There was a sig-
nificant relation between treatment modality and local control and complication 
rate. Local control for the surgery group was lower when compared to the combined 
treatment modality group (82 vs. 100%; p < 0.01). Complication rates differed sig-
nificantly between surgery and radiotherapy in favour of the latter (63 vs. 27%; p = 
0.002). Also, there were significantly more complications in the combined treatment 
group when compared to the radiotherapy group (44 vs. 27%; p = 0.016). There was 
no relation between treatment methods and recovery from pre-treatment symptoms 
(p = 0.556).  
Out of 19 patients undergoing the combined treatment modality, eight patients 
underwent additional radiotherapy 12 to 108 months post treatment (median 52 
months). 
No difference was found with respect to local control, complications, and functional 
recovery when comparing the results of patients that were treated after an initial 
wait and scan period and those immediately treated, and no statistical difference was 
found. 
Out of 29 patients undergoing radiotherapy, 17 (59%) were treated with the 
Gammaknife. Median tumour volumes for the group treated with Gammaknife, and 
the group treated with LINAC were 6.6 cc (range 1.3 – 16.8) and 16.9 cc (range 
1.2 – 47.4) respectively. This difference was statistically significant (P = 0.009). There 
Figure 1: treatment outcome per treatment modality (* refers to a significant difference between 
treatment outcomes p < 0.05)
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was a small difference in local control rates between gammaknife and LINAC treated 
patients (100 vs. 81%;, p = 0.068), albeit not significant. No differences were found 
in complication (33.3 vs. 17.6%; p = 0.331) and recovery rates (16.7 vs. 37.5%; p = 
0.227) between Gammaknife and LINAC. 
Table 4 presents the complications found post treatment, by treatment modality. 
No statistical difference in pulsatile tinnitus-control was found for the different treat-
ment modalities. Tinnitus-control was found in 2 of 11 (18%) patients post surgery, 
4 of 9 in the combined treatment group (44%) and in 2 of 9 patients treated with 
radiotherapy (22%). When pooling the results of surgery and the combined treatment 
group, there was still no statistically significant difference.
univariate analysis of variance
The results of the univariate analysis of variance are presented in table 5. Overall, no 
factors were  found that were associated with local control. A trend towards higher 
complications rates in case of pre-treatment tumour growth was found (57.9% versus 
34.6%), albeit not significant (p = 0.07). However, significantly higher symptom recovery 
rates were found in case of mutation presence (36.4% in mutation group versus 14.6% 
in non-mutation group; p = 0.048) and pre-treatment tumour growth (13% in growing 
group versus 45% in non-growing group; p = 0.03). 
With respect to the surgery group, patients suffering a complication were signifi-
cantly older (mean 46 years), when compared to patients not suffering a complication 
(mean 30 years) (p = 0.047) and mutation presence was found to be related to lesser 
symptom recovery rates (0% versus 42.9%; p = 0.03). In the radiotherapy group, 
there were no factors significantly associated with treatment outcome. 
Table 4: complications by treatment modality.
Radiotherapy Surgery Combined Total
SNHL/Tinnitus/Vertigo 7 6 2 14
CN damage 1 15 5 21
III. IV, VI 2 2
VII 5 1 6
IX 3 3
X 1 3 2 6
XI 1 1
XII 2 1 3
Total n. complications/ n. patients per treatment group 8/29 21/17* 7/19 37/65
* there was more than 1 complication in some patients.
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With respect to the combined treatment regimen, patient suffering a complication 
generally had smaller tumour volumes when compared to patients not suffering a 
complication (9.3 cc versus 24.1 cc; p = 0.02). 
binary logistic regression
Using a logistic regression model with step by step correction for potential confounders 
in the total group only pre-treatment tumour growth was identified as an independent 
negative predictor for symptom recovery (OR = 50.178, p = 0.001). This means that if 
there is tumour progression before the start of treatment, there is a significantly lower 
chance of symptom recovery (67.3% versus 35.7%). Furthermore, with respect to the 
combined treatment approach, there was an indication that presence of cranial nerve 
damage was associated with poorer local control rates (p = 0.06). 
disCussion
To our knowledge, this study presents the largest cohort of patients with Fisch class C 
and D JTPGL that compares different treatment modalities. In this study we compared 
the benefits and adverse effects of different treatment strategies for jugulotympanic 
paragangliomas of Fisch class C and D. 
Local control rates were highest with combined treatment modality, and compli-
cation rates were lowest in the radiotherapy group. One independent predictor of 
treatment outcome was found: if treatment is delayed until tumour growth occurs, 
the chance of function recovery is lower. 
Our results suggest, that attempts to achieve radical excision as a primary goal, 
should not be performed since for this group local control rates were lowest and 
highest complication rates were found when compared to the combined treatment 
approach and radiotherapy. Hence, we believe that radiotherapy and or a combined 
treatment modality with nerve sparing debulking surgery should be attempted. 
These results can provide a basis for the counselling of patients suffering from 
HNPGL, and support the decision making process to a customized management 
strategy for these patients.
Comments on management
The current study presents the motivation for treatment of Fisch class C and D tumours. 
At first presentation, feasibility of a wait and scan protocol is evaluated. In case no 
treatment-requiring tumour induced morbidity is found, such a protocol is initiated. 
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In our cohort 66 patients were initially managed by a wait and scan protocol, and 27 
patients were treated directly. When comparing these two groups at baseline, we found 
that patients which were treated directly were significantly older than patients in the 
wait and scan group (56 vs. 49 years). Potentially, this difference can be explained by 
more progressive disease at older age, however, no difference in pre-treatment tumour 
volumes could be found between those groups. Evaluating the 66 patients in which 
a wait and scan period was initiated, tumour growth was found in 24% of cases and 
treatment was necessary in 58% of cases. The choice of treatment was based on patient 
factors and no significant factors predicting treatment outcome were found.  Hence, 
at baseline we are unable to predict which tumour will in the near future become 
clinically apparent. Therefore, the current results emphasize that an initial wait and 
scan therapy should always be performed in the absence of readily present morbidity, 
particularly since we found that overall, a preceding wait and scan protocol does not 
affect future treatment outcome. 
The mere drawback we found with a wait and scan policy is, that in case tumour 
growth is found in combination with tumour induced morbidity, chances for symptom 
recovery post treatment reduce. Therefore, we believe that in case tumour growth is 
found, treatment should be considered seriously. Moreover, growth does not affect 
treatment outcome in general with respect to local control rates or complications 
independent of treatment modality in our centre. Hence, the timing of treatment 
initiation is crucial and the most challenging aspect of the management of JTPGL.
Furthermore, please note that a previous study of our group (Jansen et al. 2017) 
illustrated that age of presentation was a risk factor for enhanced risk of tumour 
growth incidences and rates. Patients under the age of 50 years were at particular 
risk of suffering from such enhanced aggressive tumour biology. We state that an 
initial wait and scan is feasible also for the younger population, however, a reduced 
time-interval between scanning of those patients should considered. 
In case treatment is required, we found lowest local control rates when patients 
were treated with surgery which is in line with previous literature. A systematic review 
demonstrated that local control rates were found in 80%-95% for class C1-4 tumours 
and 38%-86% for class De/Di tumours [9]. Post surgery, in the current study complica-
tion rates were 63%. The same review showed that complications were found in 
71%-76% of class C1-4 and 67%-100% for class De/Di tumours. The main complica-
tion found in the current study was CND (71% of all complications), with a particular 
risk of n. VII damage (23% of all complications). Therefore, we do not advise the use 
of complete surgical excision for Fisch class C and D tumours. 
We believe debulking seems a promising alternative for radical surgical excision. We 
found excellent local control with this approach. This is also observed by van Hulsteijn 
et al., who found 100% local control with adjuvant radiotherapy (95%CI 66-100) 
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[10]. Unfortunately however, no data on complication rates are reported in the latter 
study. This makes it hard to put these results in context since rendering local control 
while preserving CN function seems to be the main challenge in HNPGL management. 
Moreover, similar results were found by Willen et al, treating 5 elderly patients with 
limited surgical resection, rendering excellent local control and no cranial nerve dam-
age [11]. In our study we found lower complication rates when compared to radical 
surgery, yet higher when compared to radiotherapy alone. The main complications 
found was CND. Ultimately, 42% of patients in whom debulking was performed 
were subjected to additional RT. Although few irradiation induced complications were 
found after a follow-up of 82 months (range 8-182), a potential criticism on this 
management strategy could be that potentially patients are subjected to risks of both 
treatment modalities. Moreover, the role of surgery in the management of pulsatile 
tinnitus requires further investigation. 
As outlined above, radiotherapy seems to be the treatment of choice in general as 
it provides excellent local control and fewest complications. These results are in line 
with a systematic literature study conducted by our group, as outlined above [9]. It 
was previously suggested that radiotherapy should be reserved for older patients due 
to the risk of induction of malignant tumours or cerebrovascular accidents [8, 10]. 
Nevertheless, the lifetime risk of irradiation-induced secondary malignancies is only 
0.3% which is almost negligible compared to the 38% lifetime risk of developing can-
cer of any type in the general population in the Western world [11, 13]. What is less 
well known is that there is an increased risk of 8.9 versus 1.5 per 1000 person years of 
cerebrovascular accidents after radiotherapy to the neck due to carotid atherosclerosis 
[7, 11, 14]. These late sequelae manifesting up to 30 years post treatment should be 
considered as calculated risks and weighed against the advantages of radiotherapy 
over surgery. Overseeing this, and considering sequalae up to thirty years post treat-
ment, we feel that radiotherapy as monotherapy is a viable option from the age of 50 
years onwards [11]. Please note that this suggestion is based on theoretical grounds, 
nevertheless, it is in line with suggestions of previous studies [8-10]. Moreover, such 
severe and life threatening complications were not found in the current study after 
a follow-up of 82 months (range 8-182). Currently, the main complications found 
seemed to be due to radiotoxic effects on the cochlea (87% of all complications). 
Methodological considerations
First, the current study is a retrospective cohort study and therefore the external validity 
is limited. However, given the rarity of these tumours and their slow growth rate, 
prospective (randomized controlled studies) are hardly possible. Furthermore, although 
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the current study provides one of the larger sample size on this particular tumour type, 
for sub-group analysis the population might have been too small. 
Furthermore, as discussed above, the long-term treatment outcomes of radiotherapy 
remain uncertain. Therefore, the results of the current study might be too optimistic 
since tumour growth and recurrences may be expected over time for this group. This 
is also a limitation when considering the results of the combined treatment modal-
ity: perhaps additional treatment of residual tumour growth is required over time as 
tumour growth might occur later in time. 
Also, in the future automated tumour volume measurement software should be 
used to evaluate tumour volume, rather than manual three dimensional measure-
ments. This will provide more accurate tumour volumes and reduces the inter and 
intra-observer variability. 
ConClusion 
Our results confirm the feasibility of a wait and scan period as initial management 
strategy, and demonstrate a significant relation between treatment modality and local 
control and complication rates. Complete surgical excision is not a suitable treatment 
strategy since it induces the highest incidence of complications and local control is lowest 
when compared to tumour debulking methods and radiotherapy as monotherapy. 
Radiotherapy produces excellent local control rates and has the fewest complications 
and therefore it seems to be the treatment of choice for older patients. However, as 
radiotherapy seems undesirable for patients under the age of 50 due to an enhanced 
life-time risk of secondary tumours and stroke, tumour debulking should be at least 
considered for younger patients. The greatest challenge is the timing of therapy initiation 
because once tumour growth occurs there is less chance of symptom recovery. More 
research is required on this matter and it also implies that patients presenting with CND 
should be treated without delay to increase chances of functional recovery or these 
patients should be followed-up more carefully so that with a minimal impression of 
tumour growth, treatment should follow. 
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absTraCT
Objective: The aim of the current study is to evaluate the risk associated with different 
types of surgery for carotid body paraganglioma of different Shamblin class. A meta-
analysis was conducted to evaluate per tumour class, the local control, cranial nerve 
damage and complication rates of different techniques using internal carotid artery 
(ICA) and external carotid artery (ECA) ligation, clamping or bypassing, as well as the 
cranio-caudal versus caudo-cranial techniques.
Design: A meta-analysis is conducted after a systematic search in Pub Med and the 
Cochrane library, in accordance with the PRISMA guidelines. 
Main outcome measures: local control, cranial nerve damage, complications, function 
recovery
Results: Out of 3565 articles, 27 were selected. The overall quality of evidence of 
studies was low. Cranial nerve damage (3%, 17% and 39%) and complication rates 
(0%, 1%, 10%) were significantly related to Shamblin class (class 1, 2, 3, respectively, 
p < 0.01). For class 3 tumours an increased risk of complications was found associated 
with routine ICA manipulation/reconstruction (RR 3.12 with a 95% CI of 1.29-7.59), 
as well as a trend towards enhanced risk of routine ECA ligation (RR 3.48 with a 95% 
CI of 0.88-13.81). 
Conclusions: For class 1 and 2 tumours surgery seems a viable treatment option. 
For class 3 tumours, morbidity in terms of cranial nerve deficit and complications is 
considerable, particularly the use of ICA manipulation/reconstruction and potentially 
ECA ligation seems to be accompanied by high a stroke incidence.
Keywords: Meta analysis, head and neck, carotid body paraganglioma, meta-analysis, 
surgical techniques 
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inTroduCTion
Carotid body paragangliomas (CBPGL) are benign  neuro-endocrine tumours which 
constitute 57% of HNPGLs.1  Symptomatology of these tumours can be  considerable, 
due to their relation with the  internal (ICA)/external carotid artery (ECA), the vagal, 
hypoglossal and accessory nerves. Only a small portion of these tumours grow, and 
most of these grow very slowly. Therefore, recent literature agrees that these tumours 
should first be followed-up to evaluate tumour growth via a wait and scan period2. 
However, when tumour growth is demonstrated, or the tumour becomes clinically 
apparent, the best way of treatment remains uncertain.  
Surgery is considered the main treatment of choice, as this offers complete tu-
mour removal. However, neurovascular structures are at risk when surgery is applied 
which might impose life threatening complications such as aspiration pneumonia’s 
and CVA’s3. The precise risk associated with surgery stratified per Shamblin class 
remains uncertain, yet recent works suggested that tumour class is related to local 
control and adverse event rates.3-6 Moreover, surgical techniques have advanced to 
reduce complications and to facilitate a dry operation field with better preservation 
of neurovascular structures.7 To achieve this, routine ICA and ECA (temporary) liga-
tion and reconstruction methods have been used. Preservation of the internal and 
external carotid arteries and the smaller supplying vessels is crucial. Caudo-cranial 
surgery techniques have been described in the past but more recently cranio-caudal 
techniques are suggested to cause less cranial nerve damage as it allows for early 
proximal control of the nerves.8 However, the risks associated with these different 
surgical techniques are not well documented. 
Therefore, in the current study, we aim to evaluate the risk associated with different 
types of surgery for CBPGL of different Shamblin class. Hereby, we aim to optimize 
individualized treatment protocols for patients suffering from CBPGLs. We performed 
a systematic literature search to evaluate treatment outcome per tumour class, and 
to evaluate treatment outcome of different surgical techniques such as ICA and ECA 
/ligation, clamping or bypassing, as well as the cranio-caudal versus caudo-cranial 
techniques. 
MeTHods 
The methods as presented underneath are similar to previous literature studies of our 
group.8
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ethical considerations
This study was conducted in line with the ethical guidelines of the Radboud University 
Medical Centre, the Netherlands.
eligibility criteria
Studies evaluating the effect of surgery were included. The population consisted of 
patients suffering a CBPGL, stratified per Shamblin class as described Shamblin et 
al..9 The intervention was any form of surgery, with or without a preceding wait and 
scan period. Treatment outcomes were local control, cranial nerve damage and other 
complications. The definitions were defined according to Suarez et al..3 Local control 
was defined as a patient alive without evidence of disease throughout the entire follow-
up period. CN damage was defined as deterioration of CN function post treatment 
when compared to the pre-treatment setting, objectified by the treating physician. CN 
recovery, was defined as any improvement of CN function in post treatment setting 
when compared to pre-treatment conditions, objectified by the treating physician. 
The complications CSF leakage, wound infection, CVA, baro-reflex failure syndrome, 
aspiration resulting in pneumonia and/or tracheotomy and death were included. 
Additionally, the following surgical techniques were evaluated: whether or not 
standard extensive ICA/ECA manipulation techniques were used including clamping, 
ligation or bypassing techniques. Also, it was evaluated whether or not a cranio-
caudal-or a caudo-cranial resection technique was used. 
literature review
A systematic literature review was conducted according to the PRISMA statement for 
meta-analyses of observational studies.10 On Feb. 2016 the first author searched the 
Pub Med database for articles using the search strategy as mentioned below (no MeSH 
terms were used for inclusion of the most up to date articles). References of key articles 
were scrutinized for additional relevant articles. 
(((Treatment [Title/Abstract] OR Treatment [MeSH Terms] OR Management [Title/Abstract] OR 
Management [MeSH Terms] OR therapy [Title/Abstract] OR therapy [MeSH Terms] OR approach [Title/
Abstract] OR approach [MeSH Terms] OR procedure [Title/Abstract] OR procedure [MeSH Terms] OR 
Radiotherapy [Title/Abstract] OR Radiotherapy [MeSH Terms] OR radiation therapy [Title/Abstract] OR 
radiation therapy [MeSH Terms] OR X-ray therapy [Title/Abstract] OR X-ray therapy [MeSH Terms] OR 
radioisotope therapy [Title/Abstract] OR radioisotope therapy [MeSH Terms] OR Radiosurgery [Title/
Abstract] OR Radiosurgery [MeSH Terms] OR Gamma Knife [Title/Abstract] OR Gamma Knife [MeSH 
Terms] OR CyberKnife [Title/Abstract] OR CyberKnife [MeSH Terms] OR Linear Accelerator [Title/
Abstract] OR Linear Accelerator [MeSH Terms] OR Linac [Title/Abstract] OR Linac [MeSH Terms] OR 
LINAC [Title/Abstract] OR LINAC [MeSH Terms] OR Surgery [Title/Abstract] OR Surgery [MeSH Terms] 
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OR operative [Title/Abstract] OR operative [MeSH Terms] OR invasive [Title/Abstract] OR invasive 
[MeSH Terms] OR operations [Title/Abstract] OR operations [MeSH Terms] OR peroperative [Title/
Abstract] OR peroperative [MeSH Terms] OR perioperative [Title/Abstract] OR perioperative [MeSH 
Terms] OR intraoperative [Title/Abstract] OR intraoperative [MeSH Terms] OR excision [Title/Abstract] 
OR excision [MeSH Terms] OR resection [Title/Abstract] OR resection [MeSH Terms] OR Wait and scan 
[Title/Abstract] OR Wait and scan [MeSH Terms] OR Wait and see [Title/Abstract] OR Wait and see 
[MeSH Terms] OR Conservative [Title/Abstract] OR Conservative [MeSH Terms] OR Expectative [Title/
Abstract] OR Expectative [MeSH Terms] OR Embolotherapy [Title/Abstract] OR Embolotherapy [MeSH 
Terms] OR Embolization [Title/Abstract] OR Embolization [MeSH Terms] OR Occlusion [Title/Abstract] 
OR Occlusion [MeSH Terms]))) AND (((((((Tumour [Title/Abstract] OR Tumour [MeSH Terms] OR Tumour 
[Title/Abstract] OR Tumour [MeSH Terms] OR Tumours [Title/Abstract] OR Tumours [MeSH Terms] OR 
Tumours [Title/Abstract] OR Tumours [MeSH Terms]))) AND ((Carotid body [Title/Abstract] OR Carotid 
body [MeSH Terms] OR Vagal body [Title/Abstract] OR Vagal body [MeSH Terms])))) OR ((((Jugulare 
[Title/Abstract] OR Jugulare [MeSH Terms] OR Caroticum [Title/Abstract] OR Caroticum [MeSH Terms] 
OR Carotis [Title/Abstract] OR Carotis [MeSH Terms] OR Vagale [Title/Abstract] OR Vagale [MeSH Terms] 
OR temporale [Title/Abstract] OR temporale [MeSH Terms] OR jugulotympanicum [Title/Abstract] OR 
jugulotympanicum [MeSH Terms] OR tympanicum [Title/Abstract] OR tympanicum [MeSH Terms]))) 
AND ((Glomus [Title/Abstract] OR Glomus [MeSH Terms])))) OR ((((Head and neck [Title/Abstract] OR 
Head and neck [MeSH Terms] OR Cervical [Title/Abstract] OR Cervical [MeSH Terms] OR Temporal [Title/
Abstract] OR Temporal [MeSH Terms] OR Jugular [Title/Abstract] OR Jugular [MeSH Terms] OR Tympanic 
[Title/Abstract] OR Tympanic [MeSH Terms] OR jugulotympanic [Title/Abstract] OR jugulotympanic 
[MeSH Terms] OR Carotid [Title/Abstract] OR Carotid [MeSH Terms] OR Carotis [Title/Abstract] OR 
Carotis [MeSH Terms] OR Vagal [Title/Abstract] OR Vagal [MeSH Terms]))) AND ((paraganglioma [Title/
Abstract] OR paraganglioma [MeSH Terms] OR paragangliomas [Title/Abstract] OR paragangliomas 
[MeSH Terms] OR chemodectoma [Title/Abstract] OR chemodectoma [MeSH Terms] OR 
chemodectomas [Title/Abstract] OR chemodectomas [MeSH Terms] OR glomus tumour [MeSH Terms] 
OR glomus tumour [Title/Abstract] OR glomus tumours[Title/Abstract] OR glomus tumours [MeSH 
Terms] OR glomus tumour [MeSH Terms] OR glomus tumour [Title/Abstract] OR glomus tumours[Title/
Abstract] OR glomus tumours [MeSH Terms]))))
study selection and the data collection 
Articles written in English and German were selected and tumours had to be classified. 
The treatment modality and outcome measures needed to be reported for each tumour 
class individually. Cohort sizes had to consist of 5 or more patients. Information on 
at least one of the afore-mentioned outcome measures had to be available. Also, 
information on the surgical technique and corresponding outcome measures had to be 
provided. No unpublished articles were used, and full-text had to be available. Shamblin 
class was retrieved from each publication, appreciating that classification was reported 
based on CT, MRI or per-operative findings.
risk of bias in individual studies
A critical appraisal was performed using the PRISMA checklist for meta-analyses of 
observational studies (Moher et al. 2009). The following terms were addressed: random 
sequence generation, allocation concealment, blinding of participants and personnel, 
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blinding of outcome assessment, incomplete outcome data, selective reporting and 
other forms of bias. Risk of bias was considered high in case subjects were not men-
tioned. The risk was considered low in case the subject was addressed by the authors. 
However, please note that no articles were excluded from the study based on the critical 
appraisal since the majority of the studies show poor risk of bias prevention. The risk 
of bias is merely presented for information purposes of the readership.
statistical analyses
The outcome of the presented meta-analysis was the pooled result of several surgical 
techniques on different outcome measures after CBPGL treatment. For all studies, the 
proportion of local control, cranial nerve damage and serious adverse events were 
evaluated. Results were presented with an exact 95% confidence intervals (95% CI) 
were calculated. Meta-analysis was performed a logistic regression with a random 
effect model. All analyses were performed using RevManager 5.3. 
resulTs
study selection
A total of 3,565 articles were screened for title and abstract. Based on title and abstract, 
a total of 155 articles were selected for review of full text and the following studies were 
excluded: In 96 cases the results were not specified per tumour location or Shamblin 
class, 27 studies were case series-/reports of less than 5 patients and a total of 9 reviews 
were excluded too. Ultimately 27 articles were included in the review (figure 1). 
study characteristics and outcomes of studies
Ultimately, a total of 139 class 1 tumours are described in 10 articles, 228 class 2 in 
16 articles and 201 class 3 in 17 articles. Detailed information on the studies included 
in this systematic literature review are presented in appendix A. All study designs 
were retrospective cohort studies. Random sequence generation, proper prevention of 
allocation concealment or blinding of the participants or personnel was not performed 
in any of the studies. The risk of incomplete data presentation and risk of selective 
reporting are provided in appendix A as well. Outcome measures per tumour class post 
surgery are summarized in figure 2.
For Shamblin class 1 tumours, local control was achieved in 82%-100% (mean 
98%), CND was reported in only one study (25%) and no other complications were 
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Figure 1: flow chart.
Figure 2: treatment outcome per tumour class
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reported in these studies. For class 2 local control was 92%-100% (mean 98%). 
Cranial nerve damage was found in 0%-78% ( mean 17%). Complications were 
reported in 0-34% (mean 2% ). For class 3 tumours mean local control was 92% 
(range 73-100%), mean CND rate was 29% (range 0-75%), and mean complication 
rate was 12% (range 0- 60%).
Pooled results
Pooled results per Shamblin class are provided underneath in table 1. Not all outcome 
measures were reported in the included studies, therefore, the denominator might vary 
per treatment outcome. Local control was not significantly correlated with Shamblin 
class. Cranial nerve damage rates (p = 0.00, df = 2, F = 25) and complications (p = 
0.00 df = 2, F 15) were,  significantly related to Shamblin class. Bonferroni post-test 
illustrated that with respect to cranial nerve damage, there was a higher risk for class 
2 when compared to class 1, and a higher risk for class 3 when compared to class 2 (p 
both 0.00). There was no difference in complication rate between class 1 and 2, class 
3 differed significantly from class 2 (p = 0.00)
Details on cranial nerve damage and complications are presented in table 2, stratified 
per tumour class. Not all studies reported which cranial nerve was affected. The total 
number of CND reported might therefore be higher than the sum of the reported n. 
IX, X XI and XII damages.
Meta-analysis (surgical methods and treatment outcome)
Appendix A describes the risk of bias for each included study. Also, per study the use 
of potential ICA manipulation and/or reconstruction and ECA ligation techniques and 
the corresponding complication rates are presented. Outcome measures could not be 
compared per surgical technique for Shamblin class 1 and 2 tumours, because sample 
sizes were too small as few ICA and ECA reconstructions were performed for tumours 
of these classes. For Shamblin class 3 tumours, a meta-analysis was performed to 
Table 1: Pooled treatment outcome per Shamblin class
Shamblin class Local control
% (n/n total)*
Cranial nerve damage
% (n/n total)*
Complications
% (n/n total)*
Class 1 93% (130/139) 3% (4/145) 0% (0/145)
Class 2 98% (214/217) 18% (36/200) 1% (3/222)
Class 3 94% (126/134) 32% (50/155) 10% (18/177)
*Denominator ntotal refers to the total number of patients for which the outcome measure was 
reported.
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evaluate treatment outcome of specified surgical techniques. The treatment outcomes 
considered were local control, CND and other complications. The surgical techniques 
evaluated were: pre-operative embolization, ECA manipulation and/or reconstruction 
and ICA manipulation/reconstruction and craniocaudal versus caudocranial resection 
methods. Unfortunately, outcome measures were not properly stratified for embolization 
techniques and cranio-caudal versus caudocranial resections. With respect to ECA 
ligation and ICA manipulation and/or reconstruction techniques, complications were 
properly stratified, CND rates were not. However, no estimable risk ratio could be found 
with respect to local control. Therefore, only the results on ICA and ECA manipulation 
for Shamblin class 3 tumours are described (figure 3 and 4 respectively). 
Table 2: CN damage and complication rates post surgery per Shamblin class
Shamblin 
class
Total CND
% 
(n/n total) *
n. IX
% 
(n/ntotal) *
n. X 
% 
(n/ntotal) *
n. XI 
% 
(n/ntotal) *
n. XII % 
(n/ntotal) *
Total complications 
% 
(n/n total) *
CVA 
% 
(n/ntotal) *
Death 
% 
(n/n total) *
class 1 3% 
(4/145)
1% 
(1/145)
1% 
(1/145)
1% 
(1/145)
1% 
(1/145)
0% 
(0/145)
class 2 18% 
(36/200)
4.5% 
(9/200)
9% 
(18/200)
2% 
(4/200)
1% 
(3/222)
0.9% 
(2/222)
0.5% 
(1/222)
class 3 32% 
(50/155)
2.5% 
(4/155)
23% 
(36/155)
3.9% 
(6/155)
1.3% 
(2/155)
10% 
(18/177)
9% 
(16/177)
1% 
(2/177)
Total 18% 
(90/500)
1.7% 
(5/300)
9.4% 
(46/490)
5.1% 
(25/490)
1.4% 
(7/490)
4% 
(21/544)
4.5% 
(18/399)
0.7% 
(3/399)
*Denominator ntotal refers to the total number of patients for which the outcome measure was 
reported.
Figure 3: meta-analysis regarding risk of extensive ICA manipulation/reconstruction on serious adverse 
events.
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Pooled results illustrate a Risk Ratio of 3.12 with a 95% CI of 1.29-7.59, illustrating 
an enhanced risk of complications in case of ICA manipulation/reconstruction. 
Pooled results illustrate a Risk Ratio of 3.48 with a 95% CI of 0.88-13.81, illustrat-
ing a trend towards enhanced risk of complications in case of ECA ligation. 
disCussion
summary of main results
This study describes the risk profile associated with surgery of CBPGLs of different 
Shamblin class. After evaluating 25 studies and 559 patients we found that post surgery, 
adverse events increased with Shamblin class, and that local control rates decreased. 
With respect to Shamblin class 2 tumours, we found high adverse event rates in case 
standardized internal carotid artery clamping was used. Moreover, with respect to 
class 3 tumours, we found that ICA manipulation/ reconstruction and ECA ligation 
techniques were associated with complications (mainly CVA’s). These results provide 
valuable insights for CBPGL management in daily practice. We believe that class 1 
and 2 tumours could be treated relatively safely with surgery, when ICA manipulation/
reconstruction and ECA ligation is prevented. For class 3 tumours however, surgery 
should be applied with great caution as it goes hand in hand with high cranial nerve 
damage and higher complication rates. 
overall completeness and applicability of evidence
Unfortunately, there are no randomized controlled trials available on this subject due 
to the rarity of the disease and the slow growth rate of these tumours. Hence, the 
level of evidence for these recommendations is not optimal, and based on retrospective 
Figure 4: meta-analysis regarding risk of extensive ECA ligation on serious adverse events.
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cohort-studies albeit with a control group.  The retrospective nature of these studies 
however, reduces the internal and external validity of the results. Please note that we 
reduced this bias by applying a critical appraisal according to the PRISMA-statement. 
Furthermore, the individual study details of included studies are provided, including 
methodology and the results of a critical appraisal. Hereby, studies could be assessed 
for reliability/methodological quality and the impact can be regarded in the context 
of other studies.
Potential biases in review
There are several potential biases in the current review. The first is that we did not stratify 
for hereditary tumour syndromes and age of presentation. It has been suggested that 
both aspects are related to enhanced tumour growth or local invasiveness, potentially 
inducing lower local control and higher complication rates. However, stratification by 
these factors was not possible with the provided information in the current studies. 
Another aspect is the follow-up. The minimal follow-up in the current series was 5 
months which is short for CBPLG’s, particularly in the light of recurrences, CN function 
deterioration and recovery post treatment; as stated, one might expect alteration in 
cranial nerve function up to 12 months post treatment. Please note however that 
merely the study of Dardik et al. used such short follow-up periods.11 There are how-
ever, also studies that did not mention the follow-up interval. 
Also, the majority of the studies do not correct for patients that have died or have 
been lost to follow-up, i.e. they report absolute control and complication rates. The 
proper method for reporting outcome rates is the actuarial method where patients 
are censored when they die or are lost to follow-up. Depending on the proportion 
of patients censored tumour control rates may turn out to be significantly lower and 
complication rates significantly higher. Although a critical appraisal is performed, loss 
to follow-up was poorly handled by the majority of the included papers. Therefore, 
we decided not to consider this an exclusion criterion. Furthermore, with respect to 
the evaluation of treatment outcome for ICA/ECA manipulation it should be noted 
that none of the studies were designed to evaluate the risk of different surgical 
techniques. It is likely that such techniques were used, dependent on the local situ-
ation per-operatively. Therefore a considerable inclusion bias should be kept in mind 
when interpreting these results. Nonetheless, we believe the results provide insights 
in the potential consequences of surgery for these tumours emphasizing that CBPGL 
management is complex and should be confined to specialized centres and multidis-
ciplinary teams with experience in CBPGL management. 
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Comparison with other reviews 
Suarez et al. reviewed the results of surgical management of carotid body paragan-
glioma, and describe that after reviewing 67 articles including 2,175 surgically treated 
patients, that local control was achieved in 93.8 %. Surgery resulted in 483 (483/2,175 
= 22.2 %) post-operative permanent cranial nerve deficits. Three percent (n = 60) of 
patients developed a permanent stroke and 1.3 % (n = 26) died due to postoperative 
complications.3 These are absolute rates not corrected for patients who have died or lost 
to follow-up and, therefore, the true incidence is very likely higher. Furthermore, these 
results are not stratified by growth pattern or size (tumour class), which is of relevance 
since tumour class is considered to be related to local control and adverse event. 3-6 
Moreover, the evaluation of surgical techniques were beyond the scope of this review. 
implications for clinical practice and research
The aim of this study is to evaluate surgical techniques for these tumours once interven-
tion is required, e.g. because of tumour growth, or symptoms. The risk of (surgical) 
treatment can be summarized as follows: Our results illustrate that for Shamblin class 
1 tumours local control is generally 100% and there is a very low risk of CND or 
complications. Therefore, in case a patient requires treatment or in case growth is found 
after a wait-and-scan period surgery is advised as the main treatment option of choice. 
Mostly, a cervical approach is used, allowing for periadventitial tumour dissection. 
For class 2 tumours, local control was achieved mostly in 100% as well, but CND 
rates were described in 0-78% (mean 17%) between studies. Other complications are 
rare but not entirely absent. Lees et al. described one aspiration pneumonia (out of a 
series of 18 patients) resulting in death.12 Furthermore, Sanli et al. described 2 CVA’s 
with permanent neurological impairment resulting in one death out of 7 class 2 pa-
tients.13 Please note that Sanli et al. reported the only series using standard transient 
internal and carotid artery blockage for Shamblin class 2 tumours. The vast majority 
of patient cohorts were operated via a cervical incision, subadventitial plane dissection 
and occasional ECA resection/ligation and/or ICA reconstruction. No statistical analysis 
could be performed on the risk of surgical techniques on complications because of too 
few events. Due to the higher CND and complication rates, an initial wait and scan 
strategy should be applied before operating these tumours since potentially, these 
tumours do not require surgical intervention. In case of tumour resection standard-
ized transient ICA/ECA clamping should not be applied. Alternatively, a craniocaudal 
resection with selective CBPGL feeder vessel ligation method is advised, as described 
underneath.
For class 3 tumours, although local control rates are relatively good (80-100%), CND 
and complications are higher when compared to class 1 and 2 groups; CND rates were 
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found in 0-75% (mean of 32%), and complications were found in 10% (0-60%). A 
total of 16/218 patients suffered a CVA, and 2 patients died because of it. A meta-
analysis demonstrated a risk ratio of 3.14 with a 95% CI of 1.29-7.60, illustrating an 
enhanced risk of complications in case of ICA manipulation or reconstruction. This is 
explained by the risk of thrombosis of the graft or vascular spasms due to manipula-
tion. Unfortunately, the lack of stratification in the selected studies did not allow 
for detailed analysis of the impact of such surgical techniques on CND rates. In line, 
there were no differences in LC rates between the ICA manipulation/reconstruction 
group and the remaining tumours. Nonetheless, three studies used standardized ICA 
manipulation methods, of which only Arya et al. describe potential adverse events.13-15 
No difference in local control or CND rates were found in these studies. This might 
suggest that ICA manipulation does not result in higher LC or CND rates. With respect 
to ECA ligation techniques, which are suggested to be beneficial since CBPGL feeding 
vessels derive in nearly all cases from the ECA, our results suggest a trend towards 
higher risks of complications in case of ECA ligation (OR 4.46; 95% CI 0.92-21.57). 
Therefore, in line with class 2 tumours, generally an initial wait and scan regimen is 
advised for these tumours and we advise prudence with surgical intervention. 
In case surgery is mandatory for Shamblin class 2 and 3 tumours, selective CBPGL 
feeder artery ligation seems a promising alternative in reducing CND and complication 
rates. Such strategies were implemented by van der Bogt et al., Padriaans et al. and 
Spinelli et al..7, 16, 17
 Van der Bogt et al. suggest that for class 2 and 3 tumours, the craniocaudal surgical 
approach with consecutive feeder vessel ligation reduced the risk of postoperative 
morbidity since blood loss is reduced and carotid artery clamping is prevented. Al-
though no CVA’s were found out of a total of 111 resections, their results do not 
support the superiority of a craniocaudal method when considering class 3 tumours 
alone. Please note that for class 3 tumours alone, van der Bogt et al. found that 
cranial nerve damage rates were actually higher in the craniocaudal resection group 
(23.5%), when compared to the caudocranial group (12.5%). The local control rates, 
however, were higher in the craniocaudal group (70.6% versus 87.5%). The authors 
did not perform statistical analysis of these data.  For eight class 2 tumours treated 
with a craniocaudal resection method however, no cranial nerve damage was found, 
whereas in 59.1% of 22 class 2 patients treated with caudocranial resection perma-
nent cranial nerve damage was found Local control rates were similar (90.9 versus 
92.3% respectively. Again no statistical analysis was performed on these cohorts.7 
Later results by the same institute, (Padriaans et al.) found no CND damage  after 45 
craniocaudally resected CBPGLs (seven Shamblin I, 22 II, and 16 III) and a single case of 
transient hemiplegia.  Local control rate was 83% after a mean follow-up of 2.5 years. 
No explanation is found for the relatively low local control rates in the second series.16 
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It seems that CN function preservation comes at the cost of lesser control rates and 
visa versa. Moreover, these results are given in absolute rates and not corrected for 
death or loss to follow-up. The actuarial complication rates may therefore be much 
higher.  Critically analyzing the results of van der Bogt and Padriaans et al., we believe 
that for class 2 tumours indeed the craniocaudal resection techniques seems to be 
the preferred technique. For class 3 tumours however, more research is required to 
determine the potential beneficial effect of the craniocaudal technique.
Results regarding local control were not stratified per tumour class. In a smaller 
population Spinelli et al. found in 6 class 2 and 5 class 3 tumours, 100% local control 
and no CND or complications by using careful isolation of the origin of the external 
carotid artery and its distal branches outside the tumour and temporarily clamping 
all of these vessels after heparin administration.17 This allowed a safe and bloodless 
resection as the tumour was dissected from the internal carotid artery in the usual 
subadventitial plane. In this study, the internal carotid artery was never clamped, and 
respect of peripheral nerves was warranted in the clean and bloodless field. Therefore, 
although theoretically the selective feeder artery ligation techniques, with or without 
a craniocaudal approach, seem promising, the risk of recurrence and CND in Sham-
blin class 3 tumours remains problematic and the risks of surgery should be carefully 
discussed with patients. 
We could not identify a relation between pre-surgical embolization and outcome 
measures, the more since reports did not indicate which tumours were embolized and 
which were not. Therefore, the risks associated with embolization and its effects on 
treatment outcome remain unclear. Notwithstanding Power et al. described for 71 
Shamblin II and 33 Shamblin III tumours, that less extensive procedures were required 
in case of pre-operative embolization, when compared to no pre-operative emboliza-
tion (simple excision in 97% vs. 82%, P .03; internal carotid artery clamping in 15% 
vs. 37%, P .04) and had less blood loss (mean estimated blood loss, 263 vs. 599 mL; P 
.002) than the non-embolized group.18 However, there were no significant differences 
in operation time, temporary cranial nerve injury, clinically apparent cranial nerve 
deficits after 1 year, deaths, stroke rates, or postoperative length of stay. Therefore, it 
was concluded that is up to the preference of the surgeon whether or not emboliza-
tion is required. Please note however, that an inherent risk of 1-3% of CVA’s is found 
post-embolization.18 Another aspect that could not be evaluated in the current review 
is the risk of embolization as a tool for preoperative ECA closure , as opposed to 
intraoperative (surgical) closure. Particularly since intra-operative ECA ligation seems 
to be accompanied by higher stroke incidences. Therefore, the comparison between 
preoperative- and intraoperative ECA closure techniques with respect to stroke risk 
requires future research. 
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An alternative for CBPGL treatment is the use of radiotherapy. Since Shamblin is a 
surgical classification, the results of radiotherapy are generally not stratified per tumour 
class. Nonetheless, Suarez et al. described excellent local control post radiotherapy, 
and no cranial nerve deficits were found in this group. Albeit Suarez et al. found merely 
a single complication in form of CNS syndrome, the potential long-term complica-
tions of radiotherapy such as vascular damage and irradiation induced malignancies 
remain underreported. One of the concerns post-irradiation is the risk of carotid artery 
atherosclerosis.3 The effects of radiotherapy are cumulative, with an increase of 12 % 
in the stroke risk within 15 years following radiotherapy.19 In line, Wilbers et al. found 
an increased risk of strokes in head and neck cancer patients 7 years post-irradiation 
when compared to the general population (8.9 versus 1.5 per 1.000 person years).20 
The irradiation dose for HNPGL is lower compared to malignancies but it is likely that 
the vascular damage is nonetheless significant. Conversely, the risk of ischemic brain 
damage due to surgery is most evident in the immediate post-operative period; for 
class 3 tumours, this risk is 11%. Another long-term adverse effect of radiotherapy is 
induction of malignancies in the irradiated area with an estimated risk of about 1% 
and a latency time of at least 10-15 years. Radiation tissue necrosis has been described 
as well but this is a very rare event with the relatively low doses used for HNPGL, 
especially with contemporary techniques such as IMRT and VMAT/rapid arc. Given 
the above-mentioned limitations of both treatment modalities, our recommendation 
is, that, in case treatment is required for class 1 and 2 tumour, surgery is the better 
option. For class 3 tumours, surgery should be applied with caution and radiotherapy 
can be considered as a good alternative. 
An alternative that has not been reviewed in literature is tumour debulking and a 
wait-and-scan strategy for the residual tumour. Perhaps, for larger class tumours, deb-
ulking should be considered, in which resection remains within save margins, reducing 
the risk of carotid artery lesions and cranial nerve damage. In case the residual tumour 
is growing, additional radiotherapy could be applied. Unfortunately, little is known 
about this strategy and more experience with proper documentation is required on 
this approach. 
Another aspect is the fact that approximately 33% of CBPGL’s are part of an he-
reditary paraganglioma tumour syndrome and multifocal tumour management might 
be more problematic.1 Particularly if a larger class 2 or 3 tumour is involved. Bilateral 
n. X damage for example is a life threatening condition for which a permanent tra-
cheotomy might be required. Therefore, in the case of bilateral tumour management, 
a conservative approach is advised and for larger tumours the use of radiotherapy 
seems the best choice to avoid CND. Bilateral CBPGL surgery should be avoided at all 
times in order to prevent a baro-reflex syndrome.21 Generally, it should be noted that 
CBPGL management is complex and should be performed by a skilled surgeon with 
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extensive experience in head and neck PGL management. Decision making should be 
done in a multidisciplinary team of surgeons, neurologists and radiation oncologists.
ConClusion
The current review and meta-analysis illustrates that a wide variety of surgical methods 
are used. For Shamblin class 1 and 2 tumours, surgery renders proper local control and 
relatively low risk of cranial nerve damage or adverse events, particularly when carotid 
artery manipulation is minimized. For class 3 tumours, however, morbidity in terms of 
CN deficit and complications is considerable. Particularly the use of ICA manipulation/
reconstruction and potentially ECA ligation seem to induce high risks of morbidity. 
Therefore, it is advised that surgery for these tumours should be reserved for those 
patients in which tumour induced morbidity is inevitable, and should be performed 
by an experienced surgeon. Potentially, tumour volume reduction with consecutive 
post-operative radiotherapy in case of residual tumour growth could be applied for 
these higher class tumours. Primary radiotherapy is an alternative for these tumours 
as well. Future research is required to evaluate such alternative treatment strategies 
for Shamblin class 3, CBPGL. 
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absTraCT
Importance: The management of carotid body paraganglioma remains a topic of debate 
since surgery is associated with strokes and cranial nerve damage. An alternative option 
is radiotherapy, yet associated complication rates remain unknown. 
Objective: To determine the local control and complication rates post-surgery and 
-radiotherapy stratified per tumour class.
Design: First a retrospective cohort study was conducted with patient records from 1986 
to 2016 of all patients suffering carotid body paraganglioma. Minimal follow-up was 6 
months post surgery, and 5 years post radiotherapy. Second, a systematic review was 
conducted to evaluate literature on effects of radiotherapy. A 2016 Pub Med search 
was performed according to the PRISMA statement. 
Setting: A population based study was performed on primary referrals to the Rad-
boudumc, Netherlands. 
Participants: A total of 112 patients suffering carotid body paraganglioma referred to 
our centre. Eligibility criteria were proper diagnostic work-up and (long term) follow-up 
post-surgery/radiotherapy and 54 patients of different Shamblin class were included. 
Interventions: Interventions were surgical excision using a cervical approach and LINAC 
based radiotherapy. 
Main outcome measures: The main outcome measures were local control and complica-
tions, stratified as cranial nerve damage, and other. 
Results: Thirteen class 1, 25 class 2 and 16 class 3 tumours were included (median 
age 38; range 13-70). Seven class 2 and 3 patients were treated with radiotherapy 
(median age 74; range 29-83). Post surgery, local control rates were 100%, 90% and 
93% for class 1-3 respectively, cranial nerve damage rates were 0%, 8% and 18% 
and complication rates were 0% 4% and 6%. No complications were found post 
radiotherapy after median follow-up of 11 years (range 4-30), local control was 100%. 
In the systematic review, constituted of 10 cohort-studies (selected out of 136 studies) 
resembling 118 patients with median follow-up of 9.5 years (range: 1-34), local control 
as found in 96-100%, no irradiation induced cranial nerve damage and 1 potentially 
irradiation induced meningeoma was found. 
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Conclusions and Relevance: Post surgery, the risk of complications in class 2 and 3 
tumours is low, yet, complications are potentially severe. In case patients are not fit 
for surgery, radiotherapy should be applied.
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inTroduCTion
Carotid body paraganglioma (CBPGL) are the most common form of HNPGL and grow in 
close proximity with the carotid artery bifurcation and can also damage the surrounding 
the vagal and hypoglossal nerves.1 The management of these tumours remains a matter 
of debate. Surgery is still the mainstay of treatment, however, it poses a threat since it 
is related to neurovascular incidents and cranial nerve (CN) damage. Although surgical 
techniques have advanced, there is a still considerable risk of iatrogenic morbidity, 
particularly in the case of CBPGL of higher Shamblin class.2 
It has been advocated that a conservative treatment method should be pursued to 
prevent morbidity. Particularly in the case of multifocal HNPGL (HNPGL) disease which 
is associated with hereditary tumour syndromes, surgery should be applied with cau-
tion. Bilateral surgery should be avoided as this might be associated with severe com-
plications such as bilateral vagal or hypoglossal nerve palsy or baroreflex syndrome.3 
Therefore, mainly in the above mentioned scenario, alternative treatment methods 
such as radiotherapy should be regarded as a viable option. However, radiotherapy is 
accompanied with minor and more serious acute and long-term complications as well. 
The main acute complications found in radiation of this area are mucositis and loss 
of hair in a small area. Later, chronic fatigue has been found post-radiation as well as 
xerostomia. More life threatening long term complications are arteriosclerosis of the 
carotid artery which might result in strokes. Also, there is a risk of radiation-induced 
malignancies such as sarcomas. 4, 5 
In the current study we aim to evaluate the local control, cranial nerve and overall 
complication rates post surgery and radiotherapy of CBPGL of different Shamblin 
class. Also, we provide a systematic review of the currently available literature on 
CBPGL radiotherapy outcomes. Ultimately, we aim to provide insights that aid the 
constitution of guidelines for the management of HNPGL. 
MeTHods
Clinical analysis
Methods were similar to a previous manuscript of our group. 6 A retrospective cohort 
study was conducted with all patient records of patients presenting with a HNPGL 
between 1980 and 2016 in the Radboud University Medical Centre a dedicated tertiary 
Head and Neck Surgery and Cancer Centre, Nijmegen. Eligibility criteria were patients 
with a CBPGL. Patients with a malignant tumour were excluded. Out of a total of 358 
patients, 112 patients had a CBPGL and 54 were treated with surgery , seven were 
treated with radiotherapy and the remaining patients were subjected to a wait and 
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scan strategy. The following information was extracted from the records: gender, age at 
presentation, signs and symptoms at presentation, tumour class, gene mutation analysis, 
clinical and radiological signs and symptoms of tumour progression Tumour volume 
was estimated by expert radiologists as by the researchers themselves, measuring the 
largest size in the antero-posterior, medio-lateral and cranio-caudal direction. 
Patients were stratified by Shamblin class, class 1 tumours entailed no encasement 
of carotid arteries. Class 2 referred to partial encasement of either internal or external 
carotid arteries and class 3 implied full encasement of both internal and external 
carotid arteries with or without inclusion of hypoglossal nerve. 
The intervention was any form of surgery or radiotherapy, with or without a prior 
wait and scan period. The outcome of the treatment was compared to patients’ situ-
ation at first presentation, before any form of treatment and evaluated by a routine 
follow-up schedule. Follow-up had to be at least 6 months post treatment. Treatment 
outcomes were local control, CN damage and other complications. Definitions of 
treatment outcome  were according to Suarez et al.2 Post-surgery, local control was 
defined as a patient alive without evidence of disease or with a non-growing re-
sidual tumour throughout the entire follow-up period. Post-radiotherapy local control 
was defined as a patient alive without any evidence of progression of the disease 
throughout the entire follow-up period. CN damage and CN recovery were defined 
as deterioration and improvement, respectively, of CN function post-treatment when 
compared to the pre-treatment setting, objectified by a physician. The complications 
wound infection, cerebrovascular accident, aspiration resulting in pneumonia and/or 
tracheotomy, , malignancies and death were included. 
Patients were subjected to a routine follow-up which was organized as follows: 
Post-treatment, patients were seen within 2 weeks to evaluate immediate post-
treatment complications. Generally. routine follow-up was then every six months 
for patients in all treatment groups for two years. After two years usually a yearly 
follow-up protocol was organized. In case tumours remained stable for 5 years, 2 
year-follow-up intervals were adopted for ten years. Hereafter a five year interval 
follow-up was used. Post-treatment MRI-scans were done one year post treatment. 
In case local control was achieved, MRI-scans were subsequently done on a yearly 
basis. In case follow-up intervals were prolonged, MRI’s were done every 2 or 5 years. 
MRI scans were performed according to a local HNPGL screening protocol, optimized 
for paraganglioma growth and new tumour localization detection. In case patients 
suffered from severe comorbidities, post-treatment symptoms or in case complications 
were to be expected due to larger tumour sizes, follow-up intervals could have been 
reduced. Intervals were also reduced in case of multifocal tumour presence or in case 
of SDHD or –B mutations. Visa versa, in case patients were completely complication 
free and no mutation was found, follow-up intervals could have been prolonged. Also, 
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in case there was any sign of clinical tumour progression or potential new tumour 
localization, MRI scans were performed. 
For prediction of tumour growth the following variables were considered:, age at 
presentation defined as age at first diagnosis of HNPGL. Mutation presence was defined 
as presence of succinate dehydrogenase gene complex (SDH) associated paraganglioma 
syndromes (SDHA, -B, -C, -D, -AF2). Fisch classification was defined as described above. 
As presented by Jansen et al. tumours were considered to have an ellipsoid shape and 
the following equation was used to estimate the tumour volume: 
in which V = volume, A = the largest dimension in the antero-posterior direction, B 
= the largest dimension in the medio-lateral direction, and C = the largest dimension 
in the cranio-caudal direction.7 The measurement error was expected to be at least 
15%-20%, therefore, tumour growth was defined as a volume increase of at least 20%. 
literature study
Studies evaluating the effect of radiotherapy on CBPGL were included. Treatment 
outcomes collected were local control, cranial nerve damage and other complications. 
The definitions were no different from the analysis of the retrospective cohort. 
A systematic literature review was conducted according to the PRISMA statement.8 
On February 2017 we searched the Pub Med database for articles using the search 
strategy as mentioned underneath (no MeSH terms were used for inclusion of the 
most up to date articles). References of key articles were assessed for additional 
relevant articles. 
(((((paraganglioma [Title/Abstract] OR paraganglioma [MeSH Terms] OR paragangliomas [Title/Abstract] 
OR paragangliomas [MeSH Terms] OR chemodectoma [Title/Abstract] OR chemodectoma [MeSH Terms] 
OR chemodectomas [Title/Abstract] OR chemodectomas [MeSH Terms] OR glomus tumour [MeSH 
Terms] OR glomus tumour [Title/Abstract] OR glomus tumours[Title/Abstract] OR glomus tumours 
[MeSH Terms] OR glomus tumour [MeSH Terms] OR glomus tumour [Title/Abstract] OR glomus 
tumours[Title/Abstract] OR glomus tumours [MeSH Terms])))) AND (((Carotid body [Title/Abstract] OR 
Carotid body [MeSH Terms]) OR (Caroticum [Title/Abstract] OR Caroticum [MeSH Terms] OR Carotis 
[Title/Abstract] OR Carotis [MeSH Terms])) AND (Glomus [Title/Abstract] OR Glomus [MeSH Terms]) 
OR (Head and neck [Title/Abstract] OR Head and neck [MeSH Terms] OR Cervical [Title/Abstract] OR 
Cervical [MeSH Terms] OR Jugular [Title/Abstract] OR Jugular [MeSH Terms] OR Carotid [Title/Abstract] 
OR Carotid [MeSH Terms] OR Carotis [Title/Abstract] OR Carotis [MeSH Terms]))))) AND ((Radiotherapy 
[Title] OR Radiotherapy [MeSH Terms] OR radiation therapy [Title] OR radiation therapy [MeSH Terms] 
OR X-ray therapy [Title] OR X-ray therapy [MeSH Terms] OR radioisotope therapy [Title] OR radioisotope 
therapy [MeSH Terms] OR Radiosurgery [Title] OR Radiosurgery [MeSH Terms] OR Gamma Knife 
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[Title] OR Gamma Knife [MeSH Terms] OR CyberKnife [Title] OR CyberKnife [MeSH Terms] OR Linear 
Accelerator [Title] OR Linear Accelerator [MeSH Terms]) AND (Tumour [Title/Abstract] OR Tumour 
[MeSH Terms] OR Tumour [Title/Abstract] OR Tumour [MeSH Terms] OR Tumours [Title/Abstract] OR 
Tumours [MeSH Terms] OR Tumours [Title/Abstract] OR Tumours [MeSH Terms]))))
Articles written in English, German or Dutch were selected and tumours had to be 
classified. The treatment modality and outcome measures needed to be reported for 
each tumour class individually. Cohort sizes had to be 5 or more patients. Information 
on at least one of the afore-mentioned outcome measures had to be available. Also, 
information on the radiotherapy technique and corresponding outcome measures had 
to be provided. 
A critical appraisal was performed using the PRIMSA ‘Risk of bias’ tool.8 The fol-
lowing terms were addressed: random sequence generation, allocation concealment, 
blinding of participants and personnel, blinding of outcome assessment, incomplete 
outcome data, selective reporting and other forms of bias. Risk of bias was considered 
high in case these factors were not mentioned. The risk was considered low in case 
the factors were addressed by the authors. However, please note that no articles 
were excluded from the study based on the critical appraisal since the majority of the 
studies show poor risk of bias prevention. The risk of bias is presented for information 
of the readers.
statistical analysis
The number of patients lost to follow-up is reported per treatment outcome. Missing 
data were handled by using multiple imputation methods. The data was collected using 
filemaker pro, and was analyzed using IBM SPSS Statistics 22. For tumour-class correla-
tions a one way ANOVA test was used, with post-testing for individual characteristics 
using a Bonferroni test. For correlations between treatment outcomes and patient 
characteristics a Chi-square test was used. 
resulTs
Clinical results
Out of 112 CBPGL , 54 tumours were treated with surgery, and 7 with radiotherapy, 
the remaining tumours were subjected to a wait and scan management strategy. The 
baseline results are provided in table 1.
Mutation presence was evaluated in 14 Shamblin class 1, 16 class 2 and 7 class 3 
patients, mutations were found in 69%, 87.5% and 71.4% respectively There was 
no significant correlation between Shamblin class and treatment outcome overall, nor 
when stratified per treatment modality. A Bonferroni post-test found no differences 
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in treatment outcome per tumour class. Neither was there a relation between treat-
ment outcome and presenting symptoms, age at presentation, pre-treatment tumour 
growth, mutation presence or tumour size 
Two cranial nerve deficits were found in Shamblin class 2 tumours: one transient 
accessory nerve palsy and one permanent case of a Horner syndrome. Also, a compli-
cation in form of baroreflex syndrome was described in a patient suffering a contralat-
eral vagal body tumour. In a class 3 tumour a complication was observed resembling a 
stroke without long term effects as well as two permanent cranial nerve deficits: one 
case of hypoglossal nerve palsy and one case of a Horner syndrome. 
A total of 7 patients were treated with radiotherapy. Characteristics of these patients 
can be found in table 2. Local control was 100% in this group, no CN damage or 
adverse events were found after a median of 147 months follow-up (range 48 -360). 
There was no significant difference between results of radiotherapy and surgery for all 
CBPGL s combined with respect to local control (p = 0.44), CN damage rate (p = 0.32), 
or complications (p = 0.19),nor when stratified per Shamblin class (results not shown). 
results of the systematic literature-study
Our Pub Med search generated 136 studies that were screened for title and abstract. 
A total of 34 studies were selected for full review, and 10 articles were selected based 
on adequate follow-up, detailed information on treatment outcomes of malignant 
and non-malignant tumours. These are presented in table 3. Exclusion criteria are 
presented in figure 2. 
In these 10 studies, a total of 118 patients with CBPGLs were described who were 
treated with radiotherapy, of which 8 were malignant. Local control was achieved in 
80-100% of cases (median of 97%); 1 patient died after re-irradiation after residual 
tumour growth, it is possible that tumour growth was due to malignant progression. 
When malignant tumours are excluded, local control was achieved in 96-100% of 
cases (median 100%). No irradiation induced cranial-nerve damage was found and a 
single (potentially radiation-induced) meningioma was found after multifocal tumour 
Table 1: Baseline results and treatment outcome post surgery per Shamblin class.
Shamblin class 1 Shamblin class 2 Shamblin class 3 Total
N (%) 13 25 16 54
Median age, (range) 39 (13-63) 41 (13-73) 32 (14-70) 38 (13-70)
Tumour growth n (%) 6 (45%) 13 (53%) 8 (50%) 27 (50)
Symptomatic presentation n (%) 6 (45%) 19 (76%) 12 (75%) 37 (68%)
Median volume (Range) in cc 64 (6-238) 115 (14-348) 391 (132-800) 197 (6-800)
Median follow-up, (range) surgery/ 
Radiotherapy in months
73 (12-199)/
-
67 (10-251)/ 
88 (48-120)
65 (13-166)/ 
192 (132-360)
68 (10-251)/ 
147 (48-360)
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Table 2: characteristics of patients treated with radiotherapy
Patient age shamb.
class
Tumour
syndr.
Volume in cc 
(max 
diameter in 
mm)
Treatment
motivation
Motivation 
for rT
rT tech. follow-up 
(years)
1 74 3 - 720 (45) Complaints 
and growth
Comorbidities and 
size of tumour
50Gy 
in 25 
fractions
11 year
2 83 2 - 122 (23) Tumour 
growth
Comorbidities 46 gy. 
in 23 
fractions
10 year
3 76 3 - 290 (29) Tumour 
growth
Size of tumour 47Gy 
in 25 
fractions
30 year
4 78 3 - 1200 (60) Complaints Size of tumour 
and comorbidities
50Gy 
in 25 
fractions
11 years
5 46 3 SDHD 140 (35) Tumour 
growth
Bilateral/
multifocal disease/ 
Comorbidities and 
size of tumour
40 Gy, 20 
fractions
12 year
6 48 2 SDHD 55 (23) Tumour 
growth/ CN 
damage
Bilateral/
multifocal tumour 
localisation
25 Gy 
in 12 
fractions 
4 year
7 29 2 SDHD 39 (20) Tumour 
growth
Bilateral/
multifocal tumour 
localisation
25 Gy 
in 12 
fractions 
8 year
Figure 1: treatment outcome per Shamblin class
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irradiation. This patient was treated at age 30 for 3 paragangliomas (1 carotid and 2 
Fisch type D2 skull base) and presented a parietal meningioma 15 years after irradia-
tion. It was treated by surgery and has been in complete remission for 5 years at time 
of writing.
disCussion
The current results illustrate that surgery is a proper treatment option for CBPGL . 
However, particularly for class 2 and 3 tumours, there is a risk of serious complications 
including cerebrovascular accidents and CN damage. In the current study, no predictor 
of complications could be found. Radiotherapy is an alternative option. For 7 of our 
patients suffering class 2 and 3 tumours, radiotherapy gave 100% local control without 
complications. The main motivations for radiotherapy were comorbidities (not fit for 
surgery) and bilateral tumour presence. Our literature review, evaluating the results of 
123 patients shows that, when excluding malignant paraganglioma (6%, 8/123), local 
control is indeed achieved in 96-100% without any cranial nerve damage. A single 
case of a (potentially) radiation-induced meningioma was found. 
These results underline that in case treatment is mandatory, for class 1 tumours sur-
gery is a good option. For class 2 and 3 tumours, radiotherapy is a serious alternative, 
particularly in the case of mulitiple tumours or in case a patient is not fit for surgery. 
Figure 2: flow chart.
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Table 3: study characteristics and treatment outcome of included studies.
reference n 
carotid 
body 
Pgl
Malignant Treatment 
modality/ gy 
(range)
follow-up local 
control
Complication/ Cn 
damage
Mitchell 
and Clyne 
19869
5 2 EBRT Gy 4565;( 
3750; 5500)
65 months 
(18-96)
80%; 100% 
for non 
malignant
One death of 
malignant disease
Valdagni 
and 
amicheti 
199010
13 0 EBRT 46-60 Gy 
(mean 52.25 Gy
12-228 
months
100% None
Verniers et 
al. 199211
8 0 EBRT 50 to 60 
Gy in 20 to 25 
fractions over 4 
to 5 weeks.
120 (12-
240)
100% None
evenson et 
al. 199812
13 2 EBRT 47.8 (35-
70)  in 25-39 
fractions 
456 (12-
120).
5; years, 
96% and 
100%; 10 
years, 96% 
and 100%
One death after re-
irradiation; thought 
due to CNS syndrome, 
in case of a potentially 
malignant tumour. 
luna ortiz 
et al. 
200513
7 0 EBRT; Not 
reported
38 (Range 
not 
reported)
100% Not reported
krych et al. 
200614
4 0 EBRT: 45 Gy 
(range, 16.2–54 
Gy). 25 fr.(range, 
9–30). SRS: 
15 Gy (range, 
12–18 Gy) 
161 (4– 
429)
100% None
Hinerman 
et al. 
200815
24 0 EBRT 4500 cGy 
25 fr.  SRS in 6 
patients 1250-
1500 cGy 
10 years  
(range not 
reported)
96% Not reported
Chino et al. 
200916
3 1 EBRT 54 Gy 
( 38–65 Gy), 
median fraction 
size 180 cGy 
(range: 180–356 
cGy).
108 (24-
420)
100%   None
Ma et al. 
200917
5 3 n.r. 132 (24-
312)
100% 3 patients died.
dupin et al. 
201418
9 0 EBRT 45 Gy 
(range, 45-46 
Gy)
102 (12-
276)
100% (irradiation induced?) 
meningioma in 
multifocal tumour 
presence
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Clinical considerations
Although not statistically significant, complications were mainly found for class 2 and 
3 tumours. This relation has been described by several authors before and we believe 
the Shamblin classification is still a suitable predictor for risk of surgery.13 In order to 
reduce risk of surgery several techniques have been proposed.  Generating a bloodless 
operating field has been proposed, allowing for better 
visualization of residual tumour, cranial nerves and the carotid arteries.19 To this end, 
transient clamping of the carotids has been suggested.20 However, a recent meta-
analysis from our group demonstrated that such techniques were associated with 
an enhanced risk of cerebrovascular accidents.21  Other approaches used external 
carotid artery ligaton techniques, since 90% of the CBPGL feeding arteries arise 
from the external carotid artery. 22-24. However, our meta-analysis illustrated a trend 
towards an enhanced risk of cerebrovascular accidents with this technique as well. To 
prevent routine standard clamping of carotid arteries, van der Bogt et al. proposed in 
2009 a craniocaudal resection technique in which the external carotid artery and its 
feeder branches were targeted first, rendering minimal blood loss when dissecting the 
tumour from the internal carotid and the common-carotid artery and more accurate 
visualization of cranial nerves.19 Using this technique, no cerebrovascular accidents 
were found (n = 111), however, higher cranial nerve damage rates were found for 
class 3 tumours using this technique (23.5%), when compared to the conventional 
caudocranial surgical method (12.5%). Also, the local control rates were higher in 
the craniocaudal group (70.6% versus 87.5%). The surgical method was reviewed by 
Padriaans et al., who found no CN damage  after 45 craniocaudally resected CBPGL’s 
(seven Shamblin 1, 22 class 2, and 16 class 3). The local control rate of this group 
was 83% after a mean follow-up of 11 years.23 The exact benefit of this technique, 
therefore remains uncertain and requires further systematic research. 
Several other methods have been suggested to reduce morbidity, such as routine 
heparine administration, but there is no good evidence that this is associated with 
better treatment outcome.22 Also, pre-operative embolization techniques have been 
suggested as these reduce intra-operative blood loss and operation time.25, 26 Pre-
operative embolization is not routinely used either, as it is not clear if it really reduces 
morbidity and there is an inherent risk of a stroke associated with this method. 
In the current series surgery was not considered for patients with bilateral multifo-
cal HNPGL, because of the significant morbidity if surgery-induced bilateral cranial 
nerve damage occurs. For these patients, radiotherapy was applied and excellent local 
control rates and no irradiation induced CN damage was found, albeit that we had 
only 7 patients in our series. The systematic literature review agrees with the excellent 
local control rates (96-100%) for non-malignant HNPGL’s. However, radiotherapy is 
not free of complication risk either. 
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The most severe irradiation induced complications are found after re-irradiation. The 
first is described by Evenson et al. 1998 who found a delayed type CNS syndrome post 
treatment after using a high dose regimen twice (60Co single fraction and 47.8Gy 
in 25 fractions, respectively).12 The tumour was re-irradiated because of progression 
after the first treatment. Potentially this tumour progression was due to malignant 
paraganglioma disease. 
The second severe complication was also found after re-irradiation. This patient 
was treated with radiotherapy for 1 carotid and 2 Fisch type 2D skull base tumours. 
A parietal meningioma was found 15 years post treatment. In this series, another 
(supposedly) radiation-induced meningioma was found 18 years post treatment after 
a single RT doses of a not further specified HNPGL. Several authors have estimated the 
risk of irradiation induced neoplasms, Lalwani et al. suggest that the incidence of tu-
mour induction is approximately 1 in 1.000 to 2.000.5 Springate et al. estimated a risk 
of post-HNPGL irradiation of about 0.28%.4 For example, we found no complications 
after use of the LINAC-based treatments. However, the long term risks of radiotherapy 
remain uncertain. This is underlined by results of Gilbo et al. who found no severe 
complications post radiotherapy and a local control rate of 96.8% after 10 years for 
156 HNPGL (not stratified per tumour type).27 Although these results are promising, 
one of the concerns post irradiation is the chance of carotid artery stenosis, particu-
larly in the case of CBPGL . Gujral et al. described in 2014 that a systematic review 
of 34 articles illustrated that the relative risk of stroke in patients irradiated for head 
and neck cancer relative to the general population was 5.6 and the carotid intima-
medial thickness was significantly increased by 22-36% (when compared to matched 
control-groups) after 1 to 2 years.28 Obviously, head and neck-cancer patients cannot 
be compared to HNPGL patients, however, the late vascular effects of radiotherapy 
are undeniable and well-documented. The mean age of our surgery group was 38 
years of age which is significant lower than the mean age of Head and Neck cancer 
patients. Not only do other patient factors differ between patients suffering HNPGL 
and head and neck cancer, also treatment regimens differ. Radiotherapy doses pre-
scribed for HNPGL are lower (range 30-50 Gy in our series), when compared to the 
head-and-neck cancer population (50-80 Gy, described by Gujral et al..28 The details 
of the dose-effect relation of RT-induced arteriosclerosis are not fully known yet. 
Nonetheless, there is a serious risk of enhanced atherosclerosis development. Another 
factor that theoretically enhances the risk of carotid atherosclerosis in CBPGL-patients 
when compared to other HNPGL, is the suggestion of Dorresteijn et al. that the larger 
the part of the carotid that is irradiated, the higher the risk of atherosclerosis.29 More 
research is required on the risks of radiotherapy for CBPGL, especially on the long 
term. The option should be carefully discussed against the background of the surgi-
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cal risks. Other long-term risks of head and neck irradiation is the development of 
radiotherapy-induced malignancies, for which the risk is about 1% after 10 years.30 
Methodological considerations
In line with our other research on HNPGL, the current study is a retrospective cohort 
study and therefore the external validity is limited. However, given the rarity of these 
tumours and their slow growth rate, prospective (randomized controlled) studies are 
not possible. Furthermore, although the current study provides one of the larger 
sample size on this particular tumour type, for sub-group analysis the cohort is too 
small (Jansen et al. 2017). 
Moreover, the literature search using the terms “radiotherapy” and “CBPGL” yielded 
few results and mostly small patient numbers because generally radiotherapy remains 
the second choice of treatment after surgery. Due to this selection most studies in-
clude patient cohorts that span two to three decades or even more to reach sufficient 
patient numbers, implicating that many patients were treated with older radiotherapy 
techniques. Modern techniques such as IMRT, VMAT/rapid arc and stereotactic ra-
diotherapy are expected to reduce complication rates. However, the more clinically 
relevant complications are the long-term sequelae. This complicates the evaluation 
of treatment results because it requires meticulous life-time follow-up because the 
vascular effects of radiotherapy continue to progress. In the mean time radiotherapy 
techniques as well as methods for outcome assessment will further develop making 
comparisons with historical controls difficult.
ConClusion
The current study describes the treatment outcome of CBPGL treated in the Radboud 
University Medical Centre in Nijmegen, Netherlands. The risk of complications in class 2 
and 3 CBPGL is low, however, complications are potentially severe. In case patients are 
not fit for surgery or in case there is a risk of potential bilateral cranial nerve damage, 
radiotherapy should be seriously considered. In our series no complications were found 
with irradiation in 7 patients and local control was 100% after a median of 12 years 
(range 4-30 years) The low complication risk was confirmed by an additional literature 
research. Until recently the awareness for carotid atherosclerosis as a complication of 
radiotherapy for CBPGL was low but studies in head and neck cancer patients indicate a 
significant risk of ischemic stroke years after radiotherapy. Also with the radiation doses 
used for CBPGL there is an increased risk of late vascular complications and stroke. Ad-
ditional research is required to evaluate the overall stroke risk after irradiation of CBPGL. 
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With current knowledge we recommend that class 1 tumours should be treated with 
surgery. For class 2 and 3 tumours, radiotherapy should be discussed as alternative 
treatment option, particularly in the elderly or in case of multiple tumours. 
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absTraCT
Background: The treatment of vagal body paraganglioma is a hot topic of debate 
since surgery is associated with high morbidity rates and radiotherapy results are not 
systematically documented. 
Methods: Systematic literature review according to the PRISMA statement in August 
2017, searching the Pub Med database. 
Results: A total of 17 retrospective cohort studies were selected representing 177 
patients treated with surgery and 78 patients treated with radiotherapy. Compared to 
surgical results, post radiotherapy, there were significantly higher local control (95% 
vs. 100% resp.), and significantly less cranial nerve damage (97% vs. 0% resp.) and 
complication rates (29% vs. 0%). 
Conclusions: Surgery is not the preferred treatment option for vagal body paragan-
glioma. Local control after radiotherapy is high but long-term side effects are not well 
documented. The risk of cranial nerve damage caused by radiotherapy seems small 
when compared to the risk of iatrogenic nerve damage post surgery.
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inTroduCTion 
Vagal paraganglioma are tumours arising from the paraganglia of the vagal nerve, and 
form about 7-15% of all HNPGL [1]. Contrary to the carotid body and jugulotympanic 
paragangliomas, there is no broadly accepted classification for these tumours. 
The main treatment options for these tumours are surgery and radiotherapy, which 
are generally applied after an initial wait-and-scan policy. Although surgery is histori-
cally the main treatment of choice, it contains a high risk of iatrogenic morbidity in 
terms of vagal nerve palsy [2]. Therefore, alternatively, radiotherapy has been pro-
posed as a suitable alternative. The risks of radiotherapy of these tumours however, 
are not systematically documented. Suarez et al. attempted a systematic review on 
this topic but could find only one study containing 10 patients (100% local control, 
no adverse events) [2]. Obviously, more information is required on the advantages and 
disadvantages of surgery and radiotherapy for these tumours. 
In the current study, we aim to evaluate the benefits and risks of surgery and radio-
therapy for patients suffering vagal paraganglioma, in terms of local control, cranial 
nerve damage, complications and function recovery rates. 
MeTHods 
The methods used were as described earlier by Jansen et al.[3].
eligibility criteria
Studies evaluating the effect of surgery and radiotherapy in patients with vagal paragan-
glioma were included. The intervention was any form of surgery or radiotherapy, with 
or without a previous wait-and-scan period. The treatment outcomes were compared to 
the patients’ situation before treatment. Treatment outcomes were local control, cranial 
nerve  damage and other complications. The definitions used were according to Suarez 
et al.[2]. Local control after surgery was defined as a patient alive without evidence 
of disease throughout the entire follow-up period. Local control after radiotherapy 
was defined as a patient alive with stable or decreased size of the tumour. Cranial 
nerve damage was defined as deterioration of cranial nerve function post-treatment 
when compared to the pre-treatment setting, objectified by medical professionals. 
Cranial nerve recovery, was defined as any improvement of cranial nerve function in 
post-treatment setting when compared to pre-treatment conditions, objectified by 
medical professionals. The complications CSF leakage, wound infection, CVA, baro-reflex 
failure syndrome, aspiration resulting in pneumonia and/or tracheotomy and death 
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were included. Furthermore, immediate complications such as dysphagia, skin burns, 
mucositis, Eustachian tube dysfunction and xerostomia were evaluated. 
literature review
A systematic literature review was conducted according to the PRISMA statement [4]. In 
August 2017 we searched the Pub Med database for articles using the search strategy 
as mentioned below (no Mesh terms were used for inclusion of the most up to date 
articles). References of key articles were assessed for additional relevant articles. The 
search strategy is included in Appendix A. 
Study selection and the data collection: 
Articles written in English and German were selected and cohort sizes had to consist 
of 5 or more patients. Information on at least one of the aforementioned outcome 
measures had to be available. Also, information on the surgical and radiotherapeutic 
technique and corresponding outcome measures had to be provided. Furthermore, 
long term treatment outcomes post radiotherapy with a follow-up of more than 10 
years are individually subtracted from individual studies as well evaluated.
Risk of bias in individual studies
A critical appraisal was performed using the PRIMSA ‘Risk of bias’ tool [4]. The fol-
lowing terms were addressed: random sequence generation, allocation concealment, 
blinding of participants and personnel, blinding of outcome assessment, incomplete 
outcome data, selective reporting and other forms of bias. Risk of bias was considered 
high in case these aspects were not mentioned. The risk was considered low in case 
the subject was addressed by the authors. However, please note that no articles were 
excluded from the study based on the critical appraisal since the majority of the stud-
ies show poor risk of bias prevention and excluding them would result in insufficient 
data for subsequent review and analysis. 
statistical analyses
The outcome of the presented meta-analysis was the pooled result of several surgical 
techniques on different outcome measures after vagal paraganglioma treatment. For 
all studies, the proportion of local control, cranial nerve damage and serious adverse 
events were evaluated. Results are presented with 95% confidence intervals (95% CI). 
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resulTs
Out of 2460 articles, after screening for title and abstract, 56 articles were selected 
for full text review (exclusion criteria are provided in figure 1). Ultimately, a total of 17 
articles were selected representing 177 patients treated with surgery and 78 patients 
treated with radiotherapy. A summary of the selected articles is provided in table 1. 
Please note that no detailed information was provided on immediate radiotherapeutic 
complications. Moreover, long term treatment outcomes with a follow-up of more than 
10 years were not stratified for vagal paraganglioma. 
general results
The results of the individual studies are presented, without pooling of results . After 
surgery, local control rates were found in 67% to 100% of cases. Overall, cranial 
Figure 1: Flow chart
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nerve damage rates were found in 50%-100% of cases and reported percentage of 
complications varied from 0% to 56%. Post-radiotherapy local control was reported 
for all cases included in the studies. No cranial nerve damage was observed, albeit any 
information about cranial nerve damage was only reported in 4 manuscripts representing 
14 patients. Serious adverse events were not found either in 27 patients. 
Pooled results
Second, the pooled results of different studies are presented. Table 2 presents the 
treatment outcomes per tumour (some patients had multiple tumours), stratified per 
treatment modality. There was a significantly higher local control rate for vagal body 
tumours treated with radiotherapy. Moreover, there were significantly less cranial nerve 
deficits and complications found post radiotherapy.
Cranial nerve damage and complications
Post surgery, the vagal nerve was affected after resection in all but 6 tumours; a total 
of 267 treatment induced cranial nerve damages were found post surgery in 177 
tumours in 152 patients, rendering 1.51 nerves affected per tumour excision. Details 
on the remaining cranial nerve deficits are presented in table 3. Please note that for 
12 tumours, it was not specified which nerve was affected. Moreover, post surgery 
complications were found 50 times (30% of cases). The main complications found are 
presented in table 4.
Table 2: Pooled treatment outcome per tumour, post surgery and radiotherapy
Surgery Radiotherapy P value(df = 1)
Local control % (n/ntotal) 95%  (161/170) 100% (78/78) 0.039
Cranial nerve damage % (n/ntotal) 97%% (171/177) 0% (0/14) 0.00
Complications % (n/ntotal) 29% (50/170) 0% (0/27) 0.00
Table 3: cranial nerve deficits post-surgery
Cranial nerve No % (n/ntotal)
N VII 5% (12/255)
N. IX 6% (16/255)
N. X 66% (168/255)
N. XI 5% (13/255)
N. XII 8% (21/255)
Horner syndrome 4% (10/255)
Other 6% (15/255)
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disCussion
These results illustrate that little is known about the long term treatment effects after 
radiotherapy for vagal paraganglioma. Significantly higher local control rates were 
found post-radiotherapy when compared to surgery. Also, no complications were 
found post-radiotherapy, compared to 30% complication rate post surgery, including 
events such as aspiration pneumonia, tracheotomy, and CVA. Moreover, high cranial 
nerve damage rates were found postoperatively, with an average of 1.51 nerves being 
damaged per tumour resection in which the vagal nerve was functionally spared in 
merely 3% of tumour excisions, constituting 66% of a total of 255 cranial nerve deficits. 
The precise effect of radiotherapy on cranial nerve damage rates remains uncertain, 
yet, in the 14 patients for whom it was reported, no cranial nerve damage was found. 
The high iatrogenic morbidity rates induced by surgery in terms of cranial nerve 
damage and complications are in line with previous literature. Suarez et al. found 
a local control rate of 93%, and a risk of 1.41 nerves being damaged per tumour 
resection [2]. Moreover, a complication rate of 18.9% was found in this series: 10% 
chance of aspiration/pneumonia, CSF leakage in 2.6% of cases, wound infections in 
2.2%, stroke in 2.2% and a meningitis in 0.4%, leading to death in 1.3% of cases. No 
other reviews were found describing the effect of treatment of vagal paraganglioma 
in general. With respect to radiotherapy for vagal paraganglioma, no comparative 
systematic review is available at the time of writing. 
recommendations for daily practice 
Considering the treatment induced morbidity found post-surgery and the potential 
long-term effects of radiotherapy, an initial wait-and-scan policy seems the preferred 
option for vagal paraganglioma management. Bradshaw and Jansen et al. presented 
40 vagal paraganglioma that after an average follow-up of 8.5 years (range 1-26 
years), merely three patients developed a nerve palsy (8%) following radiation [5]. Our 
group found a risk of tumour-induced complications in 12% of cases in a series of 157 
Table 4. Complications found post-surgery
Complication No. Complications % (n/ntotal)
Wound infection 10% (5/50)
CSF leakage 8% (4/50)
CVA 14% (7/50)
Pneumonia 28% (14/50)
Tracheotomy 36% (18/50)
Death 4% (2/50)
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paraganglioma (including 29 vagal paraganglioma) in which a wait-and-scan policy was 
adopted. This risk was independent of tumour localization [6]. These results need to 
be weighed against the risks of radiotherapy for these tumours. 
In case treatment is necessary, our results demonstrate that surgery should be con-
sidered vigilantly because of the risk of severe iatrogenic complications. Other authors 
proposed exceptions where surgery can be considered. For example, Suarez et al. 
suggested that vagal paraganglioma can be surgically removed in case of an already 
present n. X palsy as this will be the main cranial nerve at risk [2]. However, our review 
describes a current risk of 1.58 nerves being affected per tumour excision as the N. 
X is damaged in almost all  cases, there remains a 0.58 chance of inducing other 
cranial nerve damage. According to our results, the hypoglossal, accessorial, glos-
sopharyngeal and facial nerve are mostly at risk. Given these limitations of surgery, 
radiotherapy should be seriously considered for patients with vagal paraganglioma, 
also in case of readily present N. X palsy. 
As suggested by Suarez et al., it seems possible to remove small vagal paraganglioma 
without inducing cranial nerve damage [2]. The rationale that smaller tumours are 
more successfully removed has been proven for jugulotympanic and carotid body para-
ganglioma, in which enhanced morbidity is found with increasing Fisch and Shamblin 
class’ respectively. In this light, it was suggested by Browne et al. in 1993 to classify the 
tumours with respect to the involvement of the jugular foramen [7]. Class I tumours 
would resemble those not involving the jugular foramen, class II would show invasion 
of the foramen but no bony destruction, whereas class III tumours are those with bony 
destruction. Unfortunately however, to date no outcome measure is associated with 
the classification. No other studies were found describing the relation between tumour 
size and surgical outcome measures. Nevertheless, it seems likely, that nerve function 
preservation is troublesome for vagal paraganglioma as even the smaller tumours 
grow in close relation with the vagal nerve, whereas small jugulotympanic and carotid 
paraganglioma grow in less proximity with cranial nerves and are therefore more suc-
cessfully removed surgically. Nonetheless, this issue might be further explored. 
Taken together, the authors suggest there is little place for surgery in the manage-
ment of benign vagal paraganglioma. On the other hand, knowledge about the long-
term effects of radiotherapy with respect to functional outcome and sequalae such 
as induced malignancies and vascular stenosis is incomplete. In our series, there were 
three studies that evaluated the long term effects of radiotherapy. Unfortunately, these 
series did not stratify results for vagal paraganglioma, rather, results are presented for 
all HNPGL types combined. With respect to recurrence free survival, Verniers describe 
in 1992, for 44 HNPGL an actuarial local control rate of 88% after 10 years using 
conventional external beam radiotherapy [8]. More modern techniques were used by 
Hinerman et al. and better results were found: after more than 10 year follow up post 
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radiotherapy for 42 HNPGL using radiosurgery the actuarial local control and cause-
specific survival rates at 10 years were 94% and 95% [9]. In line, Dupin et al. present 
for 66 patients with 81 head and neck PGL, consisting of 18 vagal PGL with median 
follow-up of 4.1 years (range, 0.1-21.2 years) an actuarial local control rate of 98.7% 
at 10 years using fractionated external beam techniques [10]. These results suggest 
that local control rates post radiotherapy seem acceptable over a course of 10 years 
with use of modern techniques. These results are in line with results of a systematic 
review regarding radiotherapy results of Fisch class C and D tumours conducted by our 
group, evaluating local control rates 10 years post radiotherapy for 66 patients. In this 
study, local control was found in 96% 10 years post treatment. 
Less is known about the long term functional nerve preservation rates. In the current 
study results seem promising, however, conclusions are weakened by the small patient 
numbers. Regarding functional outcomes of head and paraganglioma in general, 
Gilbo et al. in  2014 report for a particularly large series of 156 benign HNPGL no 
cranial nerve damage at a median follow-up of 11.5 years [11]. A recent review of our 
group however, found less favourable results: After systematically reviewing literature 
on jugulotympanic paraganglioma, we found Cranial nerve damage-rates in 3-9% of 
Fisch class C and D tumours, post-irradiation in 119 cases respectively [3]. However, 
these results are much lower than cranial nerve damage rate found post surgery. 
Furthermore, besides cranial nerve damage, irradiation induced malignancies and 
vascular stenosis are potential detrimental late complications. Dupin et al. describe 
a case of carotid artery and cerebral artery stenosis 5 years post treatment, also 
two secondary neoplasms are found within 10 years follow-up [10]. However, large 
series further elucidating the risk of vascular complications following radiotherapy 
for paraganglioma are lacking. To further evaluate the risk of vascular stenosis and 
secondary malignancies following radiation, potentially conclusions can be drawn 
from other tumour types. In patients irradiated for head and neck cancer and with a 
median follow-up of 7 years, the risk of stroke has been reported to be six-fold higher 
compared to the general Dutch age-matched population [9]. Furthermore, Gujral et 
al reported a 5.6 higher risk compared to a matched control group [10]. It should be 
noted that the radiation dose is generally higher and treatment volumes are larger for 
head and neck cancer and also these patients have a higher risk profile (smoking, diet, 
physical activity) for vascular diseases than vagal paraganglioma patients. Neverthe-
less, one should be aware that also after radiotherapy for HNPGLs there is likely a 
significant risk of cerebrovascular complications. In conclusion, although irradiation in-
duced sequelae might be expected lifelong after treatment, in our view, the inevitable 
risk associated with surgery, justifies the use of radiotherapy for treatment of these 
tumours. We strongly recommend counselling of these patients about risk factors for 
cerebrovascular disease including smoking cessation and other life style factors.
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Furthermore, there are more immediate complications associated with radiotherapy 
of the head and neck region, mainly referring to mucositis, skin burns, dysphagia 
and Eustachian tube dysfunction. Again, these outcomes were not stratified for vagal 
paraganglioma, but rather presented for HNPGL in general. Dupin et al. present such 
immediate complications in 37% of 81 HNPGL, resembling 20 cases of xerostomia 
and 10 cases of mucositis, ulceration or herpes zoster complications [10]. Hinerman 
describe less complications, as it was found in 5% of 104 HNPGLs, referring to 2 cases 
of otitis media or external otitis, 2 cases of xerostomia and a single case of mucositis 
[8]. Verniers et al. 1992 mention a single case of middle ear infection in a cohort of 
44  patients, resembling a complication risk of 2% [9]. Also, these more immediate 
complications should be taken into consideration when counselling patients as they 
might induce serious morbidity for patients. 
Another factor that should be considered is that in case of hereditary paraganglioma 
syndromes, and particularly for tumours arising from SDHB, -AF2 and -D mutations, 
enhanced tumour growth and multifocal tumour presence can be expected [1]. Bilat-
eral tumour growth can cause bilateral cranial nerve palsy, which in the case of n. X, is 
a life threatening complication that almost always requires a tracheotomy. Therefore, 
in the case of bilateral tumour presence, or in case of a hereditary tumour syndrome, 
surgery of the vagal paraganglioma should be avoided at all times. 
Another treatment method considered for jugulotympanic paraganglioma is the 
use of tumour debulking with irradiation of the residual tumour in the case of post-
operative growth. For jugulotympanic paraganglioma this may be an alternative to 
consider, since with leaving tumour mass on the cranial nerves, nerve function might 
be preserved. It remains uncertain whether or not this method can be applied for 
vagal paraganglioma due to an inherent close proximity of the tumour to the vagal 
nerve. More research is required to evaluate this treatment option. 
Methodological considerations
Due to the low incidence and growth rate of these tumours no randomized controlled 
trials are at hand and therefore the level of evidence of the included studies is low. In 
order to minimize the confounding effects of reviewing retrospective cohort studies, 
the PRISMA tool was used to assess the quality of the studies. See appendix a, for the 
results of this critical appraisal. 
Furthermore, it should be noted that there is an inherent bias in comparing the re-
sults of local control for surgical and radiotherapy series. Post surgery, no evidence of 
disease is required to achieve this, whereas post radiotherapy a stable tumour would 
suffice, where radiation would never achieve eradication of the tumour. However, 
stabilization of the tumour is the main goal in our opinion. 
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Also, particularly in the studies presenting results post radiotherapy follow-up might 
have been too short to account for late effects of radiation. Therefore, the complica-
tion rate as presented in the current series is likely an underrepresentation of total 
complications to be expected post radiotherapy. We attempted to overcome this issue 
by analyzing sub-cohorts with long term results. Unfortunately these were not strati-
fied per tumour type.  
Unfortunately, the number of studies and patients were too low to reliably esti-
mate the risk of cranial nerve damage and other late sequelae after radiotherapy. 
This prevents a firm recommendation on the management of vagal paraganglioma 
in daily practice, and even more so with regard to multifocal HNPGL. To this end, we 
advise that prospective studies are initiated with protocols that carefully document 
presenting tumour symptoms and tumour extensions. We did not stratify our results 
by surgical technique. Several groups used per-treatment embolization techniques 
which might influence the results. The impact of different irradiation techniques, frac-
tionated conventional vs. stereotactic techniques could not be analyzed because of 
unavailability of data and small numbers. This is worthy of mention since older studies 
have been included as well, resembling series of patients treated with less advanced 
treatment strategies, which might have resulted in poorer outcomes. 
Finally, we also did not evaluate the effect of different tumour syndromes with 
respect to tumour outcome. Potentially, mutation presence alters the growth rate/
invasiveness of the tumour which might affect (long term) treatment outcomes.
ConClusion
This review demonstrates that surgery is not the preferred treatment option for vagal 
paraganglioma. Local control after radiotherapy is high but long-term side effects are not 
well documented. As with other PGLs that grow in close proximity with cranial nerves, 
the risk of cranial nerve damage caused by radiotherapy seems small when compared 
to the risk of iatrogenic nerve damage and other complications post surgery. Properly 
designed (long term) prospective registration studies are needed to assess the risk of 
ischemic brain injury due to radiation-induced atherosclerosis of the carotids. Given 
that both surgery and radiotherapy are not free of side effects and complication risks, 
a wait and scan policy seems wise to adopt as a primary step in the management of 
vagal paraganglioma, particularly in the case of multifocal tumours, since bilateral N. X 
damage is a serious, potentially life threatening condition. In our opinion, radiotherapy 
should be considered in case radiological follow-up indicates persistent tumour growth 
and tumour-induced morbidity can expected, or when N. X palsy is imminent. 
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Purpose: The management of vagal body paraganglioma remains a hot topic of debate. 
The main treatment options are surgery and radiotherapy. However, little is known 
about the risk factors of associated with treatment outcomes such as local control, 
cranial nerve damage and complications. 
Methods: First a retrospective cohort study was conducted with patient records from 
1986 to 2016 of all patients suffering vagal paraganglioma
Results: Out of 16 patients 11 were treated with radiotherapy. Post surgery and ra-
diotherapy local control rates were 100% at 20 months (range 15-38) and 11 years 
(Range 3-29) follow-up respectively. Significantly less cranial nerve damage was found 
post radiotherapy when compared to surgery 27% versus 80% (one pre-treatment 
n. X paralysis was already present) respectively(p = 0.02). post surgery a total of 1. 
All post-treatment cranial nerve damages were N. X lesions. Post radiotherapy, two 
aspiration pneumonias were found for which one permanent tracheotomy was required. 
Conclusions: Surgery inevitably renders n. X lesion and poses an additional risk for 
surrounding cranial nerves. Radiotherapy has rendered new cranial nerve damage or 
worsening of cranial nerve damage function in 27% of cases. Considering these risks 
associated with treatment, it seems wise to adopt an initial wait and scan protocol and 
to treat these tumours as little as possible. 
Clinical results of Surgery and Radiotherapy for Vagal paraganglioma 145
8
inTroduCTion
Vagal paraganglioma (VPGL) are rare neuroendocrine tumours, which are usually 
benign,  yet, approximately one third of these tumours is associated with cranial-nerve 
damage [1]. 
Since these tumours grow in such close proximity with the vagal nerve, timing the 
right moment of treatment is problematic. It has been suggested that an initial wait 
and scan period should be applied to evaluate tumour growth [1, 2]. However, the 
optimal timing of treatment remains a topic of debate. In case treatment is deemed 
required, the main treatment modalities available are surgery or radiotherapy. Suarez 
et al. have illustrated that although local control rates are relatively high post surgery , 
cranial nerve damage seems inevitable. Life-threatening complications such as aspira-
tion pneumonias are found in up to 10% of patients. Alternatively, radiotherapy was 
suggested rendering similar local control rates, however little is known about the 
complication rates of VPGL radiation.
To date, no risk factors have been isolated that predict reduced treatment outcomes 
for vagal paraganglioma. It has been suggested that tumour classification is associ-
ated with treatment outcome Obholzer et al. [3]. Moreover, mutation presence or 
age of presentation has been found to be associated with more aggressive tumour 
growth, and might predispose for lesser treatment outcomes [4]. 
Therefore, the current research evaluates the motivation of treatment of VPGL, 
and aims to isolate risk factors associated with treatment outcomes local control, 
cranial nerve damage and complications post-treatment. To this end, a retrospective 
cohort-study is conducted, evaluating the indications and results and of surgery and 
radiotherapy of VPGL. 
MeTHods
A retrospective cohort study was conducted using similar methods as presented by 
Jansen et al.[5]. All patient records of patients presenting with a HNPGL between 1980 
and 2016 in the Radboudumc Nijmegen, the Netherlands were evaluated. Eligibility 
criteria were patients with a VPGL Patients with malignant tumours were excluded. 
Out of a total of 358 patients with HNPGL, 45 patients were suffering from VPGL 
and 16 patients were treated. To collect data from patient files a standardized ex-
traction protocol was used. The following information was extracted: gender, age 
at presentation, signs and symptoms at presentation, tumour class, gene mutation 
analysis, clinical and radiological signs and symptoms of tumour progression. Tumour 
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volume was estimated by expert radiologists, measuring the largest size in the antero-
posterior, medio-lateral and cranio-caudal direction.  
The intervention was any form of surgery or radiotherapy, with or without a prior 
wait and scan period. The outcome of the treatment was compared to the patients’ 
situation at first presentation, before any form of treatment and evaluated within 
6 months post treatment, at 6 months and after 1 year. Treatment outcomes were 
local control, cranial nerve damage and other complications. The definitions were 
according to Suarez et al. [1]. Post surgery, local control was defined as a patient alive 
without evidence of disease or with a non-growing residual tumour throughout the 
entire follow-up period. Post radiotherapy local control was defined as a patient alive 
without any evidence of progression of the disease throughout the entire follow-up 
period. Cranial nerve damage was defined as deterioration of cranial nerve function 
post treatment when compared to the pre-treatment setting, objectified by a physi-
cian. Cranial nerve recovery, was defined as any improvement of cranial nerve func-
tion in post treatment setting when compared to pre-treatment conditions, objectified 
by a physician. The complications wound infection, stroke, aspiration resulting in 
pneumonia and/or tracheotomy, radiation induced necrosis, malignancies and CNS 
syndrome and death were included. 
Tumours were classified according to the classification system suggested by Obhol-
zer et al. 2012. 
Patients were subjected to a routine follow-up which was organized as follows: Post 
treatment, patients were seen within 2 weeks to evaluate immediate post-treatment 
complications. Generally. routine follow-up was then organised every six months for 
patients in all treatment groups for two years. Later, a yearly follow-up protocol was 
organized. In case tumours remained stable for 5 years, 2 year-follow-up intervals 
were adopted for ten years. Hereafter a five year interval follow-up was used. Post-
treatment MRI-scans were conducted one year post treatment. In case local control 
was achieved, the MRI-scan was conducted on a yearly basis. In case follow-up 
intervals were prolonged, MRI’s were conducted every 2 or 5 years. MRI scans were 
conduced according to a local HNPGL screening protocol, optimized for paragan-
glioma growth and new tumour localization detection. This regimen could have been 
individualized depending on factors such as: age, presence of mutations, tumour size 
and co morbidities of the patient. Also, in case there was any sign of clinical tumour 
progression or potential new tumour localisation, MRI scans were performed. 
For prediction of tumour growth the following variables were considered:, age 
at presentation defined as age at first diagnosis of HNPGL. Mutation presence was 
defined as presence of succinate dehydrogenase gene complex (SDH) associated 
paraganglioma syndromes (SDHA, -B, -C, -D, -AF2). Fisch classification was defined 
as described above.  For prediction of tumour-induced complications we considered 
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tumour growth as three-dimensional value and mean percentage of volume increase 
per year was used. As presented by Jansen et al. tumours were considered to have an 
ellipsoid shape and the following equation was used to estimate the tumour volume 
[6]: 
in which V = volume, A = the largest dimension in the anteroposterior direction, B = 
the largest dimension in the mediolateral direction, and C = the largest dimension in 
the craniocaudal direction.
In line with a publication of Jansen et al., the measurement error was expected to be 
at least 15%-20%, therefore, to distinguish growing paragangliomas from stationary 
tumours, we considered a volume increase of 20% a minimum [6].  
statistics
Missing data were handled by using multiple imputation methods. The data was 
analyzed using IBM SPSS Statistics 22. Chi square analysis was performed to compare 
different cohorts. 
resulTs
Demographics are provided in table 1. Fifty percent was female, 43% were part of a 
hereditary syndrome and 2 patients were excluded due to presence of malignant disease. 
Table 1: demographics per treatment modality.
Surgery Radiotherapy Total
Total n 5 11 16
Symptomatic presentation % (n) 80% (4) 45% (5) 56% (9)
Preceding wait and scan period %(n) 20% (1) 72% (8) 56% (9)
Growth % (n) 80% (4) 63% (7) 69% (11)
Volume in median cc (range) 11707 (375-23040) 58353 (338-180960) 49872 (338-180960)
Tumour class % (n)
Tumour class 1 20% (1) 27% (3) 25% (4)
Tumour class 2 - 10% (1) 0.06(1)
Tumour class 3 60% (3) 54% (6) 56% (9)
Tumour class 4 20% (1) 10% (1) 0.1 (2)
Follow-up in median months (range) 20 (15-38) 11 (3-29) 15 (3-38)
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Figure 1 illustrates treatment outcomes per treatment modality. Significantly less cranial 
nerve damage was found post radiotherapy (p = 0.02), for the remaining treatment 
outcomes, no significant difference could be found. The motivation of treatment was 
in all these cases indeed symptomatic presentation. 
results surgery
For all surgically treated patients, the motivation for surgery (rather than radiotherapy) 
were age (n = 5), presence of tumour growth (n = 4) and pre-existent N. X palsy (n = 4). 
Patients treated with surgery were significantly younger than the general population 
(median, range 20-35). Out of 11 patients treated with radiotherapy, 2 were inten-
tionally debulked. Overall local control was 100%. All cranial nerve damages were N. 
X lesions, additionally a N. IX and XI lesion were found. No predictor of adverse events 
could be found in our series. 
results radiotherapy
The main motivation for radiotherapy were, tumour growth (n = 5) and pre-existing 
N. X palsy (n = 7). Searching for predictors of treatment outcomes, we found that the 
age of presentation was significantly related to the risk of post-operative cranial nerve 
damage (p = 0.010 95% CI 6.2-34.7). Patients suffering cranial nerve damage were 
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Figure 1: treatment outcomes per treatment modality
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generally older, than patients not suffering cranial nerve damage (61.7 SD 3.2; versus 
41.23 SD 10.4). All post-treatment cranial nerve damages were N. X lesions, also a 
single case of sensorineural hearing loss was found. The main complications were 
aspiration pneumonia (n = 2), for which one permanent tracheotomy was required. 
Moreover, a single case of baro-reflex syndrome was found. One pre-treatment N. X 
palsy recovered to normal function post-irradiation. 
disCussion
Our results illustrate that radiotherapy seems to be the preferable treatment modality 
as it renders most optimal local control and cranial nerve damage rates. In our centre, 
the main motivation for surgery was pre-existent cranial nerve damage and tumour 
growth for younger patients. The main motivation for radiotherapy was tumour growth 
and N. X palsy. Furthermore, age of presentation was suggested to be a risk factor for 
cranial nerve damage post-radiotherapy. 
advise for the clinical practice 
The current series describes good local control rates post surgery, including stable 
tumour presence in case of  tumour debulking for two patients. However, a high risk 
for n. X lesion was found, 80% suffered cranial nerve damage post treatment. This is 
also described in literature, e.g. Suarez et al found local control in 93.4% of cases and 
cranial nerve damage was found pre-operatively in 147 of 226 cases, which increased 
to 445 cranial nerve palsies after surgery [2]. In fact, the vagal nerve was functionally 
preserved in only 11 of 226 patients. Moreover, albeit no complications were found in 
the current series, Suarez et al describes a considerable risk of aspiration/pneumonias 
(10.2%), CSF leakage (2.6%), wound infections (2.2%) and stroke (2.2%)post surgery, 
and 3 patents died (1.3%) because of these complications [2]. A recent review of our 
group describes a risk of 1.58 nerves being affected per tumour excision as the N. 
X is damaged in almost 100% of cases, there remains a theoretical 0.58 chance of 
inducing other cranial nerve damage [7]. According to our results, the hypoglossal, 
glossopharyngeal and facial nerve seem to be mainly at risk. In our series a n. IX and 
a n. XI lesion were found. 
Alternatively, excellent local control was also found post radiotherapy yet cranial 
nerve damage/worsening of function was found in 27% of cases (3/11 patients), for 
two patients a consequent aspiration pneumonia was found and one of those patients 
required a permanent tracheotomy. Hinerman et al. describes in 2001 excellent local 
control rates, and no cranial nerve damage after a mean follow-up of 156 months for 
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10 patients [8]. In the current series, we found that patients suffering cranial nerve 
damage were generally older (61.7 SD 3.2), when compared to patients not suffering 
cranial nerve damage (41.23 SD 10.4). Potentially the mean age of irradiated patients 
was higher in our group. The mean age of VPGL patients treated by Hinerman et al. 
is not mentioned. 
The finding that elderly are more prone to develop n.X lesions post VPGL radio-
therapy has not been described before. A potential explanation could be the fact that 
elderly are less resilient towards irradiation sequelae. Nonetheless, we could not find 
a relation between age and irradiation induced complications in general. This topic 
requires further future research. 
Taking these results together we believe that treatment of VPGL should be pre-
vented as much as possible since both surgery (debulking and tot-resection) as well 
as radiotherapy are potentially related to considerable morbidity mainly related to n. 
X lesions. Therefore, a wait and scan option should always be considered. A recent 
study of our group illustrated that out of a total of 29 patients subjected to a wait 
and scan period with a median of 86 months (range 26-261months)  tumour induced 
complications, e.g. n.X palsy, was found in 4 patients (14%). Better results were found 
by Bradshaw and Jansen et al. whom presented in 2005 that for 40 VPGL after an 
average follow-up of 8.5 years (range 1-26 years), merely three patients developed a 
nerve palsy (8%). Two patients being part of a hereditary tumour syndrome developed 
metastatic disease (both patients are alive with stable disease). 
Methodological considerations
An important methodological consideration is the fact that the current is a retrospective 
cohort study and sample sizes are small. Therefore, the internal and external validity is 
limited. Given the rarity of these tumours, prospective study designs are not applicable. 
Furthermore, the long term follow-up of irradiated tumours might be too short 
since long term sequelae might be expected after 30 to 40 years post treatment.  Po-
tentially, over time less local control rates might be found due to late tumour growth. 
ConClusion
Treatment outcomes of VPGL treatment in the Radboudumc , the Netherlands has 
been presented. The risk of both surgery and radiotherapy seems considerable. Surgery 
inevitably renders n. X lesion in all cases, and poses an additional risk for surrounding 
cranial nerves. Radiotherapy has rendered new cranial nerve damage or worsening 
of cranial nerve damage function in 27% of cases, particularly in the elderly. Post 
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radiotherapy, this rendered 2 aspiration pneumonia’s for which one patient received a 
permanent tracheotomy. Considering these risks associated with treatment, it seems 
wise to adopt an initial wait and scan protocol and to treat these tumours as little as 
possible. 
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absTraCT
Purpose: HNPGL potentially induce significant morbidity, either tumour-, or treatment 
induced. About 37% of HNPGL are part of multifocal disease, yet little is known about 
complication free survival (CFS ) in these patients, or risk factors associated with it.  
Experimental design: Retrospective cohort study. Information was extracted from medical 
records of all our patients suffering HNPGL (n = 178). Main outcome measure was 
complication free survival (CFS), analyzed using Kaplan-Meier survival analysis. 
Results: A significantly worse CFS was found in 58 patients suffering 159 tumours 
when compared to 120 patients suffering unifocal disease (LogRank 16.3, df 1, p 0.00). 
No significant difference was found in CFS between unilateral versus bilateral tumour 
presence or (0.75) the number of tumours found (p = 0.9). Using univariate regression 
analysis, we found that when managed only with a wait and scan strategy, this was a 
negative predictor of complications. Using binary logistic regression, we found that the 
number of surgical procedures required for disease control is an independent predictor 
of complications in patients suffering multifocal disease (B = 0.797, df. = 1, p = 0.047).
Conclusions: The current results demonstrate the significantly reduced complication 
free-survival for patients suffering multifocal tumours. Mainly the treatment modality 
chosen to manage these tumours are associated with complication-free survival, and 
radical tumour removal with sacrifice of cranial nerves should be avoided.
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inTroduCTion
Head and neck paraganglioma (HNPGL) are neuroendocrine tumors that are usually 
benign. In the head and neck region, paraganglioma are mainly found around the 
carotid body, the middle ear or jugular bulb, or the vagal paraganglia. As a consequence, 
they grow in close proximity with delicate neurovascular structures (1). It is generally 
considered that for lower class jugulotympanic (Fisch class A and B) and carotid body 
tumors (Shamblin class 1 and 2) surgery is the mainstay of treatment (1). For Fisch 
class C and D jugulotympanic, Shamblin class 3 carotid body and vagal body tumors 
however, treatment remains a matter of debate. Although with surgery and radiotherapy 
local control rates are comparable, for surgery, cranial nerve damage is a frequent 
complication, and other severe complications such as strokes form a considerable risk 
(2-4). After radiotherapy, there is the risk of atherosclerosis and strokes and a very low 
risk of radiation-induced malignancies (5). It is due to these complication risks and the 
benign nature of these tumors, that a wait and scan option is adopted for many of 
these tumors to delay potentially harmful treatments as long as possible. 
A particular challenge for HNPGL management are multifocal HNPGL, which are 
found in about 37% of patients (6). Although multifocal tumor presence is not associ-
ated with decreased survival, the increased risk of cranial nerve palsy can significantly 
reduce quality of life. Particularly bilateral cranial nerve palsy should be avoided at all 
cost. Little evidence is provided for the best management strategy of multiple tumors. 
Most studies use theoretical argumentations considering surgery the main-stay of 
treatment. The rationale is that careful planning of surgery of highest risk tumors 
(based on size and tumor location) might prevent bilateral cranial nerve palsy (7-10). 
For example, in case unilateral cranial nerve sacrifice is inevitable, the contralateral 
tumor should be treated with radiotherapy. However, the primary use of radiotherapy 
to preserve bilateral cranial nerve function, or the use of an initial wait and scan 
strategy remains largely uninvestigated for multifocal HNPGL. 
Therefore, in the current study we aim to evaluate the risk of complications for 
multifocal HNPGL when compared to unifocal tumors. Moreover, the  treatment 
outcomes of surgery, radiotherapy and a wait-and-scan policy for patients suffering 
multifocal HNPGL disease are evaluated. The main outcome measure is complication-
free survival, meaning survival without (treatment or tumor induced) cranial nerve 
damage, CVA’s and other complications. Furthermore, a risk profile for prediction of 
future complications is proposed. 
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MeTHods
Methods were similar to a previous study of our group (4). A retrospective cohort study 
was conducted including all patients presenting with a head and neck paraganglioma 
between 1980 and 2016 in the Radboud University Medical Center, a dedicated tertiary 
Head and Neck Surgery and Cancer Center. Eligibility criteria were patients with a head 
and neck paraganglioma. Patients with a malignant tumor were excluded as well as 
patients with a hormone secreting tumor. 
subjects
A total of 257 patients with 358 tumors were identified, treated with surgery, ra-
diotherapy or a wait and scan strategy. The following information was extracted 
from the records: gender, age at presentation, signs and symptoms at presentation, 
tumor class, gene mutation analysis, clinical and radiological signs and symptoms of 
tumor progression. Tumor volume was estimated by expert radiologists. Carotid body 
paraganglioma were stratified according to the Shamblin classification system (11). 
Jugulotympanic paraganglioma were stratified according to the Fisch classification 
system (12). Patients were classified in low risk tumors, referring to Fisch class A, B and 
Shamblin 1, 2 tumors, and high risk tumors being Fisch class C and D, Shamblin 3 and 
vagal body paraganglioma. The interventions were a wait-and-scan policy, surgery or 
radiotherapy. Cranial nerve damage, strokes, post-operative cranio-spinal liquor leaks, 
wound infections and bleedings and radiation induced necrosis and malignancies were 
considered complications. 
outcome measures
The primary outcome was complication-free survival per patient. This was defined as a 
patient being alive without having suffered any of the above-mentioned complications 
(i.e. events were assessed per patient and denominator was total number of patients 
at risk). The secondary outcome measure was complication-free survival per tumor, 
which was defined as a patient not suffering a complication due to treatment of a 
particular tumor, or tumor-induced complications (i.e. events were assessed per tumor 
and denominator was total number of tumors). The time to complication was calculated 
by subtracting the date of diagnosis from the date the complication was first observed.
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follow-up
Patients were subjected to a routine follow-up which was organized as follows: post-
treatment, patients were seen within 2 weeks to evaluate immediate post-treatment 
complications. Generally, routine follow-up with MRI was then performed yearly. In 
case tumors remained stable for 5 years, 2 year-follow-up intervals were adopted for 
ten years. Hereafter a five-year interval follow-up was used. Post-treatment MRI-scans 
were done immediately post-treatment in case of residual disease post-surgery. MRI 
scans were performed according to a local HNPGL screening protocol, optimized for 
paraganglioma growth and new tumor localization detection. 
statistical analysis
Routine cohort description analysis was performed using X2 for subgroup analysis. To 
determine complication free survival Kaplan-Meier survival analysis were performed for 
different subgroups with different risk-profiles. Differences between survival outcomes 
were assessed by Log-rank test. Univariate and multivariate binary logistic regression 
analyses were performed to determine predictor variables for treatment outcome. The 
data was analyzed using IBM SPSS Statistics 22.
resulTs
Cohort description
A total of 178 patients with 279 tumors were included. The baseline characteristics for 
unifocal and multifocal tumors are presented in table 1. 
Figure 1 presents the localization and classification of the unifocal and multifocal 
tumours by group. Jugulotympanic tumours were mainly unifocal, whereas carotid 
body tumours were mainly part of multifocal disease. A total of 106 of multifocal 
presentations (67%) had bilateral disease. 
Table 2 describes all the complications (treatment-related and tumour-related) found 
after unifocal and multifocal tumour management for all treatments combined. Using 
X2 analysis, we found significantly more complications within the multifocal tumour 
group (p < 0.05). Overall, there were significantly less complications in the wait and scan 
group (12.9%) when compared to radiotherapy (31%) and surgery (32%) (p = 0.001). 
There was no difference between the surgery and radiotherapy groups. There were 
significantly more complications associated with high risk tumours, when compared 
to low-risk tumours (71.2% vs. 52%; p = 0.02).
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survival analysis
Figure 2 shows complication-free survival of patients with unifocal and multifocal 
HNPGL and this difference was statistically significant (LogRank 16.3, df 1, p 0.00). 
Figure 3 illustrates the difference in low and high risk tumours stratified for unifocal 
and multifocal disease. There was no significant difference in complication-free sur-
vival between low risk tumours  and high risk tumours LogRank 0.831, df 1,  p 0.36). 
The difference in complication free survival between low and high risk tumours when 
stratified for unifocal and multifocal presentation reached borderline significance (p 
= 0.06)
Table 1: Baseline characteristics for unifocal and multifocal tumours
Unifocal tumours Multifocal tumours
Npatients /Ntumors (range) 120/120 58/159
Median age (range) 52 (18-90) 40 (13-73)
Mean N tumours (range) 1 2.7 (2-5)
Hereditary syndrome N (%) 6 (5%) 42 (68%)
Primary treatment strategy:
Surgery N (%) 55 (46%) 58 (36%)
Radiotherapy N (%) 22 (18%) 17 (11%)
Wait and scan N (%) 43 (36%) 84 (53%)
Mean months follow-up (range) 59 (10-424) 99 (6-451)
Figure 1: number of tumour types in unifocal and multifocal group
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Table 2: Details of complications found per patient in unifocal and multifocal group
Complication Unifocal group 
(N = 120)
Multifocal group per patient
(N = 159)
Total 
(N = 279)
Cranial Nerve Damage n (%) 34 (28%) 75 (100%) 109 (61%)
VII 7 (6%) 12 (21%) 17 (10%)
VIII 6 (5%) 5 (9%) 11 (6%)
IX 7 (6%) 7 (12%) 14 (8%)
X 9 (8%) 26 (45%) 35 (20%)
XI 2 (2%) 11 (19%) 13 (7%)
XII 3 (3%) 11 (19%) 14 (8%)
Other Complications n (%) 0 10 (17%) 10 (6%)
Wound infection/ Bleeding 0 2 (3%) 1 (1%)
Stroke 0 2 (3%) 2 (1%)
Radionecrosis 0 0 0
Baroreflex Syndrome 0 6 (10%) 6 (3%)
Irradiation induced Neoplasm 0 0 0
Figure 2: complication-free survival of patients suffering unifocal and multifocal tumours.
Figure 3: Complication free survival of patients suffering high- and low-risk unifocal and multifocal 
tumours
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In case of multifocal tumour presence, there was no significant difference in 
complication-free survival between unilateral or bilateral tumour presence (p =  0.75). 
Also, there was no difference in complication free survival associated with number of 
multifocal tumours present (p = 0.9). 
regression analysis
Table 3 shows the results of univariate regression analysis, searching for clinical predictors 
of complications. Suffering multifocal disease or a high risk tumour were significant 
risk-factors for complications. Treatment-modality itself was not a risk-factor for 
complications in general, the number of surgical procedures was, however. Moreover, 
when managed only with a wait and scan strategy, this was a negative predictor of 
complications. 
Using a binary logistic regression model, the number of surgical procedures was 
the only independent predictor of complications (B = 0.797, df. = 1, p = 0.047). The 
remaining variables were no longer significant when corrected for confounders. 
disCussion
The current study is the first to describe a difference in complication-free survival 
between unifocal and multifocal head and neck paraganglioma patients. There was 
a significantly poorer complication-free survival in case of multifocal disease when 
Table 3: Results of univariate analysis of variance.
Variables predicting complications P-value
Age of presentation 0.11
Multifocal disease 0.00
High risk tumour 0.02
High risk tumour in unifocal disease 0.2
High risk tumour in multifocal disease 0.06
Bilateral tumour presence 0.25
More than 2 tumours 0.16
Wait&Scan 0.01
Surgery 0.73
Radiotherapy 0.81
Surgery for high risk tumours 0.16
No surgical treatments 0.04
No radiotherapy treatments 0.79
Combination surgery/ radiotherapy 0.24
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compared to unifocal disease. The number of tumors was not of influence for 
complication-free survival. However, suffering a Fisch class C/D tumor, Shamblin class 
3 or vagale tumor was associated with more complications (independent of treatment 
modality applied). Fewest complications were found with a wait and scan strategy. The 
lowest complication-free survival was found post-surgery in the case of high risk tumor 
presence, albeit, borderline statistically significant. Furthermore, the number of surgical 
procedures required for tumor control per person was an independent predictor of 
future complications. We believe the current results aid the understanding of multifocal 
HNPGL management and provide insights that aid the consultation of patients suffering 
from such tumor syndromes. 
Cohort description
Comparing the cohort of patients of multifocal versus unifocal disease, we found 
that patients suffering multifocal disease are significantly younger which is considered 
to be due to the hereditary background of these tumors. In fact, 68% of multifocal 
tumors were proven to be part of hereditary disease and this is expected to be an 
underrapportation since genetic work-up with latest understanding of associated genes 
has not been done for all patients included in the series, especially those diagnosed in 
the earlier years. Generally, we believe it is mandatory to have full understanding of 
the genetic subtype association, as this predisposes for synchronous and metachronous 
disease and it should alter clinical management. A subject further discussed underneath. 
The main complications found in the current series were those associated with 
cranial nerve deficit, and were found more in case of multifocal disease (28% versus 
100%). The most frequent cranial nerve deficit was N. X damage, and was found in 
45% of patients suffering multifocal disease. This concerns a complication associated 
with decreased quality of life, and a potential life threatening complication in case 
of swallowing disorders, particularlywhen bilaterally damaged. Seventy percent of 
cranial nerve damage was found post-surgery, whereas 30% of complications were 
found to be due to radiotherapy or due to tumor growth. Furthermore, the complica-
tions other than cranial nerve damage were merely found in the multifocal group. 
The main complication was Baroreflex syndrome (4% of cases and all post surgery) 
followed by a 1% risk of stroke post-surgery (requiring surgical internal carotid artery 
management). Radionecrosis and radiation-induced malignancies were not observed 
in the current cohort. 
166 Chapter 9
Comments on clinical management
Several reports have suggested the difference in risk associated with low-risk tumors 
and high risk tumors as presented in our study. Generally, literature agrees that surgery 
is a sensible option for low risk tumors since excellent local control rates are found and 
complication rates are generally low (13-23). However, it needs to be emphasized that 
these papers generally did not discriminate between unifocal and multifocal disease 
and therefore, the risk of surgery for multifocal disease is not well investigated. Our 
results demonstrate that complication-free survival of low risk tumors when being part 
of multifocal disease is reduced when compared to unifocal low-risk tumors (albeit 
not statistically significant). Moreover, we found no significant difference in treatment 
modalities of these tumors. Generally, we believe that surgery is a viable option, yet 
alternatives in form of a wait and scan strategy should always be considered, particularly 
when tumor- or treatment-induced morbidity is already present. 
With respect to high-risk tumors a larger difference is found in complication-free 
survival when considering tumors being part of multifocal disease versus unifocal high 
risk tumors. Recent literature generally leans towards non-surgical treatment methods 
for these tumors and our results agree (2- 4; 24, 25). Although barely significant, par-
ticularly in the background of multifocal disease surgery presented with worse com-
plication free-survival when compared to results of wait-and-scan and radiotherapy. 
While for unifocal tumors management is not always straightforward, the manage-
ment of patients suffering multifocal tumors is even more complex and requires care-
ful timing and  planning of treatment. Several studies in the past have evaluated the 
aspect of multifocal tumor management. All management strategies acknowledge 
the inherent enhanced risk of surgery for “high risk tumors”. Nonetheless, most stud-
ies implement a calculated surgery-associated risk in their strategies. 
For example Sobol et al. (10) suggest a one staged surgical procedure for multiple 
ipsilateral tumors. The philosophy of the authors being that sacrifice of the cranial 
nerves on one site facilitates surgery of remaining ipsilateral tumors as well. In this 
light, Sobol et al. present a 27-year old patient with a carotid body- and a vagal tumor 
on one side. During vagal tumor resection N. X was sacrificed which facilitated swift 
resection of the ipsilateral carotid body tumor. Hereby, the authors rationalize that 
resection of a cranial nerve is considered a means for reduction of further complica-
tions. Alternative treatment options such as radiotherapy or tumor debulking were 
not discussed in this study.
Velegrakis et al. and Boedeker et al. describe a similar management strategy for 
bilateral paraganglioma (9, 26). Both studies suggest that after extirpation of the first 
HNPGL the internal carotid artery patency and cranial nerve functions be monitored 
postoperatively. Only in case of normal clinical and radiological findings the second 
stage operation of the contralateral tumor was considered. Otherwise a conservative 
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wait and scan policy was adopted. The main goal being to prevent bilateral cranial 
nerve damage and diminish the risk of stroke. Boedeker et al. follow the method 
of Velegrakis et al., however they particularly suggest that the largest tumor should 
be removed first. Depending on the post-operative cranial nerve status, therapy of 
the remaining tumor(s) may be individually planned. This suggests that the largest 
tumor carries the highest risk of tumor and treatment induced cranial nerve damage. 
Depending on the post-operative sequelae, contralateral surgery can be planned; in 
case sequalae are found, radiotherapy might be preferred for the other side. Both the 
strategies of Szymanska and Boedeker consider surgery as the treatment of choice 
also for high risk tumors and present a means to cope with the expected iatrogenic 
damage, rather than preventing it by initial less detrimental management strategies 
such as tumor debulking or primary (stereotactic) radiotherapy. 
Another management strategy is presented by Makeieff et al. and Velegrakis et 
al., who estimate the risk of iatrogenic damage not merely based on tumor size, but 
also as a function of tumor location and relationship to the neural structures (9, 18). 
Particularly the enhanced risk of N. X palsy post-surgery of a vagal paraganglioma 
is taken into consideration. Therefore, they suggest that in case of combination of 
vagal body paraganglioma, the contralateral tumor should be operated first and in the 
absence of sequelae postoperatively the vagal body tumor can be “safely” removed 
(generally sacrificing the vagal nerve). Also for this management strategy the alterna-
tive for surgery, radiotherapy, is not considered and apparently damage of the vagal 
nerve is considered an acceptable clinical outcome. 
Fourth, and in line with the philosophy of Makeieff et al., but opposite to Boedeker 
et al., Myssiorek et al. suggest that first the smaller tumor should be resected (pos-
ing the lowest risk of cranial nerve damage), and depending on the sequelae the 
larger tumor can be exposed either to surgery, radiotherapy or a wait and scan policy. 
Again, the main goal is to prevent bilateral cranial nerve damage and not cranial 
nerve damage in general since radiotherapy or a wait and scan policy would mainly 
be considered in case the first resection would have rendered cranial nerve damage. 
The fifth strategy acknowledges that intervention is not always required. Van der 
Mey et al. suggest that for bilateral paraganglioma a more conservative monitored 
“wait and see” policy can be sensible and should be considered (27). The motivation 
being that during the follow-up period (maximal observation time 32 years, mean 
13.5 years) of 108 patients (58 with hereditary disease), none of the patients died of 
residual or recurrent tumor or developed distant metastases, irrespective of the mode 
and outcome of treatment.
We believe there are several issues with the above mentioned treatment strategies. 
First, our philosophy is that preservation of cranial nerve function should be pursued 
at all cost as this is associated with highest quality of life. Therefore, we agree with van 
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der Mey et al. that management should start with a wait and scan period, unless partial 
tumor-induced cranial nerve damage is already present. In case of the latter, treatment 
should readily be considered. Tumor growth and cranial nerve function should be 
closely monitored, and in case of further deterioration, treatment should be consid-
ered. Please note however that a previous publication of our group demonstrated that 
apparently stable tumors have a 17% risk of inducing cranial nerve damage (4). As 
the progressive tumors were all treated, the precise risk of complications induced by 
tumor growth remains uncertain. Nonetheless, we assume that tumor growth should 
be considered as a predictor of potential future complications. Although this has never 
been proven in literature this seems a logic consequence and we therefore believe that 
in case tumor growth is found action should be taken. The problem with management 
strategies that suggest planned sacrifices of unilateral cranial nerves is not only that 
quality of life is reduced inevitably, but also the possibility of metachronous tumor 
presentation is overlooked. Szymanska et al. observed this in 16.6 % of cases 4 to 21 
years post-treatment. Future contralateral tumor appearance that needs treatment 
might result in contralateral cranial nerve damage with further reduction of quality 
of life and, in the case of vagal nerve lesions even life threatening complications. We 
believe such a situation should be prevented by considering alternative initial manage-
ment strategies with higher chance of cranial nerve preservation, such as gross tumor 
debulking or primary radiotherapy. Hence, planned cranial nerve damaging methods 
should be considered obsolete since alternative treatment strategies are at hand: 
numerous studies have illustrated the excellent long-term local control rates that can 
be achieved with radiotherapy and complications found with the current techniques 
remain rare. A literature review of Suarez et al. illustrated that complication rates 
are low after irradiation of even the carotid body paraganglioma, a group of tumors 
for which radiotherapy is thought to be less applicable due to the risk of radiation-
induced stenosis (3). However, radiation-induced atherosclerosis is a very late event 
and most studies do not have sufficient follow-up for a proper risk assessment of 
this complication. Furthermore, especially in the earlier days, many physicians were 
not aware of this radiation-associated complication and may not have documented 
it. Based on data from head and neck cancer patients (5) the expected incidence of 
radiation-induced carotid stenosis in the paraganglioma population must me much 
higher than reported. Nonetheless, the current results illustrate the beneficial effects 
of radiotherapy in the presence of multifocal tumor growth, particularly in the “high 
risk population” when compared to the surgical group. Very late vascular damage 
by radiotherapy should be weighed against the immediate consequences of surgical 
iatrogenic cranial nerve damage.
In elderly patients the balance will be mostly in favor of radiotherapy. However, in 
younger patients this is different because of their longer life expectancy they are much 
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more likely to be confronted with the late sequelae of radiotherapy but also because of 
the increased risk of metachronous tumor presentation. Multiple radiotherapy courses 
should preferably be avoided in the head and neck region and previous radiotherapy 
might hinder future surgery due to fibrosis. Another issue might be that presentation 
at a younger age is associated with faster tumor growth rates (4). Therefore, the 
initial wait and scan strategy might enhance the risk of tumor-induced complications 
in younger patients. We believe that for these patients tumor debulking should be 
considered, particularly in the case of Fisch class C and D tumors. Hereby, gross tumor 
removal can be performed with safe margins from critical neurovascular structures, 
reducing the risk of iatrogenic morbidity. A previous study of our group, evaluated 
the treatment outcomes of debulking and a subsequent wait and scan strategy, radi-
cal surgery, and primary radiotherapy (4). We found similar local control rates with 
debulking when compared to radiotherapy (100 and 90% respectively), and better 
control rates when compared to radical surgery (82%) due to little residual tumor 
growth. Although there were significantly more complications post-debulking when 
compared to radiotherapy (44% vs 27%), complication rates were significantly lower 
when compared to radical surgery (63%). Potentially, for high risk tumors in other 
situations, debulking may also be a viable treatment option. 
recommendations for daily practice
Given the results from this analysis and discussion of the literature, we propose the 
following management philosophy. A wait and scan policy should be the initial step in 
most cases. In case multifocal tumors are present, and there is no tumor induced cranial 
nerve damage, an evaluation of the risk of tumor induced complications should be made 
first. We believe that tumor growth is still the foremost predictor of tumor-induced 
complications, and therefore we suggest that the growing tumor is treated first. In case 
this is a low risk tumor, surgery by an experienced surgeon could be applied. In case of 
a high risk tumor, we believe that radiotherapy should be applied for older patients. 
For younger patients surgical debulking should be considered with a post-operative 
wait and scan period, evaluating residual tumor growth. In case of growth of residual 
tumor radiotherapy can be applied if complications are to be expected due to further 
growth. An exception to this rule would be the presence of complete tumor induced 
cranial nerve paralysis. In such cases, surgery could be applied without leaving tumor 
on the vagal nerve. This should be performed however without enhancing the risk of 
other cranial nerve damage or strokes e.g. via manipulation of the internal carotid artery. 
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Methodological considerations
The main methodological weakness of this study is the fact that the conclusions are 
drawn from a retrospective cohort which results in a large selection bias which reduces 
the external validity. The choice for a treatment modality was not randomized and 
therefore comparison between treatment modalities is of little statistical relevance. 
Nonetheless we believe that the current study contributes to a functional approach in 
HNPGL management.  
Furthermore, the long-term effects of our management strategy remain uncertain. 
Although the mean follow-up was 99 months (range 6 to 451), potential metachro-
nous tumor growth can occur later and may be underestimated. Also, this follow-up 
might not be sufficient to evaluate the very long-term effects of radiotherapy i.e. 
artheriosclerosis and radiation-induced malignancies. 
The impact of the genetic background particularly in multifocal tumor presence 
remains partly uncertain in the current series. Albeit most patients are subjected 
to genetic testing, not all patients received testing for various reasons. Moreover, 
patients presenting further back might not have been tested for the more recently 
discovered mutations. Furthermore, genetic sub-types SDHD and –B are thought to 
be associated with more aggressive tumor growth and we did not stratify our results 
for this. All patients with multifocal disease were grouped in the current analysis. 
Potentially, this is a flaw since Amar et al. showed that the presence of SDHB mutation 
is a potential risk factor for reduced survival and malignant disaese. In our series 
however, the number of patients suffering an SDHB mutations (n = 11) was too small 
to allow for sub-group analysis. 
Finally, an overrepresentation of jugulotympanic tumors was found in our centre, 
which might have influenced the overall results. These tumors are overrepresented 
because the Radboudumc is a prominent skull-base center which might cause more 
referrals of jugulotympanic paraganglioma patients.
ConClusions
The current study demonstrates the complexity of multifocal HNPGL management, 
and the increased risk of severe complications in patients suffering multifocal HNPGL. 
We found that there is a significantly reduced complication free-survival for patients 
suffering multifocal tumours. The location, stage and growth rate of the tumour and the 
treatment modality chosen to manage the tumour are associated with complication-free 
survival. A risk assessment system was constructed, based on tumour location and stage 
and treatment method, which predicts the risk of future complications. In our view, 
multifocal HNPGL tumour presentation should be managed with optimal attention 
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for preservation of cranial nerve function. We believe radical tumour removal with 
sacrifice of cranial nerves should be avoided at all cost. Instead, radiotherapy should 
be considered, or, depending on age at presentation tumour debulking might be an 
option to consider. 
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The aim of the current thesis is to evaluate the risk associated with different treatment 
modalities for HNPGL of different sub-site and tumour class to aid the constitution of 
personalized guidelines for individualized patient management. To this end, in part 1, 
we evaluated the applicability of an initial wait and scan strategy for HNPGL. In part 2 
we evaluated the risk of surgery, radiotherapy and debulking for HNPGL of different 
subtypes. In part 3, we evaluated the impact of multifocal head and neck disease in 
patients and evaluated different management strategies. In the current discussion 
the results of these chapters are combined and a guideline for treatment of HNPGL is 
constituted. Aims for future research are presented as well. 
The head and neck paraganglioma treatment paradigm
Historically, surgery is the main treatment modality considered for HNPGL since this 
is the only treatment modality rendering total tumour removal. However, attempts 
for radical surgery are associated with high morbidity rates. In contrast, as illustrated 
by van der Mey et al., tumour induced morbidity seems to be particularly low [1]. 
Moreover, there is a low malignancy-rate associated with these tumours [2]. Therefore, 
alternative treatment modalities such as tumour debulking or (stereotactic irradiation) 
are potential treatment options as well. Considering the benign tumour biology, it is 
our treatment philosophy that the main concern in HNPGL management should be 
functional preservation, generally referring to cranial nerve vitality. To ensure this, we 
believe there is no “one size fits all” approach, and we believe that in every patient the 
risk of treatment should always be outweighed against the risk of a wait and scan policy. 
In order to allow for such a risk calibration, there are several patient factors that 
should be taken into consideration as they might be of influence on tumour man-
agement. Several studies have illustrated the phenotypical association of different 
SDHx related tumour syndromes [2]. We believe that awareness of such a syndrome is 
critical for tailored HNPGL management for several reasons: 
Besides the risk of associated tumour growth in the case of SHD associated HNPGL 
presence or the enhanced risk of malignant tumour growth associated with these 
syndromes which are not within the scope of this thesis, these tumour syndromes 
are of importance since they might induce enhanced tumour growth. Although we 
could not confirm this in part 1, it is likely that tumour syndromes are associated with 
lower ages of onset. We did find in part 1 that tumour growth incidences and rates 
are inversely correlated to age of presentation. The younger the patient, the higher 
its tumour growth rate, which shows an enhanced risk of tumour induced morbidity. 
Furthermore, we found that the cut-off point for enhanced tumour growth is 50 years 
of age. This hypothesis is further supported by the finding that in case of tumour 
induced morbidity we found above average tumour growth rates. This factor should 
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be taken into consideration in managing these younger patients and should hint the 
managing physician to decreased follow-up intervals for patients younger than 50 
years of age. 
Another important risk factor associated with SDHx syndromes is the risk of mul-
tifocal/metachronous tumour presence. We described in part 4 that patient with 
multifocal tumour presence show a significantly lower complication free survival 
independent of treatment modality. The main reason for this is previous tumour or 
treatment induced morbidity. The particular impact of multifocal tumour presence of 
HNPGL management is discussed underneath. 
Management of head and neck paraganglioma of different tumour class 
Underneath we outline the best treatment strategies for HNPGl of different tumour 
class as concluded from the review and clinical data obtained in part 2. 
Jugulotympanic paraganglioma. 
The best treatment modality is described per Fisch class. 
Fisch class A
Surgical excision of these tumours is considered the best practice since local control rates 
are 100% for the included studies and no adverse events were described. Although no 
studies on the effect of RT of these studies are available, we believe it is not a viable 
treatment option due to the potential radiotoxic effects on the skin and cochlea. 
Therefore, we advise primary surgical resection (if comorbidities of the patient allow 
this) in order to prevent conversion to level B tumour or further, which was little higher 
risks when compared to class A tumours. 
Fisch class B
Surgical excision should be advised in case of presented growth by means of a wait and 
scan period. Nonetheless, in case tumour-induced-morbidity such as tinnitus, vertigo 
or facial nerve pareses outweighs the potential risk of surgery primary resection is 
also advised. Albeit local control was found in 100% for all included studies,  serious 
complications have been described, such as N. VII pareses and CSF leakage. Please note 
that these complications were incidental, and potentially correlated to use of facial nerve 
rerouting. Moreover, there are suggestions that presenting symptoms such as pulsatile 
tinnitus and conductive hearing loss are potentially best treated with surgery. Although 
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there are no studies describing the effect of radiotherapy on Fisch class B tumours en 
no recommendations can be embodied with evidence; one could argue that in case a 
patient is not suitable for surgery, (stereotactic) irradiation could be used. Particularly 
in the case of CN paresis, since irradiation seems to potentially enhance CN function 
post treatment when compared to surgery as suggested in chapter 3. 
Fisch class C and D
The CND and  complication rates found post treatment of class C and D tumours suggest 
that conservative wait and scan management should always be considered.  In chapter 
4 we elaborately evaluated the pre-treatment work-up and effects of a wait and scan 
period for Fisch class C and D tumours. Out of 66 patients subjected to a wait and 
scan period 28 required further treatment due to tumour growth or tumour induced 
morbidity. There was also a cohort of patients directly treated without a preceding wait 
and scan period. We could not identify differences in treatment outcome between 
patients treated with a preceding wait and scan strategy and those immediately treated, 
suggesting that a wait and scan option is a safe first management strategy. Moreover, 
we could not identify predictors for subsequent treatment following the wait and scan 
period, which confirms in our opinion that all Fisch class C and D tumours should be 
managed conservatively. An exception to this rule would be the presence of treatment 
requiring tumour induced morbidity at time of presentation. This mainly refers to readily 
present cranial nerve damage at initial presentation. 
In case treatment is required, in general we found that radiotherapy seems to provide 
overall best treatment outcome, with local control rates of 90%, a complication risk 
of 27% and 10% function recovery. Local control rates were best when gross tumour 
debulking was attempted (100%), with postoperative radiation of potential growing 
residual disease. This rendered complications in 44% of cases. We believe attempts 
for radical surgery should not be undertaken, given the chance of local control of 
82% and a complications risk of 63%. Functional recovery was found in 30% of 
cases. Please note however, that we believe there are several factors that should be 
taken into consideration when deciding which treatment modality suits best. The main 
concern would be the age of presentation. In case patients present at younger age 
(most often found due to hereditary syndrome presence) late sequelae of radiotherapy 
are potentially severe (e.g. referring mainly to the risk of stroke and secondary ma-
lignancies). We believe that for patients younger than 50 years of age radiotherapy 
should be handled with caution. Obviously this should be outweighed against the 
risks of other treatment options. For patients older than 50 years of age we believe 
radiotherapy is the best treatment option and best results are found with stereotactical 
radiotherapeutic techniques. A potential confounding factor might be however, that 
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tumours treated with this techniques are generally smaller than tumours treated with 
other radiotherapeutic techniques. Therefore, for younger patients, rather, the use of 
surgical debulking may be a viable treatment option. We believe that careful planning 
of the tumour allows an experienced skull base surgeon to safely debulk gross tumour 
mass with safe margins from delicate neurovascular structures such as cranial nerves. 
Subsequent follow-up of residual tumour is mandatory, and in case of growth/morbid-
ity imposed by this residual re-debulking or radiotherapy can be considered. 
Please note that we could not identify a difference in tumours of different C classes, 
or C1-4 and D classes. Therefore, the treatment protocol as presented should be con-
sidered for both C and D tumours.  
Carotid body paraganglioma 
Shamblin class 1 tumours 
The results of our study combined with the results of the systematic review show that 
local control can be expected in up to 100% post surgery. Although not often found, 
there is still a theoretical risk of cranial nerve damage associated with surgery of these 
tumours. Therefore, also for these smaller tumours we advise to adopt an initial wait and 
scan strategy for these tumours as well. In case of tumour growth, surgery is advised. 
Shamblin class 2 tumours 
The results of our studies show that local control is achieved in 98% of cases post 
surgery. The risk of cranial nerve damage is 18% which mainly concerns n. X and XII 
deterioration. Moreover, potential serious complications such as strokes and pneumonias 
are found in 1%. The chance of local control found post radiotherapy is about 100% 
and no CND was found post radiotherapy of these tumours. It is important to notice 
however that sample sizes are small and follow-up ranges were relatively short with 
respect to evaluation of radiotherapy for these tumours. Therefore, the main advise 
in management of these tumours is to establish an initial wait and scan management 
strategy, and in case of tumour growth, surgical management by an experienced 
surgeon should be considered. More research on the potential use of radiotherapy for 
these tumours is required. 
Shamblin class 3 tumours
The results of surgical management of these tumours show that local control is found 
in 94% of cases. Nonetheless, the risk of CND for these tumours is considerable and 
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found in 32% of cases. Furthermore, there seems to be an enhanced risk of complica-
tions found in the management of these tumours 10%, mainly in the form of strokes. 
Nonetheless there is a potential risk associated with radiotherapy for these tumours 
as well. Therefore, initial management should always be by means of a wait and scan 
strategy. We believe surgery should be applied with great caution for these tumours and 
should solely be conducted by an experienced head and neck surgeon. Furthermore, in 
case surgical intervention is applied, our meta analysis illustrates that routine ECA and ICA 
clamping should not be conducted as this is associated with an enhanced risk of strokes. 
Although literature is sparse on this matter and our own clinical experience is limited, 
we believe radiotherapy should be considered a viable option as well as this rendered 
excellent local control and no complications in the issued follow-up period. Particularly 
in the case of multifocal disease radiotherapy should be considered for these tumours. 
Vagal body paraganglioma 
Our studies illustrate that surgical management of these tumours is associated with 
unacceptable morbidity rates particularly in the form of n. X paresis, which is in turn 
associated with aspiration pneumonias in up to 44% of cases. Furthermore, there seems 
to be an enhanced risk of strokes post surgery for these tumours. Complementary, 
local control is achieved in about 100% of cases and there were no irradiation induced 
cranial nerve damages described for these tumours. Please note however, that evidence 
for these rare tumours is based on small sample sizes with often an unsatisfactory 
follow-up rate. Therefore also for these tumours we highly recommend an initial wait 
and scan strategy as first management strategy. In case of present cranial nerve damage 
however, we believe initial radiation therapy should be conducted. 
MulTifoCal TuMour PresenCe
In the case of multifocal tumour presence in case of an enhanced risk of metachronous 
tumour presence due to and SDHx mutation, extra attention for functional preservation 
is required. Particularly bilateral cranial nerve damage should be prevented at all cost. 
Since treatment induced cranial nerve damage sequelae might remain up to 1 year 
post treatment, careful planning of treatment is required. Moreover, the management 
strategy is mainly based on the risk of CND for the particular tumour per treatment 
modality. Therefore, we believe that for Fisch class A and B tumours as well as Shamblin 
class 1 tumours, primary surgical management is still a viable option. For the remain-
ing tumours, a wait and scan strategy should be adopted and treatment should be 
avoided to induced iatrogenic morbidity, In the case of tumour growth or present partial 
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cranial nerve damage we believe radiotherapy should be initiated. It should be kept in 
mind however that late complications of radiotherapy can be expected, and therefore 
sequential treatment of synchronous HNPGL should be planned with an interval of at 
least 12 months. Surgery is generally not advised in the presence of multifocal tumour 
growth of tumours other than previously classified “low risk tumours” due to risk of 
CND. Surgery could be considered however in case of readily present (tumour induced) 
complete cranial nerve paralysis. However, please note that post surgery of Fisch class 
C and D tumours we found a mean CN damage rate of 1.58 implying that on average 
more than 1 nerve is affected post surgery. Therefore, even in the case of present cranial 
nerve paralysis of C and D tumours, surgery is not advised. 
In case of bilateral high risk tumour presence, a careful risk profile of each tumour 
should be constituted. It should first be evaluated whether there is a presence of 
cranial nerve damage. In case of cranial nerve damage, the tumour associated with 
the paralysis should be treated first with radiotherapy. Hereby, we aim to halt further 
cranial nerve function deterioration, and potentially cranial nerve function recovery 
is induced. We believe that in case of contralateral tumour growth (without cranial 
nerve function deterioration), the tumour inducing CND should still be treated first. In 
case  there is no present cranial nerve deterioration, tumour growth should be evalu-
ated. In case of unilateral tumour growth, the growing tumour should be treated first. 
In case both tumours grow, the smallest/lowest classified tumour should be treated 
first as this renders the highest chance of at least unilateral functional preservation. 
In case of younger patients (referring to patients younger than 50 years of age), the 
above mentioned suggestions for multifocal tumour management should be handled 
with great caution since the long term results of radiotherapy remain uncertain for 
these tumours and potential detrimental sequalae can be expected up to thirty years 
post treatment. Therefore, we believe patients younger than 50 should not generally 
not be treated with radiotherapy. We believe for these patients tumour debulking 
should be considered, with careful follow-up of the residual tumour. Hereby, we 
believe treatment induced complications can be reduced to a minimum and radio-
therapy can be prevented or at least be postponed with highest chances of functional 
preservation. However, more research is required to evaluated the applicability of this 
treatment strategy, particularly for younger patients. 
suggesTions for fuTure researCH
Many attempts have been made to describe the risk of the above mentioned treatment 
modalities for HNPGL, yet large (multicentre) studies are missing. Therefore, we believe 
future research should mainly be focussed on the cooperation between larger centres 
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sharing their data rendering larger samples. Potentially even allowing for prospective 
trials in which several treatment modalities can be compared and sub-group analysis’ 
can be performed. 
Particularly the aspect of hereditary tumour syndrome presence and its implica-
tions for the safety of an initial wait and scan management strategy is highly needed. 
Hereby, the potential enhanced risk of tumour induced complications during such 
a wait and scan session can be further investigated. Furthermore, the current work 
did not stratify treatment results of surgery or radiotherapy per genetic subclass. 
Potentially in case of tumour presence radiotherapy should be considered a less viable 
treatment option due to enhanced tumour growth?
Furthermore, more information is required on the long term effects of radiotherapy 
for HNPGL. Currently radiotherapy is advised for a large portion of the HNPGL, how-
ever this is mainly based on the enhanced risks of surgery for HNPGL of higher tumour 
class. We believe a large study is required that evaluates the long term complications 
of HNPGL, stratified per tumour class. 
Furthermore, in the current study the aspect of tumour debulking has been sug-
gested as a treatment for Fisch class C and D tumours. We believe this treatment 
option is a promising alternative when radiotherapy is less attractive (e.g.in case of 
younger patients). Whether or not this alternative can prevent (or sufficiently post-
pone) radiotherapy due to the absence of residual tumour growth requires further 
research. 
Moreover, evaluating the potential of surgical debulking, particularly in the case 
of jugulotympanic paraganglioma, the effects of surgery on pulsatile tinnitus and 
conductive hearing loss requires future research. Potentially, surgical debulking is a 
safe treatment option for patients suffering from this. 
ConClusions and iMPliCaTions of THis THesis
In conclusion, the studies described in this thesis contribute to the understanding of 
risks associated with different treatment modalities of HNPGL of different tumour 
class. Hereby we aid the constitution of individualized treatment protocols of patients 
suffering (multifocal) HNPGL. However, enhanced knowledge of risk factors for tumour 
induced complications for example in a wait and scan period is mandatory to better 
depict timing of treatment. Moreover, further research with large trials constituted via 
the cooperation of multiple centres is required to allow for proper sub-group analysis’ 
evaluating treatment outcome stratified per tumour class. 
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After a general introduction on head and neck paraganglioma and their diagnostic work 
up and introduction to the treatment paradigm, the first part of this thesis (chapter 
2) discusses the feasibility of a wait and scan period as initial management strategy. 
Part 1: the evaluation of a wait and scan management strategy for head and 
neck paraganglioma
In chapter 2 due to the high risk of treatment induced morbidity of all available treat-
ment modalities the feasibility of a wait and scan period to preserve potential harmful 
treatment modalities for those tumours with an enhanced risk of inducing morbidity. To 
this end a retrospective cohort study was conducted in which tumour growth rates were 
measured and clinical predictors for tumour induced morbidity were evaluated. In a large 
series resembling 59 jugulotympanic-, 71 carotid body-, and 29 vagal body tumours we 
found that 44% of head and neck paraganglioma show tumour growth and that the 
median growth rate  these tumours is only 0.44mm per year. Furthermore, a significant 
inverse correlation between growth rates and age at presentation was described. 
Ultimately seventeen tumours induced 20 complications. Six of these tumours were 
growing, and growth rates were higher than in tumours not inducing complications. 
From these results we can conclude that a wait-and-scan strategy is a feasible strategy 
for HNPGL. Nonetheless the management strategy could not prevent tumour-induced 
complications in 16% of non-growing tumours. 
Part 2: Evaluation of different treatment modalities for head and neck 
paraganglioma of different sub-site and class 
In chapter 3 we systematically analyzed the available literature on treatment of 
jugulotympanic paraganglioma. Out of 18 articles, resembling 83 patients treated 
with radiotherapy and 299 with surgery, an individualized risk profile was constituted 
regarding local control-, cranial nerve- and complication rates, post surgery for tumors 
of class A and B, and post surgery or radiotherapy for C1-4 tumors, and C1-4De/Di 
tumors. For class A and B tumors excellent local control was found post surgery and 
risk of cranial nerve damage was  negligible. For class C1-4 tumours, local control was 
80-95% post surgery (84% post radiotherapy), cranial nerve damage rates were as high 
as 71-76%, whereas no cranial nerve deficits were found post radiotherapy. Additionally, 
for class C1-4De/Di tumours, local control rates were variable post surgery (38-86%), 
but lower when compared to radiotherapy (98%), moreover, cranial nerve damage/
complication rates were found in 67-100% and only in 3% post radiotherapy. With 
this study, an individual risk profile is constituted for surgery and radiotherapy, stratified 
per Fisch class. For class A and B tumours surgery is a suitable treatment option. For 
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class C and D tumours radiotherapy results in lower complication rates and similar or 
better local control rates when compared to the surgical group
In chapter 4, the risk profile was further investigated as we evaluated treatment 
outcomes in our own population, resembling 66 C1-4 and 15 C1-4De/i tumors. In 
this cohort-study we analyzed results of surgery (n = 17), radiotherapy (n=29) and the 
use of tumor-debulking strategies (n=19). Furthermore, predictors of lesser treatment 
outcomes were evaluated. In this study we found complete local control after tumour 
debulking which was significantly higher when compared to the surgical group (80%). 
This did not differ significantly from the radiotherapy group (90%). Moreover, there 
were significantly less complications in the radiotherapy group (27%)when compared 
to surgery (63%) and the combined treatment group (44%). Therefore, in line with 
chapter 3, we conclude that radiotherapy should be the treatment of choice for the 
elderly. For younger patients tumour debulking should be considered, with potential 
radiotherapy in case of residual tumour growth.
With respect to carotid body paraganglioma, the main subject of debate is not 
so much which treatment modality to consider, as it is also uncertain which surgical 
resection technique should be used. To evaluate the treatment outcomes of different 
surgical techniques, in chapter 5, we systematically evaluated the literature on this 
matter. We summarized the clinical outcome of 139 class 1, 228 class 2 and 201 
class 3 patients, subtracted from 27 studies. A meta-analysis on routine ICA and ECA 
clamping techniques evaluated its association with clinical outcome. We found that 
Cranial nerve damage (3%, 17% and 39%) and complication rates (0%, 1%, 10%) 
were significantly related to Shamblin class (class 1, 2, 3, respectively). For class 3 
tumours an increased risk of complications was found associated with routine ICA 
manipulation/ reconstruction, mainly in form of a stroke. Moreover, a trend towards 
enhanced risk of routine ECA ligation was described. Therefore, it is concluded that 
for class 1 and 2 tumours surgery seems a viable treatment option. For class 3 tu-
mours, morbidity in terms of cranial nerve deficit and complications is considerable, 
particularly the use of ICA manipulation/reconstruction and potentially ECA ligation 
seems to be accompanied by high a stroke incidence.
Having found considerable risks associated with surgery of larger class carotid body 
paraganglioma, in chapter 6 we evaluated our own surgical results in a retrospective 
cohort study, evaluating treatment outcomes. Subsequently, and acknowledging the 
risk of surgery for these tumors (particularly in multifocal disease), we also evaluated 
the risk of 7 patients treated with radiotherapy for these tumors. This was comple-
mented by a systematic literature search evaluating the results of radiotherapy for 
118 carotid body paraganglioma (not stratified per Shamblin class), as described in 
10 carefully selected studies. Thirteen class 1, 25 class 2 and 16 class 3 tumours were 
included. Post surgery, local control rates were similar for all Shamblin tumours (range 
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90-100%). Cranial nerve damage rates increased per tumour class (0%, 8% and 18% 
respectively) and complication rates were low (0% 4% and 6% respectively). The 
complications constituted amongst others a stroke. Post radiotherapy no complications 
and 100% local control was found after median follow-up of 11 years (range 4-30). 
In the systematic review, constituted of 10 cohort-studies resembling 118 patients 
with median follow-up of 9.5 years (range: 1-34), local control as found in 96-100%. 
Furthermore, no irradiation induced cranial nerve damage and 1 potentially irradiation 
induced meningeoma was found. Therefore, it has been concluded that post post 
surgery, the risk of complications in class 2 and 3 tumours is low, yet, complications 
are potentially severe. In case patients are not fit for surgery, radiotherapy should be 
applied.
In chapter 7, a systematic literature search was executed, evaluating the treat-
ment results for vagal body paraganglioma in 17 studies, resembling 177 patients 
treated with surgery and 78 with radiotherapy. Compared to surgical results, post 
radiotherapy, there were significantly higher local control (95% vs. 100% resp.), and 
significantly less cranial nerve damage (97% vs. 0% resp.) and complication rates 
(29% vs. 0%). Therefore, it is concluded that surgery is not the preferred treatment 
option for vagal body paraganglioma. Local control after radiotherapy is high but 
long-term side effects are not well documented. The risk of cranial nerve damage 
caused by radiotherapy seems small when compared to the risk of iatrogenic nerve 
damage post surgery.
These results are complimented in chapter 8 by a retrospective cohort-study com-
paring the results of surgery versus radiotherapy for a total of 16 clinical patients. 
Out of 16 patients 11 were treated with radiotherapy. Post surgery and radiotherapy 
local control rates were 100% at 20 months (range 15-38) and 11 years (Range 3-29) 
follow-up respectively. Significantly less cranial nerve damage was found post radio-
therapy when compared to surgery (27% versus 80%). All post-treatment cranial nerve 
damages were N. X lesions. In conclusion it is stated that surgery inevitably renders n. 
X lesion and poses an additional risk for surrounding cranial nerves. Radiotherapy has 
rendered new cranial nerve damage or worsening of cranial nerve damage function 
in 27% of cases. Considering these risks associated with treatment, it seems wise to 
adopt an initial wait and scan protocol and to treat these tumours as little as possible. 
Part 3:  management of multifocal head and neck paraganglioma disease
In chapter 9 we compared the complication-free survival of patients suffering multifocal 
disease and those suffering multifocal tumor presence. A large retrospective cohort 
study was conducted of all patients suffering HNPGL and the main outcome measure 
was complication free survival , analyzed using Kaplan-Meier survival analysis. Doing 
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so we found a significantly worse complication free survival in 58 patients suffering 
159 tumours when compared to 120 patients suffering unifocal disease. No significant 
difference was found in complication free survival between unilateral versus bilateral 
tumour presence or the number of tumours found. Using univariate regression analysis, 
we found that when managed only with a wait and scan strategy, this was a negative 
predictor of complications. Using binary logistic regression, we found that the number 
of surgical procedures required for disease control is an independent predictor of 
complications in patients suffering multifocal disease. In conclusion we state that a 
significantly reduced complication free-survival can be expected for patients suffering 
multifocal tumours. Mainly the treatment modality chosen to manage these tumours 
are associated with complication-free survival, and radical tumour removal with sacrifice 
of cranial nerves should be avoided.
In the current thesis the impact of different treatment modalities of different tu-
mour types of different tumour class’ has been studied and discussed. The impact 
of radiotherapy and various surgical techniques have been evaluated. Hereby, this 
thesis contributes to the management of head and neck paraganglioma, as it aids the 
constitution of individualized treatment regimens. 
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saMenVaTTing
In hoofdstuk 1 wordt een algemene introductie gegeven over hoofd-/halsparagan-
gliomen (HHPGL) en wordt het dilemma in behandeling van deze tumoren ingeleid. 
Hierna spitst het eerste deel van het proefschrift zich toe op de toepasbaarheid van 
een wait-en-scan beleid als initiële behandelstrategie voor deze tumoren. 
Deel 1: De toepasbaarheid van een wait-en-scan beleid als initiële 
behandelstrategie voor hoofd-/halsparagangliomen. 
Door de hoge morbiditeit geassocieerd met behandelingen van deze tumoren is in 
hoofdstuk 2 onderzocht of deze potentiële schade berokkenende therapieën patiënten 
bespaard kunnen blijven door een wait-en-scan beleid te voeren. Hiermee hopen we 
behandeling alleen in te zetten voor patiënten met een verhoogd risico op morbiditeit 
ten gevolge van uitbreiding van de tumor. Hierop is een retrospectieve cohort studie 
uitgevoed waarin groeisnelheden van deze tumoren zijn geëvalueerd en klinische 
voorspellers voor tumor geïnduceerde morbiditeit zijn geëvalueerd. In een grote serie van 
59 jugulotympanicum-, 71 carotid body-, and 29 vagale paragangliomen is gevonden 
dat groei plaatsvindt in ongeveer 44% van de tumoren en dat de mediane groeisnelheid 
van deze tumoren ongeveer 0.44mm per jaar is. Verder is een significante inverse 
correlatie gevonden tussen groeisnelheid en leeftijd van presentatie gevonden. Uitein-
delijk is gevonden dat 17 tumoren 20 complicaties hebben berokkend. Zes van deze 
tumoren lieten groei zien en de groeisnelheden waren hoger dan bij tumoren waarbij 
geen complicaties zijn gevonden. Uit deze resultaten wordt geconcludeerd dat een 
wait-en-scan beleid een toepasbare behandelstrategie is voor HHPGL. Desalniettemin 
werd in 16% van de niet groeiende tumoren toch een complicatie waargenomen. 
Deel 2: Evaluatie van verschillende behandelstrategieën voor hoofd-/
halsparagangliomen van verschillende lokalisatie en tumor klasse
In hoofdstuk 3 is een systematische literatuuranalyse uitgevoerd. Uit 18 artikelen 
werden resultaten van radiotherapie voor 83, en voor chirurgie in 299 patiënten van 
verschillende Fisch klasse beschreven. Hiermee is een geïndividualiseerd risicoprofiel 
opgesteld wat betreft uitkomstmaten lokale controle, hersenzenuwuitval en complicaties 
per Fisch klasse. Voor Fisch klasse A en B tumoren is excellente locale controle gevonden 
na chirurgie en was het risico op hersenzenuwuitval nadien kleiner dan 1%. Voor klasse 
C1-4 tumoren is locale controle gevonden in 80-95% na chirurgie en hersenzenuwuitval 
is beschreven in 71-76% van de gevallen. Na radiotherapie is locale controle in gevonden 
84% en is geen hersenzenuwuitval gevonden na bestraling. Voor klasse C1-4De/Di 
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tumoren, werd locale controle bereikt in een range van 38-86%, terwijl dit 98% was 
na radiotherapie. Daarbij werd hersenzenuwuitval gezien na chirurgie in 67 tot 100% 
van de gevallen, terwijl dit na bestraling 3% was. Hiermee is een geïndividualiseerd 
risicoprofiel opgesteld voor chirurgie en radiotherapie als behandelmodaliteiten voor 
jugulotympanicum tumoren van verschillende Fisch klasse en werd geconcludeerd dat 
voor klasse A en B tumoren chirurgie een prima optie is, terwijl voor klasse C en D 
tumoren radiotherapie de beste op lijkt. 
In hoofdstuk 4 is dit risicoprofiel verder onderzocht aan de hand van resultaten 
uit onze eigen klinische serie bestaande uit 66 klasse C1-4 tumoren en 15 C1-4De/
Di tumoren. In dit cohort zijn de resultaten van chirurgie (n = 17), radiotherapie (n = 
29) en tumor debulking (n = 19) geëvalueerd. Totale locale controle is gevonden in 
alle patiënten waarbij tumor debulking-strategieën zijn gebruikt, hetgeen statistisch 
significant hoger was dan bij patiënten waarbij poging tot radicale resectie was 
uitgevoerd waarbij locale controle 80% was. De resultaten waren vergelijkbaar met 
resultaten van radiotherapie; 90% locale controle. Verder werden significant minder 
complicaties gezien in de radiotherapiegroep in vergelijking met chirurgie (27 vs. 63% 
resp.) of in vergelijking met de debulking groep (44%). Om deze reden wordt in lijn 
met hoofdstuk 3 geconcludeerd dat radiotherapie de behandeling van keuze zou 
moeten zijn voor deze tumoren, ten minste bij ouderen. In geval van jongere patiën-
ten dient chirurgische debulking overwogen te worden. Eventueel kan radiotherapie 
dan toegepast worden voor het tumor residu. 
Wat betreft carotid body paragangliomen is de discussie over behandeling niet 
alleen welke modaliteit gekozen dient te worden, maar wordt ook ingegaan op de 
chirurgische techniek. Om uitkomsten van verschillende behandelingen te evalueren 
is in hoofdstuk 5 een systematische review uitgevoerd. Hier worden de resultaten van 
139 klasse 1, 228 klasse 2 en 201 klasse 3 patiënten gepresenteerd, zoals beschreven 
in 27 studies. Vervolgens is een meta-analyse uitgevoerd naar de consequenties van 
routinematige ICA en ECA clamping technieken. Hierop is gevonden dat hersenze-
nuwschade en complicaties vaker voorkwamen bij oplopende Shamblin klasse (3%, 
17% en 39%; en 0%, 1% en 10%). Voor klasse 3 tumoren is een toenemend risico 
op complicaties gevonden met routinematige ICA manipulatie/reconstructie. De voor-
naamste complicatie gevonden was een beroerte. Daarbij is een trend gevonden in 
toename van risico van routinematige ECA ligatie. Derhalve is geconcludeerd dat voor 
klasse 1 en 2 tumoren chirurgie een goede behandelingsoptie is. Voor klasse 3 tumo-
ren is het risico op iatrogene morbiditeit in aanzienlijk, met name in het geval van ICA 
en mogelijk ook ECA manipulatie/reconstructie en wordt derhalve geconcludeerd dat 
chirurgie zeer spaarzaam toegepast dient te worden. 
Naar aanleiding van het risicoprofiel beschreven voor chirurgie van grotere carotid 
body paragangliomen wordt in hoofdstuk 6 beschreven wat de resultaten zijn van 
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onze eigen chirurgische serie. Daarbij is, gezien het risico op morbiditeit, gekeken 
naar de mogelijkheid van radiotherapie voor deze tumoren. Hiertoe zijn in onze eigen 
serie 7 patiënten bestraald, de resultaten hiervan zijn aangevuld door resultaten van 
een systematische literatuurstudie naar effectiviteit van bestraling voor deze tumoren. 
Hiertoe zijn resultaten van bestraling van 118 carotid body paragangliomen (niet 
gestratificeerd per Shamblin klasse), zoals beschreven in 10 zorgvuldig geselecteerde 
artikelen. Resultaten lieten zien dat voor 13 klasse 1, 25 klasse 2 en 16 klasse 3 tumo-
ren, na chirurgie lokale controle vergelijkbaar is voor de verschillende tumorklassen 
(range 90-100%). Hersenzenuwuitval lijkt wel toe te nemen met Shamblin klasse (0, 8 
en 18% respectievelijk) en het complicatierisico ook (0, 4 en 6%). Onder de complica-
ties werd tevens een beroerte waargenomen. In onze serie werd na radiotherapie voor 
alle patiënten locale controle bereikt zonder complicaties na een mediane follow-up 
van 11 jaar (range 4-30). In de aanvullende literatuurstudie werd na een mediane 
follow-up van 9.5 jaar (range 1-34) locale controle in 96% van de gevallen gevonden 
zonder hersenzenuwuitval. Mogelijk is een enkel radiatiegeïnduceerde meningeoom 
gevonden. Op basis van deze resultaten is geconcludeerd dat het risico op compli-
caties na chirurgie ook voor hogere klasse 2 en 3 tumoren, maar dat complicaties 
potentieel ernstig zijn. Derhalve dient in geval van een niet vitale patiënt radiotherapie 
als behandelmogelijkheid overwogen te worden. 
In hoofdstuk 7 wordt een systematische literatuurstudie uitgevoerd waarbij de resul-
taten van chirurgie en radiotherapie voor vagale paragangliomen wordt beschreven. 
In 17 studies zijn 177 patiënten beschreven welke behandeld zijn met chirurgie, en 
78 met radiotherapie. In vergelijking met chirurgie, werd na radiotherapie significant 
betere locale controle bereikt (100 vs. 95%), daarbij werd significant minder hersen-
zenuwuitval gevonden (0 versus 97%), en warden er minder complicaties beschreven 
(0 versus 29%). Derhalve wordt geconcludeerd dat chirurgie niet de behandeling 
van keuze dient te zijn voor deze tumoren. Alhoewel de lange termijn resultaten 
van radiotherapie nog niet volledig bekend zijn is dit toch de behandeling van keuze 
gezien het extreme hoge risico op complicaties na overige behandeling na chirurgie. 
Deze resultaten zijn aangevuld met onze eigen serie in hoofdstuk 8, waarbij een 
retrospectieve cohortstudie is uitgevoerd welke tevens de resultaten van radiothe-
rapie en chirurgie beschrijft. Na chirurgie en radiotherapie werd in locale controle 
beschreven in alle gevallen. Er werd significant minder hersenzenuwuitval gevonden 
na radiotherapie in vergelijking met resultaten na chirurgie (27% versus 80%). In alle 
gevallen van hersenzenuwuitval was minstens de n. X betrokken. Derhalve wordt 
geconcludeerd dat chirurgie onvermijdelijk leidt tot n. X laesie en een aanvullend 
risico voor overige hersenzenuwuitval gevonden wordt. Echter, het risico op n. X uitval 
na chirurgie is tevens aanzienlijk (27%). Derhalve wordt geadviseerd een afwachtend 
beleid te voeren voor deze tumoren. 
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Deel 3: management van multifocale hoofd-/halsparagangliomen
In hoofdstuk 9 wordt de complicatievrije overleving van patiënten welke lijden aan 
multifocale ziekte vergeleken met deze van patiënten welke aan een enkele tumor lijden. 
Als onderdeel hiervan is een grote cohortstudie uitgevoerd, waarbij de belangrijkste 
uitkomstmaat was de complicatievrije overleving. We hebben gevonden dat er een signi-
ficant slechtere complicatievrije overleving is voor 58 patiënten welke aan 159 tumoren 
lijden, wanneer vergeleken met 120 patiënten met een enkele tumor. Er is geen verschil 
gevonden in complicatievrije overleving in geval van unilateraal of bilateraal voorkomen 
van meerdere tumoren of het aantal tumoren dat gevonden is. Met univariate regres-
sieanalyse werd gezien dat wanneer alleen een wait-en-scan beleid gevoerd werd een 
verhoogde complicatievrije overleving gezien is. Na logistische regressie bleek dat het 
aantal chirurgische procedures uitgevoerd bij patiënten onafhankelijk geassocieerd is 
met een verlaagde complicatievrije overleving. Derhalve werd geconcludeerd dat een 
significante verlaagde complicatievrije overleving verwacht kan worden bij patiënten met 
multifocale tumorgroei, en met name de gekozen behandelmodaliteit van invloed is op 
de complicatievrije overleving. Met name radicale chirurgische resectie met opofferen 
van hersenzenuwen dient hierbij vermeden te worden. 
In dit proefschrift is de impact van verschillende behandelmodaliteiten op patiënten met 
HHPGL van verschillend type en tumor klassen beschreven. De impact van radiotherapie 
en verschillende chirurgische technieken zijn geëvalueerd. Hiermee draagt het huidige 
proefschrift bij aan het management van HHPGL, en geeft het inzichten voor het 
opstellen van geïndividualiseerde behandelingen. 
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Dit proefschrift heb ik niet alleen geschreven. Een aantal mensen wil ik dan ook graag 
bedanken voor hun bijdrage, zowel inhoudelijk als op een andere manier. 
Prof. dr. H.A.M. Marres. Beste Henri, vanaf mijn sollicitatie wist ik dat ik graag in jouw 
team wilde werken. Je jarenlange ervaring in het gebied van de oncologie gecombineerd 
met je kritische maar open blik waarmee je nieuwe ideeën verwelkomt zijn goud waard 
voor een jonge onderzoeker. Ik heb ontzag voor je wijze van begeleiden en leidinggeven, 
dit geldt voor de begeleiding van mijzelf als promovendus, maar meer voor de wijze 
waarop je dat doet voor deze fantastische afdeling. Er geldt een norm die gehaald moet 
worden, maar hierbinnen krijgt iedere assistent bij jou alle kansen. Ik wil je bedanken 
voor de kans die je me hebt gegeven om in het Radboud als onderzoeker en later als 
AIOS te kunnen werken. 
Prof. J.H.A.M. Kaanders. Beste Hans, vanaf het moment dat je betrokken bent geraakt 
bij mijn promotie ben je van onschatbare waarde geweest. Voor niemand zijn com-
mentaar was ik meer huiverig wat betreft de hoeveelheid rood die ik terugkreeg, 
maar tegelijkertijd heb ik van niemand zoveel opbeurende en opbouwende kritieken 
gekregen. Dit proefschrift had er niet kunnen zijn zonder je hulp. Dank voor je positieve 
en vooral inhoudelijk altijd kritische feedback en ondersteuning. 
Dr. H.P.M. Kunst. Beste Dirk. Ze moesten eens weten. Vanaf onze eerste meeting een 
klik, het begin van een synergistische samenwerking. Zonder jouw hulp en vertrouwen 
in mij was dit proefschrift er nooit geweest en was de KNO een ander vak. Ik zie je 
als mijn leermeester en heb ontzag voor alles wat je voor elkaar bokst. Zonder enige 
twijfel of blad voor de mond kan ik altijd bij je binnenlopen voor een flauwe grap of 
een inhoudelijke discussie, maar meestal beiden. Ik kan met je lezen en schrijven, de 
bar overeind houden en lachen. Je bent mijn copromotor, maar bovenal ook mentor 
en vriend. Enorm bedankt voor al je vertrouwen in mij. Ik hoop nog lang met je samen 
te werken. 
Beste dr. Timmers en G. Beute. Hartelijk dank voor de inhoudelijke bijdrage aan dit 
proefschrift. 
Manuscriptcommissie. Hooggeleerde heren, dank voor uw tijdsinvestering in de be-
oordeling van dit proefschrift. 
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Mijn paranimfen. Beste Berrend en Coen, maatjes sinds Middelburg. Dank dat jullie 
mij hebben bijgestaan op weg hier naartoe al deze jaren. Jullie kennen mij als geen 
ander, ik kan me dan ook geen betere ondersteuning bedenken tijdens de verdediging 
van dit proefschrift. 
De stafleden van de afdeling Keel-, Neus- en Oorheelkunde van het Radboudumc, en in 
het bijzonder dr. Frank van den Hoogen. Wat een mooie club mensen zijn jullie bij elkaar 
en wat vormen jullie een goede afdeling. Ik ben oprecht dankbaar door jullie te zijn 
opgeleid en heb genoten van het opleidingsklimaat maar bovenal van de gezelligheid. 
Beste S. J. de Vries. Beste Sjoerd-Jan, niet een naam op de auteurslijst, maar een o zo 
belangrijke persoonlijke mentor. Wat begon met een fles wijn, liep uit tot een reis met 
je lieve familie naar Spanje en een glashelder rapport voor de KNO-vereniging. Je kan 
me soms achter het behang plakken, maar zo gaat dat bij vrienden. Enorm bedankt 
voor je openhartigheid en vertrouwen in mij. Ik zie uit naar nog veel goede gesprekken 
met een nog betere wijn! 
De leden van de maatschap Keel-, Neus- en Oorheelkunde in het CWZ in Nijmegen 
en het VieCuri Medisch Centrum te Venlo, en in het bijzonder dr. Joost Engel en dr. 
Patrick Dammeijer. Bedankt voor het leerzame jaar onder jullie hoede, de tijd die ik heb 
gekregen voor het afronden van dit proefschrift, maar vooral ook de lol die ik met jullie 
groep heb beleefd. Van meet af aan voelde ik me thuis, het was een onvergetelijke tijd! 
Mede (oud) AIOS KNO en onderzoekers. Wat een mooie groep gezellige slimme mensen 
bij elkaar. Gouden collega’s maar bovenal ook echte vrienden geworden over de tijd. 
Dank voor alle mooie tijden samen binnen en buiten het ziekenhuis. Beste Luuk, Jeroen, 
Cindy en tot voor kort ook Henrieke, promoveren was nooit zo leuk geweest zonder 
jullie als kamergenootjes! 
Al mijn vrienden. Beginnen bij het begin. Beste Niek en Koen, en niet veel later ook 
Krystian, dank voor jullie volhardende steun over de jaren. Vanaf het schoolplein tot nu 
hebben jullie naast me gestaan. Nooit hebben jullie me uit het oog verloren wanneer 
ik niks van me liet horen. Ik laat het niet altijd zien, maar jullie vriendschap betekent 
enorm veel voor me. Lieve maatjes uit Middelburg en alle SUMMA’s, wat een heerlijke 
groep mensen zijn jullie toch. Dank voor alle mooie tijden samen! 
Lieve Maarten, Maria en Margot. Van jullie heb ik in een heel belangrijke fase in mijn 
leven onvoorwaardelijke steun en liefde gekregen. Ik ken geen mensen die meer in 
mij geloven dan jullie. Bedankt hiervoor. Dank dat ik onderdeel van jullie familie heb 
mogen zijn en ik hoop jullie nooit uit het oog te verliezen. 
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Mijn lieve familie. Lieve papa en mama, Noortje & Luis, Sophie & Eef en uiteraard Gido, 
Kassie en Jip, wat ben ik trots dat jullie mijn familie zijn. Lieve zusjes, wat heb ik het 
altijd goed gehad met jullie naast me. Ik ben zo trots op hoe jullie in het leven staan 
en ik geniet van alle momenten samen. Sophie zei het goed na haar reis, zonder jullie 
kan ik niet. Lieve papa mama. Geen idee hoe ik jullie moet bedanken voor alles wat 
jullie voor me doen. Door jullie weet ik wat onvoorwaardelijke liefde is. Ik ben trots 
dat jullie mijn ouders zijn en zou zelfs op mijn 31e nog radeloos zijn zonder jullie. Als 
ik ook maar een beetje op jullie lijk ben ik geslaagd als mens. Bedankt voor alles.
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Thijs Theo Gerrit Jansen werd geboren op 19 juli 1987 in Malden. Op vier jarige leeftijd 
verhuist hij met zijn oudere zus Noortje en jongere zusje Sophie naar Nijmegen. Hij 
behaalt in 2005 zijn Atheneumdiploma aan het Montessoricollege in Nijmegen en 
start nadien aan de Roosevelt Academy in Middelburg, een University College van de 
Universiteit van Utrecht. Hier is hij lid van het herendispuut Erodios en in 2008 behaalt 
hij zijn bachelor in Science, met aandacht voor de pre-medical track. In 2008 start hij 
het Selective Utrecht Medical MAster-programma waarbinnen hij wordt opgeleid tot 
arts en klinisch onderzoeker. Tijdens zijn reguliere coschap in het Gelreziekenhuis in 
Apeldoorn  komt hij voor het eerst in aanraking met de Keel-, Neus-, en Oorheelkunde. 
Vele wetenschappelijke en klinische stages volgde. Hij start fundamenteel onderzoek in 
het experimenteel lab van de Universiteit van Utrecht, onder leiding van dr. Klis, naar de 
ototoxiciteit van aminoglycoside-antibiotica en lis-diuretica bij muizen. Deze resultaten 
zijn gepubliceerd en vervolgonderzoek is ingezet. Simultaan wordt onderzoek opgestart 
bij dr. H.D. Vuyk, KNO-arts en aangezichtschirurg, naar de lange termijn effecten van 
rhinoplastieken. Zijn keuze-coschap volgt Thijs binnen de KNO aan de Medizinische 
Hochschule in Hannover onder leiding van prof. dr. Lenarz en prof. Lesinski-Schiedat. 
Hij zet een onderzoekslijn op tussen de KNO-afdelingen van het UMC-Utrecht en de 
medische faculteit in Hannover, waar ook wetenschappelijke publicaties uit voortkomen. 
Na de afronding van zijn laatste stage als semi-arts bij de afdeling Heelkunde van het 
Diakonessenhuis Utrecht werd de artsenbul behaald in februari 2013. 
In augustus 2013 begint Thijs aan het onderzoeksproject dat leidde tot dit proef-
schrift. Na 8 maanden voltijd onderzoek te hebben gedaan start hij in april 2014 
met de opleiding tot KNO-arts. Het tweede jaar van zijn opleiding werd in het CWZ 
in Nijmegen onder leiding van dr. Engel doorlopen, en het vierde jaar in het VieCuri 
Medisch Centrum in Venlo onder leiding van dr. Dammeijer. Tijdens de opleiding en 
naast het promotietraject coördineert Thijs met dr. Kunst en prof. Marres de totstand-
koming van de eerste nationale richtlijn hoofd-/halsparagangliomen. Daarbij werkt hij 
in samenwerking met oud collega de Sjoerd Jan de Vries aan een adviesrapport voor 
het landelijk KNO-bestuur, getiteld “de impact van de vergrijzing binnen de KNO”, 
waarvan de resultaten in juni 2019 officieel gepubliceerd zullen worden. Op het 
moment van de verdediging van dit proefschrift is hij halverege het vijfde en laatste 
jaar van zijn opleiding. 
